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Introduction and Outline of Investigation 
Ш Introduction 
The hematopoiesis is mediated by an appropriate balance between positive and 
negative regulatory molecules (growth factors, cytokines) which stimulate selfre-
newal of stem cells, progenitor cells to proliferate, to differentiate and to mature, 
and which induce selectively the occurrence of programmed cell death (apoptosis). 
Processes of cell proliferation, differentiation and cell death are under normal 
condition tightly regulated. E.g., the granulocytes have a limited life span of 8 h and 
yet their numbers in the blood remain very stable. In order to maintain an equilib­
rium in their cell numbers, a daily production of about 0.5 χ IO9 granulocytes is 
required, but during increased blood cell consumption the production may in­
crease 5-10 times. In cases of hematologic malignancies the regulation of hemato­
poiesis is disturbed, resulting in an expanding population of malignant cells and a 
decreased population of normal hematopoietic cells. 
This thesis is directed to the study of cell proliferation of some hematologic malig­
nancies. Cell proliferation can be studied by measuring kinetic parameters of the 
cell cycle. The interest in this field has been renewed by the rapid growing insight 
in the fundamental processes that regulate the cell cycle [1], and the development 
of new agents that stimulate or inhibit hematopoiesis, such as hematopoietic 
growth factors [2,3], antibodies directed against growth factor receptors [4], or 
antisense oligonucleotides [5,6]. 
Since the last few years new techniques have become available for the in vitro and in 
vivo measurement of cellular growth characteristics of tumors. Such techniques are 
of special interest for hematologic malignancies, because these tumors can be easily 
assessed and the tumor cells are commodiously isolated, manipulated and proc­
essed. 
The cell cycle 
The basic concept of the cell cycle is demonstrated in Figure 1. In a replicating 
eukaryotic cell the life-cycle can be divided into four main phases: 1) Gi-phase, the 
interval between mitosis and S-phase. The cellular DNA content in this phase 
amounts 2n. 2) S-phase, the period of DNA synthesis, the replication phase of the 
cellular genome. The cellular DNA content increases from 2n to 4n in this phase. 3) 
G2-phase, the period between S-phase and mitosis. The cellular DNA content in this 
phase amounts 4n; 4) Mitotic-phase (M-phase), the phase of cell division. The cellular 
DNA content in this phase decreases from 4n, before division, to 2n after division. 
Usually two other phases are discriminated, being the Go-phase, or resting phase, 
and the terminally differentiated phase. In both phases the cell contains 2n DNA. The 
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Fig. 1. The concept of the cell cycle. 
terminally differentiated cells are non-proliferating cells and cannot re-enter the 
cell cycle. The Go-cells are temporarily non-proliferating cells but can re-enter the 
cell cycle after adequate stimulation by growth factors or release from inhibitory 
factors. Differentiation and apoptosis (programmed cell deaths) leads to cell death 
and are important for the balance between cell growth and cell death. 
The numbers of cells in S-phase or M-phase can be easily determined and have 
been used as indicators of proliferating activity. However besides the Go-phase, the 
Gi and G2-phase are not less important. In these phases preparation for the pro­
gression through the cell cycle occurs, like synthesis of proteins, histones, RNA, 
spindle proteins, etc. There is increasing evidence that most of the regulatory 
processes to control progression through the cell cycle are associated to the Gi and 
G2-phases, controlled by different cyclins and other (phosphorylated) proteins (for 
review: [1]). 
Mitotic index 
The first cell kinetic parameter that could be analyzed was the mitotic index, 
assessed by counting of mitotic cells in tissue sections or bone marrow smears 
using conventional microscopy. However, the M-phase constitutes only a small 
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part of the cell cycle. Especially in a low proliferating cell population the number of 
mitosis is very low. Therefore the mitotic count may be subjective with a large 
inter-observer variation [7]. Moreover, technical artifacts induced by fixation pro-
cedures may affect the number of mitosis [8]. Nevertheless, the mitotic index may 
serve as a first impression of proliferative activity and may add to the classification 
and prognosis of hematologic malignancies like lymphomas [9,10]. 
Thymidine autoradiography after In vitro labeling 
The first wave of cell kinetic investigations in man was started after the introduc-
tion of techniques using incorporation of tritiated thymidine into the cellular DNA. 
Only cells that are actively synthesizing DNA (S-phase cells) will incorporate 
tritiated thymidine during a short time exposure (pulse-labeling). These cells can 
be detected using autoradiography. Therefore, pulse labeling with tritiated thymi-
dine is regarded as a functional marker of proliferative activity, reflecting the 
fraction of S-phase cells. 
This technique has been used to study cell cycle kinetics in various hematologic 
malignancies like acute myeloid leukemia [11-15], acute lymphoid leukemia [16], 
as well as malignant lymphoma [17-20]. Such studies have undoubtedly added to 
the our knowledge on proliferative activity in hematologic malignancies and sug-
gested that cell cycle kinetics might be useful as additional markers to predict 
clinical behavior. 
Some practical reasons have prevented a widespread application of this technique 
in a clinical setting. Thymidine autoradiography is time consuming, requires the 
use of radioisotopes, and for statistical reasons a large number of cells has to be 
counted. When applied w vitro there are some important methodologically short-
comings like: the requirement of undisturbed ex vivo growth of the hematopoietic 
cells, and the limited cell kinetic information describing only the number of cells in 
a certain cell cycle phase. 
Quantitative autoradiography may provide additional information on the duration 
of the S-phase [21,22] but is a rather complicated, laborious procedure and depends 
even more on the undisturbed in vitro growth of hematopoietic cells. 
Thymidine autoradiography after in vivo labeling 
Fraction labeled mitosis technique 
The technique of labeled mitosis, enables the analysis of a more detailed cell kinetic 
profile, including data on the duration of the S-phase, G2-phase and cell cycle time. 
Cells are pulse labeled by in vivo administration of tritiated thymidine. At regular 
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time intervals of 1-4 h a tissue sample (e.g., bone marrow aspirate) is taken and 
processed for autoradiography. From each time point the fraction of labeled mito-
sis (FLM) is counted, and from the fluctuation of FLM in time the distinct kinetic 
parameters are calculated [23]. The main principle of this technique is the monitor-
ing of the transition of pulse-labeled S-phase cells through the cell cycle. The time at 
which the labeled cohort enters (or after one cell division re-enters) the M-phase 
can be detected by the appearance of labeled M-phase cells. This technique requires 
the in vivo administration of radioisotopes and multiple tissue sampling during a 
period of at least the expected cell cycle time. For ethical and practical reasons, only 
some case reports have been published [24-28]. 
Double-labeling 
Double-labeling with 3H- and 14C-Thymidine in vivo and in vitro allows the analy-
sis of the duration of the S-phase from only one sample [29]. However it still 
requires the in vivo use of radioisotopes and a time-consuming autoradiography 
procedure. Therefore, its application in hematology has been limited [26,28,30]. 
Continuous labeling 
Prolonged, continuous in vivo labeling with tritiated thymidine, combined with 
multiple tissue sampling, discriminates between the cycling (Gi-, S-, G2, and M-
phase cells) and non-cycling compartment (Go-phase cells and terminally differen-
tiated cells) [31]. Continuous in vivo labeling with radioisotopes for cell cycle 
kinetics will not be permitted by ethical committees nowadays. Only three of such 
studies have been reported in the past, describing the results in a few patients with 
either chronic lymphocytic leukemia [32], acute lymphoid leukemia [33,34], and 
acute myeloid leukemia [33]. The estimation of the cycling compartment might be 
jeopardized by the occurrence of very slowly cycling cells with a duration of the 
Gl-phase longer than the labeling period. Moreover, labeled cells may leave the 
cycling compartment during continuous labeling. 
Flow cytometry 
Flow cytometry allows a rapid and reproducible analysis of multiple biologic 
parameters on a cell by cell basis. A suspension of cells (or other particles in fluid 
like bacteria, fungi, virus particles, chromosomes, liposomes, tumor spheroids etc.) 
are made to flow rapidly in a sample stream. The cells pass a light source, one by 
one, at a rate of several hundreds of cells per second. The light sources are often one 
or two, but sometimes three or more laser beams (occasionally also Arc lamps are 
used), each laser beam emitting at a different wave length. The passing cells will 
cause an absorption and scattering of light, and will generate one or more different 
14 
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Fig. 2. Schematic representation of a Coulter flow cytometer (Coulter, Hialeah, FL) 
used at our department. PMT = photomultiplier. 
fluorescence signals when appropriate fluorochromes are attached to the cells. The 
optical signals of different wave length are separated using optical filters. The light 
absorption, light scatter, and fluorescence signals are detected using photomul-
tipliers tubes, converted into electrical signals, and stored in a multichannel analy-
sis on a computer. 
The absorption and light scatter signals contain information about volume and 
shape of the cell. The fluorescence signals can be used to analyze numerous series 
of cellular characteristics, like DNA content, RNA content, cell-surface and intra-
cellular antigens, nuclear antigens, cellular pH, incorporation of halogenated thy-
midine analogues, enzyme activity, etc. The applications depend on the availability 
of adequate cytochemical staining protocols and specific fluorescence dyes [35]. 
15 
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DNA flow cytometry 
One of the most commonly used parameters of proliferative activity is the percent-
age of cells with S-phase DNA content measured using staining with DNA-specific 
fluorochromes and flow cytometry [36-38]. Special analytic models are described 
that allow the calculation of the fraction of cells in Go/Gj -phase (2n DNA content), 
S-phase (>2n and <4n DNA), and G2+M-phase (4n DNA) from a flow cytometri-
cally derived DNA histogram of a cell population [39,40]. Some restrictions have to 
be made due to overestimation of the S-phase caused by cells arrested within S-
phase [41], although this seems to be generally a minor problem in leukemia [42] 
and lymphoma [43]. The simplicity of the method has led to a frequent use of DNA 
flow cytometry in the study of acute myeloid leukemia [11,44-48], acute lymphoid 
leukemia [45,46,49,50], Hodgkin's disease [51-53] and non-Hodgkin's lymphoma 
[54-62]. Analysis of S-phase DNA content can be disturbed in aneuploid tumors, 
due to overlapping DNA histograms of the aneuploid and residual euploid popu-
lations. DNA aneuploidy is frequently found in high grade lymphomas [55,56,63] 
and acute lymphoid leukemia [46,49,57], but it is also common in acute myeloid 
leukemia [64,65] and low grade lymphomas [55,61]. One of the main limitations of 
DNA flow cytometry is the lack of information on different subpopulations, e.g. the 
different hematopoietic lineages present in normal bone marrow or the malignant 
and nonmalignant populations in non-Hodgkin's lymphoma. Like in vitro labeling 
with thymidine, DNA flow cytometry provides limited cell kinetic information, 
describing only the number of cells in certain cell cycle phases. 
Recently the flow cytometric application of DNA specific dyes has been extended 
to the study of cell death, either by necrosis or apoptosis [66-69]. 
Proliferation associated antigens 
Antigens that are preferentially expressed during specific cell cycle phases can 
serve as proliferation markers [70]. During the past years several monoclonal 
antibodies have been developed that recognize proliferation markers, such as Ki-67 
[71], Ki-Sl [72], and antibodies against cyclin/PCNA [73], P120 [70], P145 [70], 
Statin [74], DNA-polymerase-alpha [75] and DNA-methyltransferase [76]. Flow 
cytometry of proliferation associated antigens requires relatively simple staining 
protocols [77,78]. Several studies, especially in malignant lymphoma, have been 
published on the clinical relevance of proliferation markers [19,79-86]. 
Proliferation markers should not be used uncritically. The expression of such 
markers during the cell cycle may be different among hematopoietic subpopula-
tions [87] or may vary with different fixation protocols [88,89]. Moreover their 
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relationship to certain cell cycle compartments is more complex as initially re-
ported [90]. The expression of proliferation markers is also influenced by terminal 
half life times of the antigens [91,92]. 
Bromodeoxyuridine and iododeoxyuridine incorporation 
Measurement of a more extensive kinetic profile (including data on the duration of 
cell cycle phases) without the use of radioisotopes, has become feasible through the 
introduction of techniques using m vivo incorporation of bromo- (BrdUrd) or 
iododeoxyuridine (IdUrd). BrdUrd or IdUrd are nonradioactive pyrimidine ana-
logues that are incorporated into the DNA during the S-phase. IdUrd (or BrdUrd) 
can be used for in vivo labeling without toxic side effects [43,93]. 
IdUrd/DNA flow cytometry 
Bivariate flow cytometric detection of IdUrd (BrdUrd) incorporation and DNA 
content is possible using specific monoclonal antibodies against these pyrimidine 
analogues [94-96] and special cytochemical protocols [94,97,98]. The transition of 
cells through the cell cycle can be monitored using pulse labeling with IdUrd/ 
BrdUrd, sampling at regular time intervals, and IdUrd/DNA (BrdUrd/DNA) flow 
cytometry [99]. Begg et al. described a kinetic model that allows calculation of 
various kinetic parameters (including the labeling index, duration of the S-phase, 
and potential doubling time) from only one single sample, derived at several hours 
after pulse labeling [100]. Recently some refinements of this model has been de-
scribed [101,102]. More detailed information on cell cycle kinetics using IdUrd/ 
DNA flow cytometry is given in chapters 4-8. 
Such an approach allows the study of detailed in vivo cell cycle characteristics 
without substantial discomfort to the patient [85,103-107]. 
IdUrd/BrdUrd immunohistochemistry 
Calculation of detailed in vivo cell cycle kinetic characteristics from one single 
sample is also feasible from immunohistochemistry of double-labeled cells. Cells 
are pulse-labeled with BrdUrd in vivo, and either tritiated thymidine in vitro [108] 
or IdUrd in vivo [108-110]. The labeling index, the DNA synthesis time and the 
potential doubling time can be calculated from the percentages of single and 
double-labeled cells. IdUrd/BrdUrd immunohistochemistry proved to be of clini-
cal significance in hematologic malignancies [93,111]. 
Chapter 1 
BrdUrcl/Hoechst/propidium iodide quenching technique 
The BrdUrd/Hoechst/propidium iodide quenching (or ethidium bromide) tech-
nique is based on quenching by BrdUrd from the fluorescence of the DNA stain 
Hoechst 33258. The cells are continuously labeled in vitro with BrdUrd and proc-
essed for simultaneous staining with two DNA dyes: Hoechst 33258 (quenched by 
BrdUrd) and propidium iodide (not quenched by BrdUrd). From the Hoechst/ 
propidium iodide analyses the transition of the cells through the cell cycle can be 
monitored up to two or three cell cycles. The analysis discriminates also between 
the fraction of cycling and non-cycling (Go-phase cells) cells [112]. This technique is 
a promising tool to study in vitro cell kinetics in hematologic malignancies [113], 
but it requires a flow cytometer equipped with an UV-light source. Due the pro-
longed labeling with relatively high concentrations of BrdUrd, it is not suitable for 
in vivo studies. 
9 Outline of investigation 
The subject of the current thesis is to study cell cycle kinetics in hematologic 
malignancies using new techniques that can be easily implemented in a clinical 
setting. 
Chapter two addresses the problem of cell heterogeneity in hematopoietic tissues 
like normal bone marrow and aneuploid leukemia. A simple staining protocol was 
developed that allows the measurement of S-phase DNA content in immuno-
phenotypically defined subpopulations. 
In clmpter three this method is applied to study cell cycle kinetics in normal and 
leukemic bone marrow subpopulations. 
Chapter four describes a staining protocol for bivariate flow cytometry of BrdUrd (or 
IdUrd) incorporation and DNA content. This protocol appears suitable for the 
relatively fragile hematopoietic cells and it is prerequisite for cell kinetic studies 
using IdUrd incorporation. 
Chapter five shows the principle of in vitro cell cycle kinetics using pulse labeling 
with IdUrd. Using subsequent IdUrd/DNA flow cytometry, the transition of pulse 
labeled cells through at least one cell cycle can be monitored. The technique was 
applied to study the effect of doxorubicin on cell cycle kinetics of human leukemia 
cells. 
In the next three chapters the IdUrd technique is used to study in vivo cell cycle 
kinetics in hematologic diseases from only one single sample. 
18 
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Chapter six validates the kinetic model of the single sample technique and describes 
the results of a prospective study in patients with acute myeloid leukemia. 
Chapter seven is dedicated to in vivo cell cycle kinetics in malignant lymphoma. It 
shows how the cell kinetic information can be extended by combining IdUrd/DNA 
and Ki-67/DNA flow cytometry. 
Chapter eight describes a study on cell cycle kinetics after in vivo administration of 
GM-CSF in patients with refractory anemia. In this chapter also two extension of 
the IdUrd technique are reported: 1) The measurement of the release time of 
granulocytes from the bone marrow into the peripheral blood. 2) In vivo cell cycle 
kinetics of small subpopulations using an additional cell separation procedure. 
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DNA Flow Cytometry of Bone Marrow Subpopulations 
Ш Abstract 
This paper describes the measurement of S phase DNA content in human bone 
marrow subpopulations using a single laser method for bivariate analysis DNA 
content and cell-surface immunofluorescence (s-IF). Low-density (< 1.077 g/ml) 
bone marrow cells were labeled with a panel of unconjugated monoclonal antibod­
ies (MoAb) for the lymphoid (CD2 + CD19), T- lymphoid (CD2), B-lymphoid 
(CD19), erythroid (anti-glycophorin-A), myelomonocytic (CD13, CD33; single and 
as cocktail), and monocytic (CD14) lineages. A fluorescein isothiocyanate (FTTC)-
conjugated goat anti-mouse label was used as second step. Unfixed, MoAb-labeled 
cells were incubated for 24 h with a hypotonic propidium iodide solution for DNA 
staining. Cells were analysed on single-laser flow cytometer, operating at 488 nm. 
The effect of the combined staining protocol upon both s-IF and DNA stainability 
was evaluated. Only a slight decrease (mean: 29.0%) in s-IF intensity was observed 
after DNA staining. The percentages of immunofluorescent cells in the bone mar­
row samples of 10 normal individuals before and after DNA staining were essen­
tially unchanged for all the MoAbs used. The DNA histograms of the immunophe-
notypically defined subpopulations were of excellent quality with a mean coef­
ficient of variation of 1.8%. This procedure allows the assessment of very low levels 
of S-phase DNA content, as measured in normal low-density blood cells of 8 
healthy volunteers (mean 0.07%). 
Considerable differences in percentages of cells with S-phase content were seen 
between the four main bone marrow subpopulations (Ρ < .0001). The erythroid 
hematopoietic lineage showed the highest proportion of S- phase DNA cells 
(26.4% ±4.7), the lymphoid lineage the lowest (2.5% ±0.8) while the monocytic 
lineage (6.1% ± 0.9) and the myelomonocytic lineage (8.5% ± 1.4) were in between. 
Within the lymphoid lineage the percentage of S-phase cells was significantly 
lower in T-cells (2.0% ± 0.7) compared with B-cells (5.1% ± 1.5) (P < .0001). 
We conclude that bivariate measurement of S-phase DNA content and s-IF is 
feasible with use of a single laser flow cytometer and that dais approach provides 
important additional biological information. The value of this method to study 
hematologic malignancies is demonstrated in a bone marrow sample from a patient 
with erythroleukemia. 
Chapter 2 
Ш Introduction 
Measurement of 5-phase DNA content by flow cytometry (S-DNA FCM) has been 
widely used as an indicator of proliferative activity in hematopoietic cell popula­
tions. Although some restrictions have to be made due to overestimation of the S-
phase caused by arrested S-phase cells [1], the ease of the method has resulted in a 
widespread application in hematologic malignancies [2-7]. However, one of the 
major restraints of S-DNA FCM is that the heterogeneous composition of hemato­
logical cells requires relevant information about distinct cell subpopulations. 
The availability of monoclonal antibodies (MoAbs) directed against specific cell-
surface antigens, in combinations with the immunofluoresence technique, has ena­
bled the detection of distinct subpopulations by FCM [8,9]. Several investigators 
have reported methods for simultaneous staining of DNA content and cell-surface 
markers. Loken et al. [10] used the vital DNA stain Hoechst 33342 in combination 
with cell-surface immunofluorescence (s-IF). Recently they described an improved 
method using paraformaldehyde fixation and subsequent detergent treatment [11]. 
However, a widespread application of this method is restricted due to the require­
ment for a dual laser flow cytometer. 
For non-vital DNA dyes special procedures have to be applied to permealize the 
cell membrane, while preserving s-IF. Ethanol fixation for subsequent DNA stain­
ing after s-IF resulted in cell clumping [12] and/or non-specific immunofluore­
scence [13], whereas pretrearment with paraformaldehyde is laborious and re­
sulted in a broadening of the DNA histogram [13,14]. Simultaneous fixation of cells 
in paraformaldehyde and permeabilisation by lysolecithin resulted in cell recover­
ies less then 50% and broad DNA histograms with coefficients of variation (CVs) of 
8-10% [15]. Jackson et al. showed that, on unfixed rat megakaryocytes, s-IF was 
retained after DNA staining with propidium iodide (PI) in hypotonic citrate solu­
tion [16]. 
In this paper we present the results of s-IF and subsequent hypotonic PI staining on 
human bone marrow using a large panel of monoclonal antibodies. The influence 
of the combined protocol on s-IF as well as DNA staining was tested and S-phase 
DNA content of the four main hematopoietic lineages were determined in ten 
normal individuals. The potential power of this method for studying leukemias is 
demonstrated in a bone marrow sample from a patient with erythroleukemia. 
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Ш Materials and Methods 
Cell Separation 
Bone marrow aspirates from ten healthy volunteers and one patient with erythro-
leukemia were collected in sterile buffered acid-citrate dextrose formula A (pH 7.0). 
Simultaneously, a peripheral blood sample was drawn for the calculation of pe­
ripheral blood admixture [17]. Only bone marrow aspirates with less than 15% 
nucleated peripheral blood cell admixture were used. For detection of the lower 
limit of S-phase, blood samples from 8 healthy volunteers were used. 
Low-density blood and bone marrow cells were collected by density centrifugation 
on Ficoll-Isopaque (1.077 g/ml; Pharmacia, Uppsala, Sweden). The nucleated cells 
from the interphase were washed in buffer (phosphate-buffered saline, containing 
1% bovine serum albumin and 0.1% sodium azide) and resuspended at 5 χ IO6 
cells/ml in buffer containing 20% human pooled serum. 
Monoclonal Antibodies (MoAbs) 
The following MoAbs were used: OKT11 (CD2; Ortho Diagnostic Systems, Rari tan, 
New Jersey); MCA 233 (anti-glycophorin-A; Instruchemie, Hilversum, The Nether­
lands); My7 (CD13), My4 (CDU), B4 (CD19), and My9 (CD33) (Coulter Corpora­
tion, Hialeah, Florida). 
Cell-Surface Immunofluorescence (s-IF) 
Bone marrow subpopulations were discriminated by indirect immunofluore­
scence. Briefly, a saturating concentration of MoAb was added to the cell suspen­
sion and the cells were incubated for 30 minutes at 4°C. After washing, cells were 
incubated with FITC-conjugated goat anti-mouse IgG F(ab')2-fragment (GAM-
FTTC; American Qualex International, La Mirada, California) in buffer containing 
20% human pooled serum. Cells incubated with GAM-FITC only served as control 
to detect non-specific immunoglobulin binding. Cell suspensions were washed, 
resuspended in 1 ml buffer and divided over two tubes. The content of one tube 
was analysed for s-IF and light scatter, the other was processed further for s-IF and 
DNAFCM. 
Chapter 2 
Hypotonic DNA Staining 
The cells were spun down (400 g, 5 min at 5°C), the supernatant was discarded and 
the pellet placed on ice for 10 minutes. Subsequently 900 μΐ of an icecold hypotonic 
PI solution [18], containing 25 μg/ml PI (Calbiochem, San Diego, California), 0.1% 
w/v tri-sodium citrate dihydrate (Merck, Darmstadt, Germany), 10% v/v RNA-se 
solution (RNA-se A, Sigma, St. Louis, Missouri; 1 mg/ml in phosphate buffered 
saline with 0.5 mM EDTA) and 0.1% v/v Triton X-100 in distilled water, was 
added. Cells were kept overnight on ice and analysed for DNA and s-IF. 
Cell Recoveries 
The effect of hypotonic DNA staining upon cell recoveries of nucleated low-density 
bone marrow cells was tested by cell counting before and after hypotonic PI 
staining for 24 h on ice with a Coulter Counter ZF (Coulter Electronics LTD, Luton, 
England). 
Flow Cytometry 
Cells were analysed on a flow cytometer (50H Cytofluorograf, Ortho Diagnostic 
Systems, Westwood, California). The 488 nm line of a 5-W Argon ion laser at 0.4 W 
output was used for excitation and a 0.8 mW HeNe laser for red forward scatter 
(RFS). A high-pass filter RG630 nm for red fluorescence (RFL; DNA content), and a 
bandpass filter 515/30 for green fluorescence (GFL; s-IF), were used. For bivariate 
measurement of GFL and RFL the fluorescent light was separated using a 580 nm 
dichroic mirror. 
A minimum of 20,000 cells was analysed at a flow rate of 100 cells/s. Sheath fluid 
consisted of distilled water. The areas of the GFL, RFL, and RFS were recorded 
linear in list mode on a MINC computer (Digital Equipment, Galway, Ireland) 
using linear converters. To prevent the very bright fluorescent CD14+ and glyco-
phorin-A+ cells going off scale, the GFL of these samples were recorded at a lower 
gain setting. For DNA measurements, besides the area of the signal also the peak 
height of the RFL was recorded in order to discriminate single cells and cell clumps 
[19]. 
The percentages of positive and negative immunofluorescent cells before DNA-
staining were determined in a 256-channel histogram of the GFL. The RFS was used 
to gate out the residual red blood cells. Since red blood cells contains no DNA, 
these cells were not recorded after DNA staining. 
For the bivariate measurement of DNA/s-IF a correction was made for crossover of 
the PI emission in the FITC channel, standardized with samples stained with PI 
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alone. No correction was needed for crossover of the FITC emission in the PI 
channel. Assessment of the percentage positive cells after DNA staining was made 
in a two-dimensional presentation of the list data of RFL versus GFL. 
Calculation of the cell cycle compartments was performed on a 256- channel DNA 
histogram from the overall cell population as well as from the subpopulations 2 
positive for s-IF according to Baisch et al., model 1 [20]. 
From two bone marrow aspirates, cells stained for s-IF only were sorted into an 
immunofluorescence positive and negative fraction. Sheath fluid consisted of phos-
phate-buffered saline. Cells were collected in buffer and cytocentrifuge prepara-
tions were made for staining with May Grünwald-Giemsa. 
•" Statistical Analysis 
Standard variance analyses (ANOVA, Duncan's Multiple Range Test, t- test; SAS 
Institute Inc., Cary, North Carolina) were applied to test differences in the percen-
tage S-phase cells of the distinct subpopulations. 
S Results 
Cell-Surface Immunofluorescence 
In ten separate bone marrow samples of normal individuals, the percentages 
immunofluorescent cells were assessed before and after hypotonic DNA staining. 
The MoAbs used were specific for the erythroid (anti- glycophorin-A), lymphoid 
(CD19 and CD2), monocytic (CD14), and myelomonocytic lineages (CD13 and 
CD33). 
Most of the MoAbs allowed a clear manual discrimination between the positive 
and negative cells as two separate clusters were seen. Only for the dimly stained 
CD13+ samples was no clear discrimination seen. These samples were evaluated 
according to the level set in the control sample. The mean values of false positive 
cells in the controls (incubated with the second step antibody only) before and after 
DNA staining were 1.5% and 1.1%, respectively. The results are listed in Table 1. 
Although hypotonic lysis caused a morphological decrease in cell volume, as well 
as in FCM light scatter signal, the percentage of immunofluorescent cells remained 
essentially unaltered. No decrease in cell recovery was observed after hypotonic 
DNA staining, as tested on low-density bone marrow cells of eight normal controls 
(cell recoveries > 95%). 
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Table 1 
Percentage of Positive Cells Before and After Hypotonic Treatment 
of Bone Marrow Aspirates of 10 Normal Individuals 
Labeled With Different Monoclonal Antibodies 
Monoclonal 
Antibody 
Controlb 
CD2 
CD19 
CD2 + CD19 
Glycophorin-A 
CD14 
CD13 
CD33 
CD13 + CD33 
Before treatment 
mean (%) 
1.5 
17.7 
8.8 
25.0 
5.7 
10.2 
18.5 
58.7 
58.6 
After treatment 
mean3 (%) 
1.1 
17.5 
8.0 
24.6 
6.2 
11.8 
18.7 
56.4 
59.2 
Difference 
mean ± SD (' 
-0.4 (±0.9) 
-0.2 (± 1.8) 
-0.8 (±1.5) 
-0.4 (±2.9) 
+0.5 (±1.2) 
+1.6 (±1.3) 
+0.2 (±4.5) 
-2.3 (±5.4) 
+0.6 (±3.1) 
" Cells were treated with a hypotonic propidium iodide solution, as described in the Materials 
and Methods, 
b Cells iticubated with the second step antibody only. 
For comparison of the mean intensity of the FTTC signal of the fluorescent cells 
before and after hypotonic treatment, the flow cytometer was calibrated using 
fluorescent microspheres and a correction was made for crossover of the PI emis-
sion in the FITC channel. Only a minor decrease in s-IF intensity was seen after 24 h 
of hypotonic DNA staining for the eight (combinations of) MoAb tested: mean 
26.6% (CD2 = 41.5%; CD19 = 24.6%; CD2 + CD19 = 10.5%; glycophorin-A = 16.6%; 
CD13 = 36.6%; CD33 = 29.2%; CD13 + CD33 = 27.8%; CD14 = 29.7%). Figure 1 
shows the s-IF of bone marrow labeled with CD2 before and after hypotonic 
treatment. Although some decrease is observed in mean s-IF intensity after DNA 
staining, there is still a clear discrimination between the positive and negative cells. 
DNA-Staining 
To achieve optimal stoichiometrical DNA staining and for convenience, overnight 
incubation on ice in hypotonic PI was chosen and appeared possible without 
jeopardizing the s-IF. This resulted in excellent DNA histograms with CVs of 2% 
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Fig. 1. Cell-surface immuno­
fluorescence (s-IF) before (A) 
and after (B) hypotonic DNA 
staining of a normal bone mar­
row sample labeled with CD2. 
Although some decrease in mean 
fluorescence intensity is seen, 
there is still a clear discrimina­
tion between positive and nega­
tive cells. 
and lower (Fig. 2 F). The procedure allows the assessment of very low percentages 
of S-phase cells, even in a heterogeneous population such as low-density blood 
cells. S-phase DNA content measured in normal low-density blood cells of eight 
healthy individuals varied from 0.06-0.09% (mean 0.07%). Only few doublets, 
interfering with the calculation of G2+M-phase DNA, were seen, usually less then 
3% of all counted cells. 
Proliferative Activity in Human Bone Marrow Subpopula­
tions 
The percentages of S-phase cells were measured in the four main hematopoietic cell 
lineages, defined by expression of s-IF. The erythroid lineage was defined by 
expression of glycophorin-A [21,22], the lymphoid lineage by a cocktail of CD2 
(pan-T cell marker) [23] and CD19 (pan-B cell marker) [24,25], the monocytic 
lineage by CD14 [26,27], and the myelomonocytic lineage by a cocktail of CD13 
[27,28] and CD33 [29]. s-IF activated cell sorting (on two different occasions) of 
normal bone marrow that had not been stained for DNA, and subsequent mor­
phological examination, showed an enrichment of 85-94% for the different lineages 
in the various positive fractions with only 1-8% of these cells present in the negative 
fraction. Further, using a cocktail of all the MoAbs used (anti-glycophorin-A + CD2 
+ CD19 + CD14 + CD13 + CD33), 97% of low-density human bone marrow cells 
were positive, indicating that these MoAbs cover nearly completely all of the 
human bone marrow cells. 
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The lymphoid lineage was further discriminated into a T-cell subpopulation (CD2) 
and a B-cell subpopulation (CD19), and the myelomonocytic lineage into partially 
overlapping subpopulations of CD13 and CD33 positive cells. 
Figure 2A-E shows the bivariate linear analysis of DNA content versus s-IF of a 
normal bone marrow sample for the (combinations of) MoAbs identifying the four 
main hematopoietic lineages. In order to visualize the non-fluorescent cells in the 
scatter plot, 400 fluorescent units were added to the level of green fluorescence of 
each cell. The horizontal lines indicate the level used for discrimination between 
positive and negative for s-IF. A lower gain setting was used in Figure 2D,E to 
prevent the s-IF going off scale. A clear discrimination is seen between the positive 
and negative cells. The DNA histograms of the positive cells are shown in Figure 
2G-J, from the control sample the DNA histogram of the overall population is given 
(Fig. 2F). 
The mean (± SD) percentage Gì-, S-, and G2+M-phase cells in the bone marrow 
subpopulations of ten healthy individuals are listed in Table 2. The subdivision into 
the four main lineages in respect to the percentage S-phase cells was highly signifi-
cant (ANOVA, P< .0001) with all four levels different among themselves (Dun-
can's Multiple Range Test; α = .05). The erythroid lineage showed the highest 
proportion of S- phase cells (26.4% ± 4.7) and the lymphoid the lowest (2.5% ± 
0.8%). The monocytic lineage was less proliferating (6.1% ±0.9) than the myelo­
monocytic lineage (myelomonocytic1:8.5% ± 1.4%). However the S-phase values of 
these myelomonocytic cells were still significantly lower than of the overall popu­
lation (10.0% ± 1.6; t-test: Ρ = .038). Within the lymphoid lineage the percentage of 
S-phase cells was significantly lower in T-cells (2.0% + 0.7) compared with B-cells 
(5.1% ± 1.5; t-test: Ρ < .0001). Thus, the low percentage of S-phase measured in the 
lymphoid population is mainly due to the T-cells. No significant difference in 
proliferation activity of the strongly overlapping myelomonocytic2 (CD13+) and 
myelomonocytic3 (CD33+) subpopulations were seen (8.9% and 8.7%, respectively; 
Ρ > .05). 
Bivariate Measurement of Cell-Surface Immunofluore­
scence and DNA Content in a Bone Marrow of a Patient 
with Erythroleukemia 
The described method was applied also on a bone marrow aspirate of a patient 
with erythroleukemia. Analysis by s-IF showed a high percentage of glycophorin-
A+ cells (67.7%) and 10.7% and 5.7% expressing CD33 and CD2, respectively. After 
hypotonic treatment the fraction of glycophorin- A+ cells decreased to 47.6%. Part 
of this decrease may be explained by overestimation of the glycophorin-A+ cells in 
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Table 2 
Mean Percentage of G,-, S-, and G2+M-phase Cells in Bone Marrow 
Subpopulations of 10 normal Individuals 
Subpopulation3 
Unfractionated 
Lymphoid 
Erythroid 
Monocytic 
Myelomonocytic1 
T-Cell 
B-Cell 
Myelomonocytic^ 
Myelomonocytic3 
Gl 
86.9 
95.7 
63.5 
91.2 
88.9 
96.7 
92.3 
88.9 
88.5 
S fcfc S.D.) 
10.0 (±1.6) 
2.5 (±0.8) 
26.4 (±4.7) 
6.1 (±0.9) 
8.5 (± 1.4) 
2.0 (± 0.7) 
5.1 (± 1.5) 
8.9 (± 1.6) 
8.7 (± 1.4) 
G2+M 
3.0 
1.7 
9.7 
2.6 
2.6 
1.3 
2.5 
3.1 
2.7 
CVb 
1.8 
1.9 
2.2 
2.2 
1.8 
1.9 
1.8 
2.1 
2.1 
" The subpopulations were identified by a (cocktail) of different MoAbs: Lymphoid (cocktail 
ofCD2 + CD19); Erythroid (anti-glycophorin-A); Monocytic (CD14); Myelomonocytic1 
(cocktail of CD13 + CD33); T-Cell (CDD; B-Cell (COI S); Myelomonocytic2 (COU) and 
Myelomonocytic? (CD33). 
b
 Coefficient of variation of the G^-peak of the DNA histogram. 
the analysis before DNA staining due to the relative high admixture of red blood 
cells in the low-density bone marrow sample from this patient. The ratio between 
the red blood cells and nucleated bone marrow cells was 5:1 and probably the red 
blood cells were not completely gated out by light scatter. This problem occurs 
incidentally after density centrifugation of pathologic bone marrow (own observa-
tions). Since red blood cells have no DNA content, these cells are not included in 
the analysis after hypotonic DNA staining. The fraction of CD33+ and CD2+ cells 
after hypotonic treatment were 13.5 and 7.3%, respectively. 
In Figure 3, the bivariate distribution of s-IF and DNA content of the control and 
samples labeled with CD2, CD33, and anti-glycophorin-A (Fig. 3A-D), the DNA 
histogram of the overall population (Fig. 3E) and the respective positive popula-
tions (Fig. 3F-H) are shown. A lower gain setting is used in Figure 3D to prevent the 
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s-IF going off scale. A clear DNA-aneuploidy is seen in the overall population (Fig. 
3E). The first Gi peak appeared diploid and the second Gi peak hyperploid with a 
DNA-index compared with the diploid T-cells of 1.42. The fraction of aneuploid 
cells, defined as [area second G] peak / (area first Gi peak + area second Gi peak)], 
amounted 65.4%. The anti-glycophorin-A+ cells were 96.7% aneuploid (Fig. 3H). 2 
On the contrary, the CD2+ and CD33+ cells appeared diploid, with an aneuploid 
fraction of only 5.3% and 2.6%, respectively (Fig. 3F,G). 
The percentage of S-phase cells can not be calculated from the overall population 
(Fig. E) because of overlapping DNA-profiles of the diploid and aneuploid popula­
tions. As the glycophorin-A+ cells (Fig. H) were almost completely aneuploid and 
the few diploid cells did not interfere with the DNA profile, the S-phase fraction of 
the aneuploid subpopulation was calculated directly from the DNA histograms. In 
the DNA histograms of the CD2+ (Fig. F) and CD33+ cells (Fig. G), the minor 
admixture of aneuploid cells could affect the calculation of the S-phase percent­
ages. However, the contribution of the contaminating fractions can be estimated 
form the clear and sharp aneuploid Gi peak. The correction is made by substracting 
a proportional amount of the aneuploid DNA profile (Fig. H). But, the corrections 
made are minor, as the enrichment of the diploid population is very high. 
A high percentage of S-phase cells (23.0%) was seen in the aneuploid anti-glyco-
phorin-A+ cells. However, the S-phase fraction of these cells was comparable to 
their counterparts in normal bone marrow (Table 2; 26.4% ± 4.7). The percentage of 
S-phase cells measured in the CD2+ cells (2.7%) corresponded also to their normal 
counterpart cells (2.0% ± 0.7). However, the S-phase fraction of the CD33+ cells 
(5.6%), was lower, than in CD33+ cells in normal bone marrow (8.7% ± 1.4) suggest­
ing a suppression of the normal myelomonocytic lineage. 
Ш Discussion 
The method presented in this paper permits the measurement of the proliferation 
pattern of the four main lineages in bone marrow. Several other approaches have 
been described for simultaneous staining of s-IF and DNA content. Recently, Hol­
lander at al. described an improved method using the vital DNA dye Hoechst 
33342 [11]. Even two color immunofluorescence combined with DNA staining was 
possible [11,30]. However, this method requires a dual laser flow cytometer, emit­
ting at 488 nm and 360 nm. Further, although the DNA staining was improved 
resulting in CVs of the histogram of 4-6.5%, our DNA resolution with hypotonic PI 
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staining, with CVs of 1-2%, permits more exact calculation of S-phase DNA content 
and DNA aneuploidy 
Lakhanpal et al. reported a single laser procedure using pretreatment of peripheral 
blood mononuclear cells with paraformaldehyde followed by ethanol fixation [13]. 
Application of this technique on heterogeneous human bone marrow resulted in 
our hands in very broad DNA histograms, not permitting a reliable determination 
of the cell cycle compartments. 
Since we define subpopulations in human bone marrow by s-IF, the loss of light 
scatter information in our method offers no problem. However, it has been stated 
that light-scattering gating could be necessary for circumventing autofluorescence 
of myeloid cells that interfers with the discrimination of s-IF [31]. In our setting, we 
hardly detected any measurable autofluorescence after hypotonic lysis, probably 
due to loss and/or alteration of intracellular components. Furthermore, the correc-
tion for crossover of the PI emission in the FTTC channel may also partially correct 
for the fraction of green autofluorescence that is correlated with the red autofluore-
scence [32]. 
In some of the subpopulations (like the CD2+ cells and CD19+ cells in normal bone 
marrow and the CD2+ and glycophorin-A+ cells in the bone marrow of a patient 
with erythroleukemia) a somewhat high proportion of G2+M cells was seen in 
comparison with S-phase cells. Although a correction for cell clumps was made 
based on the peak/area ratio of the RFL signal, probably not all doublets are 
excluded. For that reason we have chosen to present the percentages of S-phase 
cells as a parameter for assessment of the proliferation pattern. The DNA histo-
grams of the subpopulations, with low CVs and based on data from 1,500 to 12,000 
cells allow a reliable calculation of S-phase DNA. 
The proliferation activity measured in the various subpopulations in normal bone 
marrow showed the highest percentage of S-phase cells in the glycophorin-A+ 
(erythroid) cells. This is in agreement with the observation of Hollander et al. [11] 
and own observations using a two step procedure of cell sorting and subsequent 
DNA staining (unpublished data). 
A proliferation index (defined as percentage of cells > 2n DNA) of 6% in CD19+ 
cells has been reported [30] which somewhat is lower as found in our study 
(5.1% ±1.5 S-phase cells + 2.5% ±1.7 G2+M-phase cells = 7.6%). This difference 
may be due to biological variations between individuals, by the underestimation of 
S-phase cells by the graphic analysis described in the study of Hollander et ai, and 
the somewhat high proportion of G2+M cells in our study. 
The percentage of CD13+ and CD33+ bone marrow cells was higher than reported 
in other studies [27-29]. The s-IF with these MoAbs is relatively weak and we have 
chosen to include also the dimly labeled cells. Using a cocktail of CD13 and CD33, 
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s-IF intensity was increased resulting in a clear discrimination between positive 
and negative cells. A sorting experiment showed that with this combination the 
entire myelomonocytic lineage was labeled from the myeloblast stage to the meta-
myelocytes, bands and segmented neutrophils, and monocytes. The percentage of 
S-phase cells observed in the myelomonocytic cells (8.5% ±1.4) was 1.5% lower 
than in the overall population. CD13 is predominantly expressed in immature cells 
including myelomonocytic progenitor cells (CFU-GM) [28] whereas CD33 covers 
also the more mature cells [27,28]. However, no significant difference in S-phase 
was seen between CD13+ and CD33+ cells. 
CD14 appears in the course of normal monocyte differentiation but is not detect-
able on the myelomonocytic progenitor cell [26,27]. The monocytic lineage, defined 
by expression of CD14, showed a lower percentage of S-phase cells (6.1 ± 0.9) 
compared with the myelomonocytic lineage (8.5 ± 1.4), which includes also imma-
ture monocytic cells. 
The lowest percentage of S-phase cells in bone marrow was observed in the T-cell 
population (2.0% ± 0.7). This was still significantly higher than the lower detection 
limit in low-density blood cells (mean: 0.07%). A S- and G2+M-phase percentage of 
only 0.5% of mature T-cells in bone marrow has been reported [11]. This suggests 
that immature T-cells contribute mainly to the proliferation activity measured in 
the T-cell population. 
The method described here is relatively simple and suitable for a single-laser flow 
cytometer and is in principle also applicable for studying the proliferative activity 
of different maturation stages and smaller subpopulations within these four line-
ages, using other MoAbs. This protocol is now implemented in routine cell-surface 
immunophenotyping in leukemia at our institute. Preservation of s-IF appeared to 
be maintained also with other MoAbs, like WT1 (CD7); OKT1 (CD5); OKT3 (CD3); 
OKT4 (CD4); OKT8 (CD8); Bl (CD20); J5 (CD10); EA3 (CD10); BAI (CD24); OKDR 
(HLA-DR); OKT10 (CD38); OKT9 (transferrine); BOM; MylO (CD34); Glycophorin-
IIB/IIIA; WT14 (CD14); OKM5. Insight in the proliferative pattern of these pheno-
types may be very important to characterize abnormal bone marrow, to monitor 
treatment effects (biological response modifiers, e.g. growth factors, and cell cycle 
specific drugs like Ara-C) and to add to our knowledge of cellular maturation and 
proliferation in leukemia. 
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S-Phase DNA Content in Subpopulations of Leukemie Bone Marrow 
S Abstract 
One of the major limitations of DNA flow cytometry (FCM) in hematologic malig-
nancies is the lack of information about the proliferation activity of subpopulations 
of the heterogeneous bone marrow (BM) compartment. We studied the S-phase 
DNA content of immunophenotypically defined BM subpopulations (CD2+; 
CD19+; CD2/CD19+; glycophorin-A+; CD14+; CD13+; CD33+, and CD13/CD33+) 
in 18 patients with acute myeloid leukemia (AML), including three patients with 
M6 AML. The results were compared with the findings in twelve normal BM 
aspirates. The measurements were performed using a special protocol for bivariate 
FCM of DNA content and cell-surface immunofluorescence (s-IF). In patients with 
AML the proportion of BM cells expressing the myelomonocytic and monocytic 
markers (M1-M5 AML) or erythroid marker (M6 AML) was expanded. However, 
in many patients other subpopulations were 4% or higher permitting the calcula-
tion of their S-phase DNA. No essential differences in median S-phase DNA per-
centages of the distinct subpopulations were observed between normal and leuke-
mic bone marrow though the ranges in AML patients were much wider. These data 
suggest that AML is not characterized by an increased nor a decreased proliferation 
activity, but rather by a situation of cell growth independent to the normal regula-
tory mechanisms. Additional information was obtained upon DNA aneuploidy 
using CD2+ or CD2/CD19+ cells as an intrinsic DNA standard which allowed us to 
define differences in the DNA index as small as 2% as aneuploid. This approach 
appeared suitable for detecting small-degree numerical chromosomal aberrancies, 
as found by cytogenetics, in 4/6 cases. 
• Introduction 
Proliferation activity of hematologic malignancies has been studied for many years 
with the perspectives that this information could be of prognostic relevance and 
that knowledge of proliferation in normal and malignant hematologic tissues may 
lead to a more rational use of common and novel therapeutical modalities. 
One of the most commonly used parameters of proliferative activity is the percent-
age of cells with S-phase DNA content measured by flow cytometry (FCM) [1]. 
Although overestimation of the DNA synthesizing fraction due to arrested S-phase 
cells incidentally has been described [2], the ease of the method has led to a 
frequent use of DNA FCM in the study of adult acute leukemia [3-8]. DNA FCM is 
less time consuming and better reproducible than autoradiography determining 
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the percentage of cells incorporating 3H-thymidine, and does not require the use of 
radioisotopes [9-12]. Cell kinetics studied with non-radioactive thymidine ana-
logues like bromodeoxyuridine or iododeoxyuridine, provides information about 
additional kinetic parameters like the DNA synthesis time. This method is rela-
tively laborious, necessitates the in vivo administration of these synthetic DNA 
precursors and requires an optimal sampling time [13-16]. 
One of the major limitations of DNA FCM and of cell kinetic studies with iodo-
deoxyuridine or bromodeoxyuridine is the lack of information about the prolifera-
tion activity of distinct subpopulations. As human bone marrow (BM) is a hetero-
geneous composition of subpopulations belonging to different hematologic cell 
lineages, insight in the kinetics of the distinct subpopulations is obligatory for the 
understanding of normal and malignant cell growth. Moreover, in cases of DNA 
aneuploidy, common in acute myeloid leukemias [4,17], the calculation of S-phase 
DNA content can be jeopardized by overlapping DNA histograms of the aneuploid 
and residual diploid population which necessitates a separate DNA analysis of 
these fractions. 
Measurement of cell-surface immunofluorescence (s-IF) has enabled the detection 
of immunophenotypically defined subpopulations in human BM [18,19]. Recently 
we reported the application of a single laser flow cytometric method for simultane-
ous measurement of s-IF and DNA content in hematopoietic cells [20]. By combin-
ing DNA staining with a hypotonic propidium iodide solution and s-IF staining 
with a panel of monoclonal antibodies (MoAb) we were able to measure S-phase 
DNA content of distinct subpopulations in BM aspirates of normal individuals. 
Furthermore, with this cytometric protocol the DNA index can be calculated with-
out addition of an external DNA standard, using the non-malignant lymphocytic 
subpopulation as an intrinsic reference. 
In this paper we report the results obtained in 18 patients with AML, including 
three patients with erythroleukemia. We describe the immunophenotypic compo-
sition of the leukemic BM samples and the proportion of S-phase cells within the 
distinct immunophenotypic subpopulations. These results are compared with the 
findings in twelve normal BM aspirates. Finally, we relate determination of DNA 
aneuploidy by combined measurement of s-IF and DNA, to the outcome of cyto-
genetic studies. 
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Ш Materials and Methods 
Patients 
BM aspirates were obtained from twelve healthy volunteers and eighteen patients 
with AML at first presentation. None of the patients had received chemotherapy or 
immunosuppressive treatment prior to diagnosis. The diagnoses and morphologic 
subclassification were made according to the FAB classification [21] and confirmed 
by the Netherlands Bone Marrow Committee, Rotterdam. FAB subtypes were: Ml 
(»ι = 2); M2 (» = 4); M3 (н = 1); M4 (и = 5); M5 (и = 3) and Мб (и = 3). Median age 
of the leukemic patients was 50 years (range 23-81 years) and of the normal 
volunteers 58 years (range 39-71 years). The median percentage of leukemic blasts 
in the BM smears of the patients was 50% (range 12-91%). The admixture of 
peripheral nucleated blood cells in the BM aspirates was determined according to 
the method from Holdrinet et al. [22]. The median values were 13% (range 3-33%) 
and 15% (range 1-40%) for normal and AML BM, respectively. 
Monoclonal Antibodies 
The following MoAbs were used: OKT11 (Ortho Diagnostic Systems, Raritan, New 
Jersey); MCA 233 (Instruchemie, Hilversum, The Netherlands); My7, My4, B4, and 
My9 (Coulter Corporation, Hialeah, Rorida). The antibodies with their cluster 
designation [19], their specificity and references [23-31] are listed in Table 1. 
Staining of DNA Content and Cell-Surface Immunofluore­
scence 
Simultaneous staining of DNA and s-IF was performed as described previously 
[20]. Briefly: From the BM aspirates the low-density cells (< 1.077 g/ml) were 
collected by density centrifugation and stained for indirect immunofluorescence 
using the MoAbs listed in Table 1. A FITC-conjugated goat anti-mouse IgG F(ab')2 
fragment (GAM-FITC; American Qualex International, La Mirada, California) was 
used as second step fluorescent antibody. Cells incubated with GAM-FITC only, 
served as control to detect non-specific immunoglobulin binding. Cell suspensions 
were divided over two tubes. The cells of one tube were used for measurement of s-
IF before DNA staining and analyzed within 3 h after the last incubation step. The 
cells of the other tube were stained for DNA, using an overnight incubation on ice 
with a hypotonic propidium iodide solution, and analyzed for combined measure­
ment of DNA content and s-IF. 
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Cluster 
designation 
CD2 
CD19 
CD2/CD19 
• CD14 
CD13 
CD33 
CD13/CD33 
— 
Table 1 
(Cocktails of) Monoclonal Antibodies Used 
MoAb 
OKT11 
B4 
ΟΚΤΠ + B4 
My4 
My7 
My9 
My7 + My9 
MCA 233 
glycophorin-A 
Specificity 
Pan-T cell (rosette receptor) 
Pan-B cell 
Pan-T + pan-B cell 
Pan-monocyte 
Monocytes; myelomonocytic 
progenitors; immature (+ 
mature) myeloid cells 
monocytes; myelomonocytic 
progenitors; immature + 
mature myeloid cells 
Monocytes; myelomonocytic 
progenitors; immature + 
mature myeloid cells 
Erythroid precursors; 
erythroid cells 
Reference 
[23] 
[24,25] 
[26,27] 
[27-29] 
[28] 
[30,31] 
Flow Cytometry 
Cells were analyzed on a flow cytometer (50H Cytofluorograf, Ortho Diagnostic 
Systems, Westwood, California) equipped with a 5 W Argon ion laser for simulta­
neous excitation of green fluorescence representing s-IF, and red fluorescence 
representing DNA content. A HeNe laser of 0.8 mW was used for detection of the 
forward scatter signal measuring cell size. After DNA staining the residual red 
blood cells were gated out based upon their lack of DNA content. Before DNA 
staining Ulis was done by gating on the light scatter signal. Filter settings, data 
storage of the linear signals and correction for fluorescence crossover have been 
described previously [20]. A minimum of 20,000 cells were analyzed for s-IF and 
DNA content. For the DNA analyses cell doublets were excluded based upon the 
ratio area / peak of the DNA signal [32]. 
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Estimation of S-IF 
The percentages of positive immunofluorescent cells before DNA-staining were 
determined from a 256-channel histogram of the green fluorescence and after DNA 
staining from a two-dimensional presentation of the list data of the red fluores­
cence vs green fluorescence. In most cases the clear discrimination between the 
positively and negatively labeled cells allowed a manual discrimination between 
these two populations. Only for the dimly stained samples (usually CD13+ and 
incidentally CD19+ and CD33+) the discrimination was set according to the level 
obtained from the control sample. 
Measurement of S-Phase DNA Content in BM Subpopula­
tions 
Only subpopulations which amounted at least 4% of the overall population were 
included for detection of the S-phase fraction. This arbitrary level was chosen to 
avoid inclusion of small subpopulations with a relatively large admixture of non­
specific fluorescent cells. Calculation of S-phase DNA was performed according to 
the method of Baisch et al., model 1 [33]. 
Measurement of the DNA Index 
Measurement of the DNA index was performed using non-malignant autologous 
T-lymphocytes (CD2+) or Τ + B-lymphocytes (CD2/CD19+) as an intrinsic diploid 
reference. The DNA index was calculated as [Go-Gi peak channel of the negative 
fraction / Go-Gi peak channel of the positive lymphoid reference fraction]. In one 
patient with a M4 AML no labeling with lymphocytic markers was done and in this 
patient the glycophorin-A+ cells were used as reference. For comparison of this 
new approach of DNA indices determination with a more conventional method, 
the DNA index was also calculated using chicken red blood cells as a standard in 
7/12 normal BM samples. 
Cytogenetics 
Chromosome studies on non-stimulated BM samples of all the patients with acute 
myeloid leukemia were performed at the Department of Human Genetics of our 
institute by Dr D. Smeets. Preparations were G-banded. In all but one cases at least 
15 metaphases were analyzed. In the latter case only three metaphases could be 
analyzed which showed a normal karyotype. 
51 
Chapter 3 
Statistics 
The Mann-Whitney U test, a non-parametric test for two independent samples, was 
employed to test differences in percentages of S-phase cells of the distinct subpopu­
lations between normal and M1-M5 leukemic bone marrow. The number of pa­
tients with M6 AML was to small for statistic analysis. 
Ш Results 
. Cell-Surface Immunofluorescence 
s-IF after DNA staining of low-density human BM cells labeled with different 
MoAbs is shown in Figure 1. In each column the data of one MoAb are shown. 
Within each column the circles indicate the results in normal BM cells, the triangles 
BM cells from AML M1-M5 and the rectangles BM cells from AML Мб. The median 
values, the range and the number of observations are listed in columns 2-4 of Table 
2. No essential difference was observed between the percentages immunofluore-
scent cells before and after DNA staining [20]. 
Obviously the immunophenotypic composition of normal low-density BM is rather 
heterogeneous with a wide range in percentage positive cells for the MoAbs used. 
The CD33+ and CD13/CD33+ cells represent the major subpopulations. Neverthe­
less, in all cases the other subpopulations (CD2+, CD19+, CD2/CD19+, glycopho-
rin-A+, CD14+ and CD13+) were at least 4%. 
As expected, the BM from patients with M1-M5 AML showed higher median 
percentages of the myelomonocytic (CD13+; CD33+ and CD13/CD33+) and mono­
cytic markers (CD14+) in comparison with normal BM. However in many patients 
other subpopulations were 4% or higher: CD2 8/13; CD2/CD19 8/8 and glycopho-
rin-A 8/15. In one patient there was evidence for a biphenotypic leukemia as the 
BM consisted of 50% cells expressing the CD19 antigen and 80% expressing the 
CD33 antigen. The CD19+ subpopulation of this patient was excluded for measure­
ment of S-phase DNA content, labeling with a cocktail of CD2 and CD19 was not 
performed. 
This study includes three cases of M6 AML. The first one was examined with a 
panel of only four MoAbs: CD2; CD19, glycophorin-A and CD33. In concordance 
with the morphological classification all cases demonstrated a high percentage of 
cells positive for the erythroid marker glycophorin-A. But still minor subpopula­
tions positive for the T-lymphoid and (myelo)-monocytic markers were present. 
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Fig. 1. Cell-Surface immunofluorescence of normal and acute myeloid leukemic bone 
marrow. In each column the data of one monoclonal antibody are shown. Within each 
column the values of individual patients are presented: Circles, normal bone marrow; 
triangles, M1-M5 AML; rectangles, M6 AML. The median of each group is repre­
sented by a horizontal line. 
DNA Aneuploidy and Cytogenetics 
The low CVs of the Go/Gi peak in the DNA histograms (usually 1.5-3%) allowed a 
sensitive assessment of DNA aneuploidy. When using the lymphocytic subpopula­
tion as an intrinsic reference, the mean DNA-Index (DI) of the CD2-negative cells in 
normal BM was 1.005. The coefficient of variation (.007, и = 12) was small as 
compared with ducken red blood cells as reference (.032, и = 7). Based on the 
findings in normal BM samples, we defined DNA aneuploidy if the DI was out of 
the range of the mean normal DI ± 3 χ standard deviation: 0.984-1.026. DNA 
aneuploidy was observed in 6/18 patients (DI: 0.974; 0.975; 1.036; 1.036; 1.041; 
1.420). Only in one case evidence of DNA aneuploidy was seen in the histogram of 
the overall population, exhibiting two separate Gj peaks. In the other cases no 
doubling of Gi peaks were observed. Table 3 shows the relation with cytogenetic 
aberrations. 
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Table 2 
Cell-Surface Immunofluorescence and S-phase DNA Confenf of Distinct 
Immunophenotypic Subpopulations in Normal and Leukemic Bone Marrow 
MoAb 
Overall 
Blanc 
CD2 
CD19 
CD2 + CD19 
Glyco-
phorin-A 
CD14 
CD13 
CD33 
CD13 + CD33 
Normal 
. 
-
-
1.0Í 
(0.2-2.5) 
12 
16.6 
(8.4-28.3) 
12 
7.9 
(4.2-10.7) 
12 
23.4 
(16.6-31.5) 
12 
6.3 
(3.6-11.6) 
12 
11.5 
(7.5-17.2) 
12 
17.7 
(13.0-24.9) 
12 
53.8 
(43.0-69.2) 
12 
58.4 
(47.0-69.9) 
12 
S-1F(%) 
Ml-5 AML 
-
-
-
0.6 
(0.3-3.0) 
15 
5.8 
(1.5-22.1) 
13 
1.8§ 
(0.8-50.0) 
13 
5.2 
(3.9-18.2) 
8 
4.5 
(0.2-13.7) 
15 
15.7 
(1.0-78.8) 
13 
31.0 
(0.8-79.4) 
14 
63.6 
(5.5-90.7) 
15 
71.5 
(44.6-94.6) 
13 
M6AML 
. 
-
-
1.4 
(0.7-1.8) 
3 
73 
(3.1-11.8) 
3 
3.2 
(2.4-3.4) 
3 
103 
(4.7-15.9) 
2 
41.1 
(31.2-47.6) 
3 
3.1 
(1.8-4.4) 
2 
19.6 
(11.7-27.5) 
2 
13.5 
(11.1-30.7) 
3 
26.5 
(21.8-31.2) 
2 
S-phase DNA (%) 
Normal 
10.8 
(7.8-13.1) 
12-12* 
-
-
-
1.9 
(1.1-3.3) 
12-12 
4.8 
(2.7-7.8) 
12-12 
2.4 
(1.4-4.0) 
12-12 
29.2 
(19.4-33.1) 
12-12 
5.8 
(3.4-7.4) 
12-12 
8.8 
(5.6-12.2) 
12-12 
9.0 
(6.9-11.7) 
12-12 
8.8 
(7.0-11.2) 
12-12 
Ml-5 AML 
6.9 
(2.3-28.0) 
15-15 
-
-
-
1.4 
(0.9-2.8) 
13-8 
-
-
13-0§ 
3.2 
(1.2-10.4) 
8-8 
29.4 
(14.6-35.2) 
15-8 
7.8 
(4.2-28.6) 
13-9 
7.0 
(1.1-31.3) 
14-13 
7.2 
(1.1-27.6) 
15-15 
6.5 
(2.8-29.5) 
13-13 
M6AML 
11.6 
(4.6-18.5) 
3-2+ 
-
-
-
22 
(1.7-2.7) 
3-2 
-
-
3-0 
2.6 
(2.5-2.8) 
2-2 
23.0 
(11.5-33.1) 
3-3 
3.2 
-
2-1 
4.6 
(4.0-5.2) 
2-2 
8.3 
(2.5-13.5) 
3-3 
6.6 
(2.5-10.7) 
2-2 
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Table 3 
Comparison of DNA aneuploidy with cytogenetic findings0 
Numerical aberrant Numerical normal 
karyotype karyotype 
FCM aneuploid 5 1 
FCM diploid 2 10 
" DNA aneuploidy was determined using CD2+ or CD2/CD19+ cells as an intrinsic 
reference. According to the findings in normal bone marrow a DNA Index out of the range 
of 0.984-1.026 was defined as aneuploid. 
S-phase DNA Content 
The percentages of S-phase cells of the distinct immunophenotypic subpopulations 
are shown in Figure 2. The S-phase DNA values of the overall population are 
shown in the first column. In the other columns the data of the different immuno-
phenotypic subpopulations are shown. Within each column the circles indicate the 
results in normal BM cells, the triangles BM cells from M1-M5 AML, and the 
rectangles BM cells from M6 AML. The median values, the range and the number 
of observations are listed in columns 5-7 of Table 2. As stated in the Materials and 
Methods section, S-phase DNA was analyzed in subpopulations which amounted 
at least 4% of the overall population only. 
The proportion of S-phase cells of the overall population was lower in BM samples 
from M1-M5 AML than from normal volunteers (6.9% vs 10.8%, respectively). 
Legend to Table 2 
* Median value, range, number of observations and number of subpopulations évaluable for 
S-phase DNA content. Only subpopulations which amounted at least 4% of the overall 
population were included for detection of the S-phase fraction. 
t From one patient no S-phase DNA content of the overall population coidd be calculated due 
to a DNA aneuploidy with overlapping DNA histograms. 
t Median value, range and number of observations. 
§ In one patient there was evidence for a biphenotypic leukemia with 50% of the cells 
expressing the CD19 antigen and 80% expressing the CD33 antigen. The CD19+ 
subpopulation of this patient was excluded for measurement of S-phase DNA content. 
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Fig. 2. Percentages S-phase cells of immunophenotypic subpopulations of normal and 
acute myeloid leukemic bone marrow. The data of the overall population are shown in 
the first column. In each other column the data of one subpopulation are shown. Only 
subpopulations which amounted at least 4% of the overall population were included for 
detection of the S-phase fraction. Within each column the values of individual patients 
are presented: Circles, normal bone marrow; triangles, M1-M5 AML; rectangles, M6 
AML. The median of each group is represented by a horizontal line. 
However a wide range was seen within the M1-M5 cases, completely overlapping 
the S-phase DNA values measured in normal BM aspirates. From one patient with 
AML Мб S-phase DNA of the overall population could not be calculated due to 
DNA-aneuploidy with overlapping DNA histograms. From the remaining two 
patients the percentage of S-phase cells of one patient was within the range of 
normal BM, the other exceeded the upper level. 
The lowest level of S-phase DNA was observed in T-lymphoid (CD2+) and Τ + B-
lymphoid (CD2/CD19+) cells in all the three patient categories. No data from S-
phase DNA values of B-lymphoid (CD19+) cells in M1-M5 AML and M6 AML 
could be calculated as this subpopulation was always < 4%. The S-phase DNA 
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values of the CD19+ cells from the patient with biphenotypic leukemia, was ex­
cluded from the analysis. 
The highest proportion of S-phase cells was found in the cell-population expressing 
the erythroid marker glycophorin-A. Again a remarkable similarity was noticed 
between BM from normal volunteers and M1-M5 AML with median S-phase DNA 
values of 29.2 and 29.4, respectively. This indicates that, although in 7/15 M1-M5 
cases this cell pool was below the level of 4%, the proliferation activity of glycopho-
rin-A+ cells in the remaining patients was essentially comparable to the situation in 
normal BM. Also the median S-phase DNA content of glycophorin-A+ of patients 3 
with M6 AML (23.0%) was close to the value observed in normal BM. 
There was only a modest decrease of the median percentages S-phase cells of the 
three myelomonocytic subpopulations (CD13+; CD33+ and CD13/CD33+) in Ml-
M5 AML in relation to their immunophenotypic counterparts in normal BM (differ­
ences: 1.8-2.3%). But unlike the situation in normal BM, showing a relatively small 
range, S-phase DNA values of these subpopulations showed greater variations. 
Due to the predominance of these subpopulations in M1-M5 AML, the mean S-
phase DNA content of these cells were almost identical to the values measured in 
the overall population (differences: 0.1-0.4%). In normal BM median S-phase DNA 
levels of these subpopulations were somewhat lower than the levels measured in 
the overall population (differences: 1.8-2.0%). The median S-phase value of the 
CD33+ cells in patients with M6 AML was also close to the value in normal BM. In 
only two patients S-phase DNA of CD13+ and CD13/CD33+ cells was measured. 
Finally, median S-phase DNA of the monocytic lineage was somewhat higher in 
M1-M5 AML, with two outliers in the upper level, than in normal BM (7.8% and 
5.8%, respectively). Only in one case of AML Мб a CD14+ population > 4% was 
present. 
Statistics 
Statistical analysis revealed no significant differences in median S-phase percent­
ages of the different subpopulations between BM samples from normal volunteers 
and patients with M1-M5 AML (Ρ > .10), except for the CD14+ subpopulation 
which appeared weak significant (P = .033). 
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Ш Discussion 
For a better understanding of leukemic cell growth a comparison between the 
proliferation activity of normal and leukemic BM cells is obligatory. To study this 
relationship the measurement of S-phase DNA of the overall population is a fast, 
objective and reproducible aid but at the same time also a very crude approach. 
Because of the cellular heterogeneity of human BM, separate information about the 
distinct hematopoietic cell lineages is needed. In our study this was realized by 
simultaneous measurement of s-IF and S-phase DNA. This approach required a 
special staining protocol suitable for human BM cells in order to achieve optimal 
DNA staining without affecting s-IF of the different MoAbs [20]. 
A continuing growing panel of MoAbs offers the possibility for an objective dis­
crimination of numerous, yet partially overlapping, subpopulations in BM [18,19]. 
We have chosen a panel of MoAbs to discriminate the main four cell lineages: 
erythroid, lymphoid, monocytic and myelomonocytic, plus the T- and B-lymphoid 
cells. In this setting the proliferation activity of the lineage involved in the leukemic 
transformation (e.g. erythroid lineage in M6 AML) as well as the residual cells of 
the other lineages could be studied and compared with the situation in normal BM. 
This study is actually the first report on S-phase DNA measurement in immuno-
phenotypically defined subpopulations in BM from patients with AML. In previ­
ous studies, using 3H-thymidine incorporation, the proliferation activity of mor­
phologically defined subpopulations have been compared, between leukemic and 
normal myeloblasts. A lower labeling index of leukemic blasts was reported in 
comparison with their morphologic counterparts in normal BM [34-36]. But as Ml-
M5 AML is characterized by a block in the differentiation of myeloblastic cells to 
mature myeloid cells, it is questionable to compare the labeling index of these cells 
with their morphologic counterparts in normal BM. Such a comparison would 
merely reflect changes in cell differentiation than changes in cell proliferation [3]. In 
our setting a comparison was made between the S-phase DNA content of the 
distinct hematopoietic lineages in normal and AML BM in order to study solely 
changes of proliferation activity. 
As expected, in patients with M1-M5 AML the main proportion of BM cells con­
sisted of cells expressing the myelomonocytic and monocytic markers. This ex­
plains the similarity in the percentages in S-phase cells of the overall population 
and these subpopulations. Despite the relatively large range, the median S-phase 
DNA values of the leukemic involved lineages (myelomonocytic, M1-M5 AML; 
erythroid, M6 AML) were close to the values measured in their immunophenotypic 
counterparts in normal BM. This suggests that the leukemic transformation in this 
disease can not be characterized by an increased nor a decreased proliferation 
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activity. Nevertheless, looking to individual cases, in some patients there was a 
clear deviation from normal values, to both lower and higher levels of S-phase 
DNA. This may rather reflect a situation of uncontrolled, autonomous cell growth, 
independent from the fine regulatory mechanisms as seem to exists in normal BM. 
The heterogeneous and unpredictable proliferation response after stimulation with 
hematopoietic growth factors of leukemic BM in comparison with normal BM 
would support such a conclusion [37]. In several M1-M5 AML patients the leuke-
mic non-involved lineages (lymphoid, T-lymphoid, B-lymphoid and erythroid lin-
eages) were smaller than 4%, beyond the lower limit for measurement of S-phase 3 
DNA. However, in those cases where S-phase DNA measurement was possible, 
there was also a remarkable similarity in the percentage S-phase cells of the non-
involved lineages in comparison to the values observed in normal BM. Despite the 
normal proliferation activity, as estimated by S-phase DNA content, the cell pro-
duction might be decreased due to a reduction of the relative proportion of these 
lineages. A decreased relative cell production of erythroblasts (cell production per 
1000 nucleated bone marrow cells) has been described in a study of five patients 
with AML [36]. This was explained by intramedullary cell loss of mature erythro-
blasts. 
The immunophenotypic discrimination of hematopoietic lineages in leukemic BM 
could be jeopardized by aberrant co-expression of cell-surface antigens of different 
lineages on leukemic cells [38,39]. Aberrant expression of CD2 or CD19 is however 
uncommon in AML and accounts for only 2-5% of the cases [40,41]. In our series of 
20 patients only one case of biphenotypic leukemia with large co-expression of 
CD19, CD13 and CD33 was observed. Of the other leukemic patients, the non-
involved lineages were rather small, and were considered to be residual normal 
cells. 
All measurements were performed on marrow aspirates instead of marrow biop-
sies as this way of sampling causes only minor discomfort to the patient. Uncon-
trolled contamination of peripheral blood cells in the marrow aspirates may affect a 
reliable measurement of S-phase DNA [22,42,43]. The peripheral admixture of 
nucleated blood cells was calculated in all the unseparated aspirates and appeared 
relatively small (median values: 13 and 15% for normal and AML BM, respec-
tively). The peripheral blood admixture was further reduced by collecting low-
density BM cells using density gradient centrifugation. This physical separation 
method eliminates the mature myeloid cells, which are preferentially present in the 
peripheral blood. 
One of the gains of combined measurements of DNA and s-IF is that it provides an 
intrinsic reference for detection of DNA aneuploidy. Therefore this standard meets 
perfectly the criteria for the ideal reference cells: "an individual and tissue specific 
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reference" (44]. In our study the subpopulations of T- or Τ + B-Iymphoid cells 
served as reference. A similar approach has been described in malignant B-cell 
lymphoma [45]. According to the small range of the DI in normal BM, deviations of 
the DI of more than 2% can be defined as aneuploid. This allowed us to detect DNA 
aneuploidy in four cases with only cytogenetically small-degree numerical chro­
mosomal aberrancies in addition to one case with large-degree aberrancies. In both 
the FCM and cytogenetic analysis two were hypodiploid and three hyperdiploid. 
One false negative FCM result could be explained by an equal mixture of normal 
cells and cells with a monosomy 16 associated with a trisomy 11, resulting in a near 
diploid DNA content. In the other case with a false negative FCM result a normal 
karyotype was found in the majority of the cells while only few cells showed a 
trisomy 21, one of the smallest chromosomes. In only one patient a normal karyo­
type was found while FCM revealed a DNA aneuploidy (DI: 1.036). A selection of 
only proliferating diploid cells by the cytogenetic analysis can not be excluded. 
In conclusion: (1) simultaneous measurement of S-phase DNA content of distinct 
immunophenotypic subpopulations in normal and leukemic BM contributes to our 
knowledge of normal and malignant hematopoiesis and (2) it provides an intrinsic 
DNA-reference suitable for studying low- degree numerical chromosomal aberran­
cies. 
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Pepsin in 2N HCl for BrdUrd/DNA Analysis 
Ш Abstract 
This report describes an immunocytochemical procedure for the simultaneous 
quantification of bromodeoxyuridine (BrdUrd) incorporated into cellular DNA 
and total DNA content in individual cells in suspension. Improvement of existing 
methods was achieved by combining acid denaturation and proteolytic enzyme 
digestion (0.2 mg/ml pepsin in 2N HCl for 30 min at room temperature). Acid 
denaturation preceded by enzyme digestion resulted in a large amount of debris 
and the occurrence of naked nuclei. In contrast, the simultaneous denaturation/ 
protein digestion procedure did not damage the cellular structure, is rapid and 
reproducible, and has cell recoveries of more than 85%. Although experimental 
conditions were tested on human cultured keratinocytes, this method also ap­
peared applicable to bone marrow cells and cells obtained from solid tissues. 
I I Introduction 
Simultaneous measurement of incorporated bromodeoxyuridine (BrdUrd) and 
relative DNA content by flow cytometry allows detailed analysis of cell cycle 
kinetics [1-5]. Several immunochemical procedures for cell staining have been 
described using anti-BrdUrd and propidium iodide, measuring simultaneously 
DNA synthesis and relative DNA content [2,6-8]. Binding of the monoclonal anti-
BrdUrd antibody requires regions of single-stranded DNA, while propidium io­
dide, an intercalating dye, requires double-stranded DNA. Acid treatment [7] or 
thermal denaturation [2], the best compromises, have most often been used. Im­
provements on these techniques have recently been reported using additional cell 
treatments, such as extraction of chromatin proteins by detergent, reduction of 
autofluorescence by sodium borohydride [6], or an extra protein degradation step 
using a proteolytic enzyme [8]. However, these protocols are either time-consum­
ing or, at least in our hands, cause substantial cell loss, especially when applied to 
hematopoietic cells. 
Here we describe an improvement of the method of Schutte et al. [8], combining the 
protein digestion and acid hydrolysis steps and using FITC-conjugated anti-
BrdUrd. 
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Ш Materials and Methods 
Cell Culture and Tissue Preparation 
Human neonatal foreskin keratinocytes were cultured on 3T3 feeder cells [9]. 
Epidermal cells were seeded on lethally irradiated (3,000 rad, 3 min) Swiss mouse 
3T3 fibroblasts in DMEM/F12 3:1 v/v (Flow Laboratories, Irvine, Scotland) supple­
mented with 0.4 μg/ml hydrocortisone (Collaborative Research Inc., Lexington, 
Massachusetts). Isoproterenol (10"6 M) (Sigma, St. Louis, Missouri), 100 U/ml 
penicillin plus 100 μg/ml streptomycin (Gibco, Breda, The Netherlands), 5% v/v 
fetal bovine serum (Seralab, Nistelrode, The Netherlands) and, starting at day 3 
after seeding, 10 ng/ml epidermal growth factor (Collaborative Research Inc.). 
Cells were grown at 37°C, 95% relative humidity, and 7.5% CO2 in air. EDTA-
treated, trypsinized keratinocytes from the primary culture or from the first one to 
two passages were used in the experiments. 
Human skin biopsies (3 mm in diameter and about 0.3 mm thick) obtained from 
healthy volunteers, were cut as previously described [10]. Epidermal cell suspen­
sions were prepared by trypsinization [11]. Human bone marrow was collected in 
sterile buffered acid-citrate dextrose (ACD, formula A, pH = 7.0). Erythrocytes 
were removed by gradient centrifugation at 500 g for 30 min on 1.077 kg/1 Ficoll-
Isopaque (Pharmacia, Uppsala, Sweden). The nucleated cells from the interphase 
were washed twice in phosphate-buffered saline (PBS) and preincubated in RPMI 
1640 (Boehringer Mannheim, Germany), supplemented with 100 mg/ml strepto­
mycin, 2.10"3 M glutamine, and 10% v/v fetal calf serum (Flow Laboratories). 
BrdUrd Labeling 
Cultured cells and human bone marrow cells (106 cells/ml) were pulse-labeled in 
vitro (15,30, or 60 min) in medium containing BrdUrd. The final BrdUrd concentra­
tion was 10 μΜ. Cells were harvested, washed in ice-cold PBS, fixed in ice-cold 70% 
ethanol, and stored at -20°C until use. 
Skin biopsies were floated, dermal face downward, on 2 ml medium 199 containing 
10 μΜ BrdUrd (final concentration) at 37CC. After 1 h, the tissue was trypsinized, 
and isolated cells were fixed in ice-cold 70% ethanol and stored at -20°C until use. 
Denaturata and Staining 
Between 0.5 and 1.0 χ IO6 ethanol-fixed cells were used for further preparation. 
Cells were washed once with PBS. Acid hydrolysis was tested in a variety of pH, 
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time, and temperature conditions. The effect of pepsin (Serva, Heidelberg, Ger­
many) was investigated; experimental conditions are specified in the Results and 
Discussion section. Hydrolysis was terminated with excess 0.1 M №26407. After a 
minimum of two washes with PBS, denatured and/or protein-digested cells were 
pelleted. Cells were resuspended in 50 μΐ PBS containing 0.5% v/v Tween 20 
(Sigma) and 5 μΐ FITC-conjugated anti-BrdUrd (Becton Dickinson, Mountain View, 
California) were added. After a 30-min incubation at room temperature in the dark, 
500 μΐ PBS were added, and cells were sedimented and washed once with PBS. The 
cells were resuspended in 400 μΐ PBS containing 20 μg/ml propidium iodide 
(Calbiochem, San Diego, California) and incubated for 15 min with 50 ul 1% w/v 
RNAse (Sigma). Prior to flow cytometric analysis, cell suspensions were filtered 
through gauze (50 μπι mesh, V. Wijk, Santpoort, The Netherlands). 
Flow Cytometry 
Cells stained with FITC and propidium iodide were measured with a flow cyto-
meter 50H (Ortho Instruments, Westwood, California). The 488-nm line of a 5-W 
Argon ion laser was used for excitation. A 580 nm dichroic mirror, a high-pass filter 
RG630 nm (for red), and a bandpass filter 515/530 nm (for green) were used. If 
possible, 5 χ 104 cells were measured at a flow rate of approximately 100 cells per 
second. The area of the green fluorescence signal and both area and peak value of 
the red fluorescence signal were recorded in list mode. The ratio area:peak dis­
criminates between artefacts due to doublets of diploid cells and real single tetra-
ploid (or late S) cells, when intact cells are used [12]. The data were stored on and 
analysed with a PDPH/34 computer (Digital Equipment, Galway, Ireland). 
Ш Results and Discussion 
The incorporated BrdUrd is detected immunocytochemically in partially dena­
tured DNA using a monoclonal antibody [13]. The applicability depends on se­
lected conditions to allow antibody binding. The integrity and architecture of the 
cells should be preserved as far as possible for additional morphological and 
immunocytochemical characterization. Another requirement is the appropriate 
staining of DNA with propidium iodide. BrdUrd staining requires regions of 
single-stranded DNA, while propidium iodide is an intercalating dye requiring 
double-stranded DNA. 
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Fig. 1. Bivariate BrdUrd/ 
DNA analysis of cultured 
human keratinocytes 
pulse-labeled for 1 h with 
ΙΟμΜ BrdUrd. Compari­
son of pretreatment with 
0.2 mg/ml pepsin in 2N 
HCl (A), 2N HCl only (B), 
and without treatment (C). 
The lower panels (D-F) 
show the corresponding 
DNA histograms. 
Acid hydrolysis at different HCl strengths (range 0.1-4N) and different incubation 
temperatures (room temperature, 37°C, 60°C) are generally used [1,2,5]. However, 
with cultured keratinocytes or cells derived from human skin biopsies pulse-
labeled for 1 h with 10 μΜ BrdUrd, we were not able to obtain the results reported 
with these staining protocols (Fig. IB). Concentrations greater than 2N HCl and/or 
longer incubation times lead to increased cell loss, naked nuclei, or even total 
destruction of the nuclei and a large amount of debris. Preincubation of ethanol-
fixed cells with 0.4 mg/ml pepsin in 0.1N HCl for 30 min at room temperature 
followed by denaturation using 2N HCl [8] resulted in some improvement. As 
expected, this procedure resulted in naked nuclei, but flow cytometric analysis was 
hampered because of large amounts of debris. 
Substantial improvement was obtained with simultaneous acidic denaturation and 
pepsin digestion showing high sensitivity (Fig. 1A) and low background fluores­
cence (Fig. 1С). Pepsin has a pH optimum of 1.5 but is still sufficiently active in 2N 
HCl. We tested pepsin concentrations from 0.1 mg/ml to 1.0 mg/ml in 2N HCl at 
room temperature; 0.2-0.4 mg/ml gave optimal results. Surprisingly, 0.2 mg/ml 
pepsin in 2N HCl kept most of the cytoplasmatic structure intact, as visible with a 
phase-contrast light microscope. However, when the neutralization step with 
Na2B4Û7 was omitted and when the cells were washed with PBS alone, only naked 
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Fig. 2. Bivariate BrdUrd/ 
DNA analysis of human 
bone marrow cells pulse-
labeled for 1 h with ΙΟμΜ 
BrdUrd in vitro after 
treatment with 0.2 mg/tnl 
pepsin in 2N HCl (A) and 
without hydrolysis (B). 
The lower panels (C and 
D) show the corresponding 
DNA histograms. 
nuclei were obtained. DNA histograms derived from Figure ΙΑ-C are shown in 
Figure 1D-F, respectively. Comparison of Figure ID and F with E shows that the 
combined pepsin/denaturation step does not affect the distribution of cells over 
the different cell cycle phases, as detected with propidium iodide. Moreover, this 
method resulted in DNA histograms with remarkable, lower coefficients of varia­
tion for the staining with propidium iodide compared with acid denaturation only, 
although the absolute intensity of the red signal was somewhat decreased. In terms 
of sensitivity, the procedure described above is better or at least comparable with 
results obtained from other protocols [6,8]. The method described allows detection 
of S-phase cells after a 5-10 min pulse. Even when only 0.5-1.5% of all cells were in 
S-phase, as is the case in normal human epidermis, BrdUrd-positive cells were 
clearly separated from G0/Gi and G2+M cells after a 15-min pulse. Cell recoveries 
were greater than 85%, which can be attributed to the relative mildness of this 
procedure and/or to the reduction of the number of incubation and wash steps; the 
total processing including measurement can be completed in less than 2 h. 
Figure 2A and В illustrate that this procedure can be applied to cell types other than 
keratinocytes. Human bone marrow cells were pulse-labeled with 10 μΜ BrdUrd 
for 60 min, and after overnight fixation in 70% ice-cold ethanol, the cells were 
stained for BrdUrd incorporation and relative DNA content, as described for epi-
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dermal cells. Similar Invariate BrdUrd/DNA distributions were obtained, com­
pared with stained epidermal cells and the small coefficients of variation of the 
DNA histograms (< 1.5%) were striking. 
In conclusion, the procedure described is relatively simple, maintains reasonable 
morphological integrity of the cells, and is applicable to a variety of cells, including 
cultured keratinocytes, cells derived from solid tissue, and human bone marrow 
cells. Work is in progress to apply this BrdUrd technique to the investigation of 
epithelial regeneration following injury and to the study of epidermal disorders 
characterized by abnormal proliferation, such as psoriasis. Furthermore, in vitro 
and in vivo cytokinetics of normal and malignant hematopoietic cells are under 
study. 
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Effect of Doxorubicin on Cell Cycle Kinetics 
Ü Abstract 
Cell kinetics of two human leukemic cell lines (Molt-4 and K562), following a 2-h 
exposure to doxorubicin, were studied. DNA flow cytometry provided static infor-
mation that for both cell lines a dose-dependent accumulation occurred at the 
G2+M compartment that disappeared in time. Kinetic information was provided 
by time-monitoring cells labeled with 5-iodo-2-deoxyuridine (IdUrd) by two-pa-
rameter flow cytometry, analyzing the IdUrd label and the DNA content. The cell 
cycle time (Tc) of exponentially growing Molt-4 cells was determined to be 20 h. 
Twenty-four hours after a 2-h exposure to 0.25 μg/ml doxorubicin, the T
c
 had 
increased to 23 h; following exposure to 1.0 Mg/ml, it increased to 33 h. Cell kinetics 
of K562 cells following doxorubicin exposure were monitored in time up to 4 days. 
The average T
c
 of exponentially growing K562 cells was determined to be 24.7 h. 
Twenty-four hours following 2-h exposure to 0.25 or 0.5 Mg/ml doxorubicin the T
c 
were determined to be 28 and 32-h, respectively. After an additional 2 days, the T
c 
were both determined to be 24 h. The dose-dependent, reversible cell cycle delay 
that persisted at least 48 h should be taken into account as an additional mode for 
decrease of a (tumor) cell population doubling time after exposure to doxorubicin. 
S Introduction 
Doxorubicin is a powerful, non-cell cycle specific [1], cytostatic drug that is in­
cluded in many anti-cancer treatment regimens. Because of the frequent combina­
tion with cell cycle specific drugs (e.g., the antimetabolite cytosine arabinoside 
[Ara-C]), it is essential to have knowledge concerning the effects of doxorubicin on 
cell kinetics. 
The described effects of doxorubicin on cell kinetics described are: 1) growth 
stimulation after exposure to low dosages [2], 2) cell cycle arrest at the G2+M-phase 
after exposure to intermediate dosages [1 ], and 3) immediate cell kill after exposure 
to high dosages [1]. An effect that is of particular importance considering the 
influence on the efficacy of cell cycle specific drags in combination therapy is 4) 
delay of the cell cycle traverse at intermediate dosages. A short-term delay (2-4 h) 
of the cell cycle traverse has been described [1]. However, for these studies cell 
synchronization methods were used that interfere with cell kinetics. Moreover, 
synchronization methods only allow short-term studies on cell kinetics due to 
rapid loss of synchronicity. The 5-iodo-2-deoxyuridine (IdUrd) labeling technique 
provides a tool for direct measurement of cell cycle times (T
c
) without interference 
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with cell kinetics [3,4] and allows cell kinetic studies over a longer period of time. 
Therefore, we studied the doxorubicin-induced changes in cell kinetics with the 
IdUrd labeling technique, monitoring the cells up to 4 days after the drug exposure. 
Ш Materials and Methods 
Cell Lines and Culture Conditions 
The Molt-4 and K562 human leukemia cell lines were maintained at exponential 
growth in RPMI1640 medium (Flow Laboratories, Irvine, Scotland) supplemented 
with 10% (v/v) heat-inactivated (HI; 30 min, 56°C) fetal calf serum (FCS); (Gibco, 
Grand Island, New York), 100 Mg/ml streptomycin, 100 IU/ml penicillin, and 2 
mM L-glutamine (Flow laboratories); this will be referred to as growth medium. 
Cells were cultured in a 5% C02- 95% air fully humidified atmosphere at 37°C. Cell 
cultures were routinely checked for absence of Mycoplasma infection. 
Drug Exposure 
Doxorubicin (Roger Bellon, Neuilly sur Seine, France) was added at final concen­
trations of 0, 0.25, 0.5, and 1.0 μg/ml from a frozen stock made in phosphate-
buffered saline (PBS). Drug incubations were performed at a density of 106 cells/ml 
for 2 h in a shaking waterbath at 37°C. Subsequently, the cells were washed twice 
with glucose PBS (GP buffer; 134 mM NaCl, 5.4 mM KCl, 1.4 mM Na2HP04, 3.3 
mM KH2P04, and 5.1 mM glucose) plus 1% HI FCS at 37°C, resuspended in 250 ml 
drug-free growth medium at a density of 0.01 χ IO6 cells/ml and returned to the 
incubator in 150-cm2 flasks (Costar, Cambridge, Massachusetts). 
IdUrd Labeling and Cell Sampling 
Prior to the IdUrd labeling (Sigma, St. Louis, Missouri), cell densities were adjusted 
to 1 χ 106 cells/ml. The surplus of medium was saved for resuspending the cells 
after the IdUrd labeling in order to maintain cell densities and growth medium 
conditions close to the conditions prior to the labeling. IdUrd was added from a 1.0 
M frozen stock in PBS to a final concentration of 10 μΜ. After a 30-min incubation 
at 37°C, cells were washed twice with GP buffer and resuspended in the surplus 
medium that was saved. Subsequently, the 250-ml cell suspensions were each 
divided in series of 25 parallel cultures of 10 ml in 25-cm2 flasks (Costar) and 
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returned to the incubator. At regular time intervals (2-3 h), one 25-cm2 flask from 
each IdUrd labeling series was taken from the incubator, the cells were washed 
twice in cold (4°C) PBS plus ethylenediaminetetraacetic acid (EDTA; 0.5 mM), fixed 
in cold (-20°C) 75% (v/v) ethanol/PBS, and stored at -20°C until further use. 
Three parallel cultures of K562 cells were labeled with IdUrd at 0 h, 24 h, or 70 h 
following doxorubicin exposure (T-post). This strategy allowed monitoring of cell 
kinetics for 4 days. Molt-4 cells were monitored by one IdUrd labeling on T-post = 
24 h. 
Estimation of Drug Toxicity 
Cell densities from one designated flask for each series were determined daily by 
counting samples with a Coulter Counter ZF (Coulter Electronics Limited, Luton, 
UK). Drug toxicities were estimated by comparing growth curves of drug-treated 
cells with those of the control cells. Ultimately, the contribution of the killed cells to 
the size of the total population would be so small that a backward extrapolation 
should give an estimate of the fraction killed. The first-order regression line for the 
control cells during logarithmic growth was determined. This regression line was 
used for backward extrapolation of the drug-treated data starting from the highest 
cell density available for each curve that was within the range of logarithmic 
growth (minimizing the contribution of dead cells). 
IdUrd Propidium (PI) Flow Cytometry 
The stored samples were handled according to the method described by Van Erp et 
al. [5]. In short: ethanol-fixed cells were washed with PBS, and DNA was denatu-
rated by a 30-min incubation with 1 ml pepsin/HCL (1 mg/ml pepsin (Serva, 
Heidelberg, Germany), 2 N HCL) at room temperature, followed by neutralization 
with 1 ml 0.1 M sodiumtetraborate. Subsequently, the cells were washed twice with 
PBS, labeled with (20 μ1/106 cells) fluorescein isothiocyanate (FITC)-conjugated 
anti-bromodeoxyuridine (BrdUrd) monoclonal antibody (Becton Dickinson, 
Mountain View, California), which is cross-reactive with IdUrd. DNA was stained 
with 0.5 ml 25 μg/ml PI (Sigma). 
Cells stained with anti-BrdUrd/FITC and PI were analyzed with a flow cytometer 
50H (Ortho Instruments, Westwood, California). The 488-nm line of a 5-W argon 
ion laser was used for excitation. A 580-nm dichroic mirror, a high-pass filter 
(RG630 nm; for red), and a bandpass filter (515/530 nm; for green) were used. Fifty 
thousand cells were measured at a flow rate of approximately 100 cells/s. The area 
of the green fluorescence signal and both area and peak values of the red fluores-
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cence signal were recorded in list mode. The ratio area : peak discriminates be-
tween artifacts due to doublets of diploid cells and real single tetraploid (or late Su-
plíase) cells when intact cells are used. The data were stored on and analyzed using 
a PDP11/34 computer (Digital Equipment, Galway, Ireland). 
Tc Analysis 
Cell cycle times were determined according to the method described by Pallavicini 
et al. [6] with modifications. In short: of each sample, green fluorescence (IdUrd 
incorporation) was plotted against red fluorescence (DNA content). IdUrd-labeled 
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Fig. 1. Transition of IdUrd-labeled (0.5 h, 10 μΜ) Molt-4 cells (control) as determined 
with bivariate Idllrd/PI flow cytometry. IdUrd (ordinate, green fluorescence) is plotted 
against the DNA content (abscissa, red fluorescence). Samples were taken at several 
time inteivals after resuspending the cells in IdUrd-free growth medium, as indicated 
in each plot. The traverse of IdUrd-labeled cells from S-phase (0 h) towards the G2+M-
phase (3 h), on to the next G^-phase (7 h 30 mm) and S-phase (17 h 45 min), and finally 
reaching the G2+M-phase for a second time (23 h 15 min) is shown. The windows in 
each plot reflect the mid-S-phase window in which the IdUrd labeled cells (in the upper 
part of the window) were monitored. The threshold discriminating IdUrd-labeled cells 
from non-labeled cells luas set based on the green background fluorescence signal of 
control (non-IdUrd-labeled) cells. 
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cells were discriminated from non-labeled cells by setting a threshold for back­
ground green fluorescence at the level of non-IdUrd labeled control cells. The 
fraction of IdUrd-labeled cells with mid-S-phase (lower limit 1.4 χ Gì, upper limit 
1.6 χ Gì) DNA content (fraction labeled S-phase, FLS) at several time intervals after 
IdUrd labeling were analyzed from the sequential IdUrd/DNA distributions. 
The FLS value of the first sample immediately following the IdUrd labeling is high 
(= first maximum); the FLS values decline when the labeled cells reach the G2+M 
and Gi compartment and rise to a second maximum when the labeled cells re-enter 
the S-phase for a second time. From these oscillations of the FLS in time the Tc is 
calculated. The cell cycle time corresponds to the time it takes the FLS to reach the 
second maximum. Figure 1 shows the transition of exponentially growing, IdUrd-
labeled Molt-4 cells (control cells not exposed to doxorubicin) through the cell cycle 
phases. 
. Curve Fitting 
Determination of Tc requires accurate determination of the position of two subse-
quent peaks or nadirs in time. The position of each peak or nadir was determined 
by plotting a second-order regression line through the data points comprising the 
curves. 
PI-DNA Flow Cytometry 
DNA distribution histograms were obtained simultaneously with the bivariate 
IdUrd/PI measurements as described in the previous section. 
• Results 
Drug Toxicity 
Growth curves of Molt-4 cells and K562 cells are presented in Figure 2. The first-
order regression line for the control cells during logarithmic growth (solid lines) 
were used for backward extrapolation of the drug-exposed curves (dashed lines) to 
estimate the cell kill. A dose-dependent cell kill was observed with both cell lines. 
The surviving fractions, as determined from the growth curves, are presented in 
Table 1. 
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Fig. 2. Growth curves from control (O) and drug-exposed (*, 0.25 Hg/ml; D, 0.5 ng/ml; 
V, 1.0 ]íg¡ml) Molt-4 cells (A) and K562 cells (B). The solid lines represent the first-
order regression line for control cells during logarithmic growth. The dotted lines are 
extrapolations of these lines to the drug-exposed data. The intercepts of the dotted line 
with the ordinate give an estimate of the initial number of viable cells. 
Table 1 
Drug Toxicity of 2-h Doxorubicin Exposure to Molt-4 cells or K562 Cells as 
Estimated from Growth Curves of Control Cells and Drug-Treated Cells 
doxorubicin 
concentration 
(цс/ті) 
0 (control) 
0.25 
0.5 
1.0 
Percent survival 
Molt-4 cells 
100 
28 
N D a 
0.4 
K562 cells 
100 
49 
22 
ND 
a
 NO, not done. 
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DNA Flow Cytometry 
Cell cycle phase distributions from samples taken before and at several time inter­
vals after doxorubicin exposure were monitored. A reversible doxorubicin concen­
tration-dependent accumulation at the G2+M-phase was observed for both cell 
lines and with all drug concentrations (data not shown). An example showing 
initial accumulation at the G2+M-phase and subsequent reversal is shown in 
Figure 3. 
4 }J L—,—, J 1 f Ά 
DNA content 
T-post- 0 h T-post- 16 h T-post- 30 h T-post- 5β h 
Fig. 3. DNA histograms of K562 cells as determined with PI-FCM following 2-h 
exposure to 0.25 Hg/ml doxorubicin. Samples were taken at several time intervals 
following doxorubicin exposure, as indicated under each histogram. A drug-induced 
accumulation of the cells at the G2+M-phase is observed (T-post = 16 h and T-post = 30 
h). A restoration toivard the original distribution is obseri'ed at T-post = 58 h. 
Tc analysis by Bivariate IdUrd/PI Flow Cytometry 
FLS χ 100% were plotted against T-post. Figures 4 and 5 show the changes of FLS in 
time of Molt-4 cells and K562 cells, respectively. T
c
 were determined by measuring 
the elapsed time between two subsequent peaks from the oscillations of the FLS in 
time. The T
c
 as determined for each cell line are summarized in Table 2. 
The range of error for determining T
c
 can be derived from comparing the T
c
 values 
for K562 control cells as determined on three different days. The average T
c
 ± SE for 
K562 control cells was 24.7 ± 1.4 h. The fractions of doxorubicin-exposed K562 cells 
labeled on Τ = 0 that were able to enter a second S-phase following the IdUrd 
labeling were too small to ensure accurate T
c
 analysis. However, the times elapsed 
before their FLS values reached their nadirs were already prolonged. Control K562 
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Fig. 4. Cìwnges of FLS χ 100% of Molt-4 cells 24 h following 2-h exposure to 0 
(O O), 0.25 (Ύ • ) , or 1.0 (Π •) \íg¡ml doxorubicin. Twenty four hours 
after drug exposure, the cells were labeled with IdUrd (0.5 h, 10 μΜ), and the 
transition of the IdUrd-labeled cells through the cell cycle phases was time monitored. 
The fraction of IdUrd-labeled mid-S-phase cells χ 100% (ordinate) is plotted against 
the time after drug incubation (abscissa). The lines represent second-order regression 
lines determined from the data comprising the corresponding parts of the curves. 
Table 2 
Cell Cycle Times Determined for Molt-4 and K562 Cells Following 2-h 
Exposure to Doxorubicin 
cell line and 
drug exposure 
Molt-4 control 
Molt-4 0.25 μξ/πύ 
Molt-4 1.0 Hg/ml 
K562 control 
K562 0.25 μg/ml 
K562 0.5 μg/ml 
T
c
 day 0 
N D a 
ND 
ND 
27 
N E b 
NE 
T
c
 day 1 
20 
23 
33 
22 
28 
32 
T
c
 day 3 
ND 
ND 
ND 
25 
24 
24 
" ND, not done. 
b
 NE, not évaluable. 
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Fig. 5. Changes ofFLS χ 100% of K562 cells following 2-h exposure to 0 (A), 0.25 (B) 
or 0.5 (C) \iglml doxorubicin. The cells were labeled with IdUrd (0.5 h,10 μΜ) either 
on day 0 (T-post = 0h, O), day 1 (T-post = 24 h, ·), or day 3 (T-post = 70 h, V). The 
relative number of IdUrd-labeled mid-S-phase cells (ordinate) is plotted against the 
time after doxorubicin incubation (abscissa). The lines represent second-order regres­
sion lines determined from the data comprising the corresponding parts of the curves. 
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cells reached a first nadir at 14 h, compared with 18 h and 28 h for K562 exposed to 
0.25 and 0.5 μg/ml doxorubicin, respectively. 
For both cell lines, with Τ = 24 h labeling, a concentration-dependent delay of the 
cell cycle traverse was observed. The K562 data show that the cell cycle delay is 
reversible since the T
c
 determined at Τ = 70 h were comparable to the control. In 
addition to the cell cycle delay, a dose-dependent decrease of the initial FLS values 
was observed when comparing drag-exposed cells to the controls. This might 
indicate immediate arrest of cells at S-phase (cells with S-phase DNA content but 
no DNA synthesis and therefore no IdUrd labeling). If no arrest had occurred (as 
with the control), approximately all S-phase cells would have been labeled with 
IdUrd (initial FLS =1.0). 
The synchronicity of the three K562 control cell data (Fig. 5a) is coincidental. It is 
caused by the coincidence of completion of the cell cycle traverse of cells labeled by 
one labeling and the initiation of the next IdUrd labeling. 
I I Discussion 
In this study, it was demonstrated that doxorubicin not only induces a dose-
dependent cell kill and/or arrest at the G2+M-phase but also a dose-dependent 
long-term delay of the cell cycle traverse. The observed cell kill and/or cell cycle 
arrest are well-established features of doxorubicin toxicity [1]. Doxorabicin-related 
delay of the cell cycle has been suggested [7,8] and also demonstrated [1]. How­
ever, the reported cell cycle delays were only short-lived (2-4 h) and considering 
the presently available methods the suitability of the methods used can be ques­
tioned. 
A frequently applied method to study cell kinetics is monitoring the DNA histo­
grams that reflect the static cell cycle phase distribution of an overall cell popula­
tion. However, based on DNA histograms only, a non-cell cycle phase-specific 
delay of the cell cycle traverse can not be determined. The IdUrd technique used in 
this study provides kinetic information and therefore provides additional informa­
tion. 
From the K562 cells labeled at Τ = 0 h it is clear that doxorubicin effects the cell 
cycle traverse almost immediately because the traverse of the labeled cells out of 
the S-phase compartment is already prolonged. This is in agreement with previous 
reports [1]. The increase of FLS at Τ = 0 h following the nadir indicates that there 
are labeled cells re-entering S-phase. However, we were not able to extend the data 
analysis of Τ = 0-labeled cells beyond the last data point presented in each curve 
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due to inaccuracy of the measurements for DNA content because of cell death. 
Therefore it is not known whether these cells were destined to die. 
From FLS monitored for cells labeled on Τ = 24 h, however, we can state that these 
labeled cells were able to complete their cell cycle (S => G2+M/G1 = first nadir) and 
the subsequent cell cycle (Gi => S = second peak; S => G2+M = second decline of 
FLS) and therefore had survived at least 48 h following drug exposure. It seems 
unlikely that these slow-growing labeled cells were destined to die. 
Data have been published that could be explained by cell cycle delay effects of 
doxorubicin but that were not interpreted as such by the authors. In a study by 
Ellwart et al. [9], survival curves of doxorubicin-treated HL-60 cells were presented. 
The curves were constructed exclusively based on vital cells by discrimination with 
fluorescein diacetate. Nevertheless, doxorubicin dose-related differences were ob­
served in the slopes of the survival curves that were interpreted as delayed drug 
effects. Sasaki el al. [10] observed doxorubicin-induced postponement of the cell 
cycle traverse of HeLa cells while cell cycle progression was not completely 
blocked and BrdUrd incorporation into DNA was less than one third that of the 
untreated cells. This phenotype fits with a drug-induced delay of the cell cycle 
traverse. 
Although the cells in the present study were only exposed for 2 h to doxorubicin, 
the cell cycle delay persisted for at least 48 h. One might expect that the effects of 
long-term exposure to doxorubicin are even more persistent, but additional experi­
ments are needed to confirm this. 
The observed cell cycle delay after doxorubicin exposure should be taken into 
consideration with short-term survival assays since multiple cellular systems will 
affect or will be affected by cell cycle kinetics. Artificially high drug effects may be 
observed when the decline of the parameter studied is considered only to be caused 
by cell kill. An example for this might be found in a paper by Zaffaroni et al. [11] in 
which doxorubicin toxicities, determined with a short-term anti-metabolic assay 
and a long-term anti-proliferative assay, were compared. The authors described an 
overestimation of the effects of doxorubicin determined with the anti-metabolic 
assay relative to the anti-proliferative assay [11]. 
When doxorubicin is used in combination with cell cycle-specific drugs, the effects 
on cell kinetics of the doxorubicin exposure alone should be considered in order to 
design a rational time schedule for drug exposition. 
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Proliferation Patterns in Acute Myeloid Leukemia 
Ш Abstract 
In a prospective study in 33 newly diagnosed patients with acute myeloid leukemia 
(AML), we analyzed the relationship of proliferation parameters with clinical pa­
rameters, response to induction therapy, and survival. The median follow-up was 
26 months. The proliferative capacity of the leukemic progenitor cells was studied 
using colony-forming assays (number of colony-forming units, growth pattern, 
and spontaneous clonogenic growth capacity). The cell kinetic parameters of the 
bone marrow blasts were determined by in vivo labeling with iododeoxyuridine 
and subsequent flow cytometry: labeling index (LI), DNA synthesis time (T
s
), 
potential doubling time. No or only weak relationships were observed between the 
experimental and clinical parameters such as age, sex, % blasts, white blood cell 
count, FAB subtype, cytogenetics, and % CD34+ cells. This suggests that clonogenic 
growth and cell cycle kinetics of bone marrow blasts are independent cell biologic 
properties of AML. No association between the proliferation parameters and in­
duction response rate was noticed. Analysis of the overall survival and event-free 
survival revealed trends to longer survival rates in patients with a below-median LI 
(< 7.6%) and below-median T
s
 value (< 14.3 h). These trends were more pronoun­
ced in the group of de novo AML (и = 23), where the prolonged event-free survival 
in patients with below-median T
s
 reached statistical significance (P = .02). None of 
the other parameters appeared significantly correlated with survival, although 
there was a trend to longer survival rates in patients who had no spontaneous 
clonogenic growth capacity (P = .13). In conclusion, proliferation parameters in 
leukemic cells provide additional information on the cell biologic characteristics of 
AML, and these parameters may have prognostic value for response and duration 
of survival in AML. 
l î Introduction 
For some decades, cell proliferation has been studied in acute myeloid leukemia 
(AML). The interest in this field of investigation has been renewed recently. This is 
related to the development of new assays to measure parameters of in vivo and in 
vitro growth of leukemic cells, and to the increasing evidence that such information 
has prognostic relevance [1-4]. 
Clonogenic assays that reflect the growth properties of leukemic progenitor cells 
can be implemented easily in a clinical setting [5,6]. The reproducibility has im-
proved due to the availability of recombinant hematopoietic growth factors [7-9]. 
91 
Chapter 6 
Measurement of cell kinetic parameters in AML has also made progress. In the 
past, cell kinetics were studied using measurement of S-phase DNA content by 
flow cytometry (FCM) [10-15] or by measurement of the labeling index (LI) after in 
vitro labeling with radioactive thymidine and autoradiography [14,16-18]. How­
ever, autoradiography is time consuming and it requires undisturbed ex vivo 
growth of leukemic cells. The results of DNA FCM may be jeopardized when cells 
are arrested in S-phase [19] or when DNA histograms overlap due to aneuploidism. 
But the major limitation of both methods is that they provide only information 
about the number of cells in particular cell cycle phases. Until recently, the meas­
urement of a more extensive kinetic profile, including data on the duration of 
distinct cell cycle phases, required the in vivo administration of radioisotopes and 
multiple sampling. For practical and ethical reasons, few of these studies have been 
performed [20-23]. The introduction of cell kinetic methods using in vivo adminis­
tration of bromodeoxyuridine (BrdUrd) or iododeoxyuridine (IdUrd) has over­
come many of these technical and ethical problems. 
BrdUrd and IdUrd are nonradioactive thymidine analogous which are incorpo­
rated into the DNA during the S-phase. Their incorporation can be detected using 
monoclonal antibodies [24,25] and special cytochemical staining methods [26,27]. 
Using in vivo IdUrd labeling and FCM, several cell kinetic parameters can be 
calculated, such as the labeling index, the DNA synthesis time, and the potential 
doubling time, even from one single sample [28]. The dose of IdUrd administered 
in this study, 200 mg, is far below the dose that may induce cytotoxic effects [29,30]. 
The present paper provides an analysis of biologic parameters that characterize the 
cell growth on different levels of hematopoiesis. It includes data regarding: (a) the 
number of colony-forming units (CFU-L), the CFU-L growth pattern, the spontane­
ous colony growth capacity and (b) the labeling index, the DNA synthesis time, the 
potential doubling time of low-density bone marrow (BM) cells, determined with 
FCM after in vivo labeling with IdUrd. The relationship of these proliferation 
parameters with clinical parameters, response to induction therapy, and survival 
are studied in a group of 33 consecutive patients with untreated AML. 
Я Materials and Methods 
This prospective study in patients with untreated acute leukemia was started in 
September 1989, and accrual was closed in September 1991. Thirty-three consecu­
tive adult patients with AML who gave written informed consent for the IdUrd 
protocol were subjects to the present study. Median follow-up at time of the clinical 
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evaluation was 26 months. All patients were diagnosed according to the FAB 
classification [31]. The diagnosis of AML-MO was made according to the proposal 
of Catovsky et al. [32]. Further standard workup included cytogenetic analysis of 
the leukemic bone marrow blasts using the G-banding technique and flow cyto-
metric immunophenotyping with an extended panel of monoclonal antibodies, 
including the CD34 monoclonal antibody (MylO, Coulter, Hialeah, Rorida). Per-
mission to administer IdUrd to AML patients was obtained from the National 
Cancer Institute, Bethesda, Maryland (Protocol NCI T89-0075) and from the local 
ethical committee. Four of the 33 patients were studied again at the time of relapse. 
Treatment 
Patients were treated according to EORTC protocols for newly diagnosed AML, 
which included a standard remission induction regimen of Ara-C and anthra-
cyclines. Depending on age, patients were treated according to the EORTC proto-
cols AML 8A (No. 06863, < 45 years) and AML 8B (No. 06864, 45-60 years). Both 
protocols consisted of an induction regimen with Ara-C 200 mg/m2 days 1-7 and 
daunorubicin (DNR) 45 mg/m2 days 1-3. Patients older than 60 years were treating 
according to EORTC protocol AML 60+ (No. 06892), which consisted of an induc-
tion regimen with Ara-C 200 mg/m2 days 1-7 and DNR 30 mg/m2 days 1-3. Partial 
responders to the above schedules received an additional induction course. Non-
responders were treated by salvage treatment with 500 mg/m2 Ara-C q 12 h days 
1-7 and idarubicin 12 mg/m2 days 1, 3, 5 (according to the EORTC protocol No. 
06901). In the AML 8A protocol, after successful remission induction a first consoli-
dation course was given, with Ara-C 500 mg/m2 q 12 h days 1-6 and amsacrine 120 
mg/m2 days 5-7. Following the first consolidation course, patients younger than 50 
years who had an HLA-identical sibling were eligible for an allogeneic bone mar-
row transplantation (BMT) with T-cell depleted bone marrow. The others were 
randomized between autologous BMT with unpurged bone marrow and a second 
consolidation course with Ara-C 2000 mg/m2 q 12 h days 1-4 and DNR 45 mg/m2 
days 5-7. In the AML 8B protocol patients were randomized between the two 
intensive consolidation courses as given in the AML 8A protocol, and a single 
consolidation course consisting of Ara-C 200 mg/m2 days 1-7 and DNR day 1, 
followed by six maintenance courses with Ara-C 100 mg/m2 q 12 h days 1-5 and 
DNR 45 mg/m2 day 1. In the AML 60+ protocol patients achieving complete 
remission received a consolidation course of Ara-C 200 mg/m2 days 1-7 and DNR 
45 mg/m2 day 1, followed by six maintenance courses with Ara-C 20 mg days 1-14. 
Four patients underwent allogeneic BMT and two autologous BMT. The condition-
ing regimen for autologous and allogeneic BMT is identical and has been described 
elsewhere [33]. 
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Response Criteria 
Complete remission (CR) was defined as absence of clinical manifestations of 
leukemia, normal blood cell counts, and less than 5% blasts in a normocellular 
marrow with normal morphology. Resistant disease was defined as failure to 
achieve CR after all induction and salvage chemotherapy courses, according to the 
EORTC protocols. At least two courses were given to each patient. Patients who 
achieved complete remission after the first cycle of induction chemotherapy with 
Ara-C/DNR were classified as 'first responders'. Those who failed to respond after 
the first cycle were defined as 'non-first responders'. Overall survival was defined 
as the time from the diagnosis of AML until death. The event-free survival (EFS) 
was defined as the time from the diagnosis of AML until the occurrence of relapse, 
or death, or no achievement of CR, the latter event being projected 1 day after the 
date of diagnosis. 
Clinical Characteristics and Response 
FAB subtypes were: MO (» = 1); Ml (и = 8); M2 (н = 11); M4 (π = 4); М5 (η = 6); Мб 
(н = 1); not classified (н = 2). Median age was 45 years (range 17-75) years, 15 
patients were female and 18 were male. The median percentage of leukemic blasts 
in the BM smears of the patients was 60% (range 17-97%) and the median initial 
white blood cell count (WBC) was 10.5 χ 109/1 (range 0.8-139.5 χ 109/1). From 32/33 
patients cytogenetic data were available; 15 showed an abnormal karyotype. The 
median percentage of CD34+ cells in the BM aspirates was 19% (range 0-70%). 
Secondary AML was defined if AML occurred in patients with either a history of 
chemotherapy or radiotherapy for a nonhematological malignancy, or with a his­
tory of myelodysplastic syndrome for at least 3 months prior to the development of 
AML. None of the patients had received any cytostatic treatment or radiotherapy 
within 8 weeks before entering the present study. 
One patient died early during the aplastic phase, 21 days following the first induc­
tion therapy. This patient was not included in the analysis of response to the 
induction scheme but was included for the overall survival and EFS. Nineteen 
patients achieved a complete remission (CR) after the first induction course (59%), 
and nine patients after two or more courses (28%). Only four patients (13%) were 
resistant to induction chemotherapy. 
During the follow-up period, 20/33 (61%) patients died, including all patients with 
resistant disease. Five of the 13 surviving patients relapsed, leaving 7/33 (21%) 
patients alive and disease-free at the end of the follow-up. The median EFS was 15.9 
months and the median overall survival was 19.4 months. 
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Cell Cycle Kinetics 
Cell cycle kinetics were studied prior to therapy with in vivo administration of 
IdUrd and flow cytometry. 
In Vivo IdUrd Labeling and Sampling 
The National Cancer Institute supplied vials of 200 mg sterile freeze-dried IdUrd. 
Prior to the infusion, the IdUrd was dissolved in 30 ml NaCl 0.9%. All patients 
received 200 mg IdUrd as a 15-min intravenous infusion. Between 4.6 and 7.0 h 
(median value 5.4 h) after in vivo IdUrd labeling a BM aspirate was obtained from 
the sternum. The BM aspirate was collected in buffered acid-citrate dextrose for-
mula A (pH 7.0) on ice. The peripheral admixture of nucleated blood cells was 
determined in each BM aspirate [34]. The median value was 19%. Low-density 
nucleated BM cells were collected by density centrifugation on Ficoll (density 1.077 
g/ml). Cell suspensions were divided into three portions, for (a) IdUrd/DNA 
FCM, (b) immunophenotyping, and (c) clonogenic assays. The cells used for IdUrd-
/DNA FCM were fixed in cold 75% ethanol [27] and stored at -20°C in the dark 
until analysis. The other assays were performed on unfixed cell suspensions and 
were initiated within 2 h after sampling. 
IdUrd/DNA Staining 
Bivariate staining for IdUrd incorporation and DNA content was performed using 
a previously described protocol [27]. It consists of simultaneous proteolytic enzyme 
digestion with 1.0 mg/ml pepsin and acid hydrolysis denaturation with 2 N HCl, 
to allow access of the anti-IdUrd MoAb to the DNA chains. Denaturation is termi-
nated with excess N828407. The anti-IdUrd HN-IU MoAb, developed at our de-
partment, and an FITC-conjugated IgG goat anti-mouse second step antibody 
(GAM-FITC; American Qualex International, La Mirada, California) were used for 
detection of IdUrd. The HN-IU MoAb shows cross-reactivity with BrdUrd but not 
with fluorodeoxyuridine, and it provides a good separation of labeled and non-
labeled cells. The DNA was then stained with an isotonic propidium iodide 
(Calbiochem, San Diego, California) solution. IdUrd/DNA staining of each BM 
sample was always performed in duplicate. Non-IdUrd-labeled low-density blood 
cells of a healthy volunteer served as negative controls. 
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Flow Cytometry 
The IdUrd/DNA stained samples were analyzed on a Coulter Epics Elite flow 
cytometer (Coulter, Hialeah, Florida), equipped with a 40 mW Argon ion laser 
running at 15 mW with filter settings and correction for fluorescence crossover as 
described previously [30]. Elimination of cell debris and cell doublets were elimi­
nated based on their DNA content and the ratio are/peak of the red fluorescence 
signal [35]. A minimum of 20,000 cells was analyzed for IdUrd/DNA staining. In 
cases with a low LI, the number of cells analyzed was extended to 200,000 to allow 
a more reliable calculation of the cell kinetic parameters. Data were recorded on a 
linear scale in Hst mode. 
Calculation of Kinetic Parameters 
The duration of the S-phase (T
s
) was determined from the bivariate IdUrd/DNA 
analysis according to the model of Begg et al. [28]. The main principle and assump­
tions of this model are: 
(1) Directly after IdUrd pulse labeling, the mean DNA content of the IdUrd-labeled 
cells is in the middle of the interval between the Gi (2n DNA) and G2+M (4n DNA) 
peak. Therefore, the movement of the labeled cells (relative movement, RM) at the 
end of the labeling (To) is 0.5, relative to that interval. 
(2) The rate of cell progression through the S-phase is constant in time. Therefore, 
the RM will increase linearly in time, from 0.5 at To to 1.0 after a time interval equal 
to the DNA synthesis time (T
s
). 
The RM is calculated from the DNA content of the IdUrd-labeled cells, excluding 
the labeled cells which have divided and entered the Grphase. This is performed 
in the computer analysis by placing a window around the cells which have not 
divided. The T
s
 is then calculated from the RM and the time elapsed between IdUrd 
administration (To) and the time of the bone marrow aspirate (Ti): 
т
'
( 1
" - ( ю ^ д х < т ' - Т о ) 
The labeling index (LI) was defined as the percentage IdUrd-labeled cells. A correc­
tion was made for the cells that had divided since the IdUrd labeling [30]: 
L I ( % ) = IdUrdNon-divided + (IdUrd Divided * 0-5) χ 1 ( χ ) 
100 - (IdUrdoivided * 0.5) - (G2+M-phase χ 0.5) 
From the T
s
 and the LI, the potential doubling time (Tpot) is calculated: 
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x
 ., . T
s
 100 Tpot (days) = ^ χ — 
The Tpot represents the tumor doubling time, assuming that no cell loss occurs. Due 
to IH vivo cell loss, which cannot be measured, the actual tumor doubling time will 
be longer than the Tpot. 
Leukemic Clonogenic In Vitro Assays 
Leukemic clonogenic assays were performed in semi-solid medium as described 
previously [36]. The following combination of growth factors was used for stimula­
tion: 40 ng/ml recombinant human interleukin 3 (kindly donated by Sandoz BV, 
Uden, The Netherlands), 25 ng/ml recombinant granulocyte-macrophage colony-
stimulating factor, and 5 ng/ml recombinant granulocyte colony-stimulating factor 
(the latter two were a gift from Behring, Marburg, Germany). After 10 days, the 
total number of aggregates containing 5 cells or more was determined (CFU-L). The 
growth pattern was classified according to the criteria of Moore et al. [37] with 
minor modifications. Pattern A: hypoplastic growth, defined as less than 10 aggre­
gates per 2 χ 105 plated cells. Pattern B: predominantly small clusters, defined as at 
least 10 aggregates per 2 χ 105 plated cells, and at least 90% of them being smaller 
than 20 cells. Pattern C: predominantly large clusters or colonies, defined as at least 
10 aggregates per 2 χ 105 plated cells, more than 10% of them being larger than 20 
cells. Spontaneous clonogenic growth capacity was defined as the ability to growth 
aggregates without stimulation by external growth factors. 
Statistics 
Correlations between numerical variables (percentage S-phase cells, LI, T
s
, Tpot, 
percentage CD34+ cells, number of CFU-L, percentage blasts, WBC, age) were 
analyzed with the Spearman's rank test. The Wilcoxon rank sum test was em­
ployed to test differences in the values of numerical clinical and kinetic parameters 
between response groups or patient categories. The chi-square test was used to test 
differences between dichotomous and nominal variables (response; normal vs. 
abnormal karyotype; spontaneous clonogenic growth capacity; sex; FAB subtypes 
Ml, M2, M3 vs. M4, M5; de novo vs. secondary AML and growth pattern). Survival 
analyses were performed using the Kaplan-Meier product-limit method. Actuarial 
curves were plotted for overall survival and EFS. Each numerical data set was 
classified into two groups: < median value or > median value. The effect of differ­
ent variables on the curves was then tested using the log-rank test and Wilcoxon 
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test. For all tests, Ρ values < .05 were considered significant. The statistical analyses 
were performed using the software package of SAS Institute Incorporation (SAS 
Institute Inc., Сагу, North Carolina). 
S Results 
Validation of the Single Sample Model 
The principle and validity of the single sample model of Begg et al. for in vivo 
kinetics of leukemic cells was demonstrated with a patient with proliferating blasts 
in the peripheral blood compartment due to a terminal stage myelofibrosis. Blood 
cells were drawn at ten time points after IdUrd labeling. Figure 1 shows six 
examples of bivariate DNA vs. IdUrd FCM. Directly after pulse labeling (t = 0 h) 
the mean DNA distribution of the IdUrd-labeled cells was halfway across the G] 
(2n DNA) and G2+M-phase (4n DNA). The cellular DNA content increased in time, 
and the labeled cells moved towards the G2+M-phase. At 23 h, two IdUrd-labeled 
populations were observed, one population with DNA content that approached 4 η 
and a second, large population with 2 η DNA originating from divided cells. 
From each time point the T
s
 was calculated using the single sample model. The T
s 
values calculated from the first time points (1 h, 2 h and 3 h), were unreliable and 
showed a large variation (SD 28.5 h). This is an intrinsic consequence of the single 
sample model. In contrast, reproducible results were obtained from succeeding 
time points (4 h, 5 h, 6 h, 7 h 20 min, 8 h 12 min, and 23 h), with T
s
 values of 32.1 h, 
33.6 h, 29.3 h, 35.8 h, 31.5 h, and 30.3 h, respectively. Thus, even in this case with a 
relatively long T
s
, the single sample model provided a reliable estimation of the T
s 
when an interval of at least 4 h between the labeling and the sampling of the tissue 
was used. 
Clonogenic Growth and Cell Cycle Kinetics 
In all patients the cell kinetic parameters were successfully determined. The kinetic 
analyses were generally well reproducible; the median coefficients of variation 
values between the duplicate sample were < 4% for all the five parameters ana­
lyzed (S-DNA, LI, T
s
, and Tp0t· For 31 /33 patients sufficient cells were available for 
clonogenic assays. The median values and ranges for the numerical experimental 
parameters are shown in Table 1. There is a wide variation of all the parameters in 
AML patients. Bone marrow culturing showed growth pattern A in 11 patients, 
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Fig. 2. Bivariate IdUrdjDNA FCM of in vivo labeled nucleated blood cells from a 
patient with proliferating blasts in the peripheral blood compartment. The samples 
were drawn at regular time intervals after IdUrd labeling. It demonstrates clearly the 
in vivo transition of IdUrd-labeled S-phase cells through the cell cycle: Directly after 
pulse-labeling, all labeled cells were in S-phase; the cells then moved in time towards 
the G2+M-phase. At 23 h, two IdUrd-labeled populations were observed, one popula­
tion that had reached the G2+M-plwse and a second, larger population that had divided 
and entered the Gj-phase. 
pattern В in 11 patients, and pattern С in nine patients. In 11/33 patients a sponta­
neous clonogenic growth capacity was found. 
The Internal Relationships of Experimental and Clinical 
Parameters 
The internal correlations of the numerical experimental and clinical parameters are 
shown in Table 2. 
IdUrd kinetics. A strong correlation was found between percentage S-phase cells 
and the LI (r = .94) and also between these two parameters and the Tpot (r = -.69 
and r = -.80, respectively). The T
s
 seems to increase with higher WBC (r = .53). All 
other correlations appeared weak (r < .50). No significant relationship was found 
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Table 1 
Pretreatment Cell Cycle Kinetics and CFU-L in 33 Patients 
with Newly Diagnosed AML 
Parameters 
S-phase cells (%) 
LI (%) 
T
s
(h) 
Tpot (days) 
CFU-L 
(per 2 χ 10 5 cells) 
Median 
6.2 
7.6 
14.3 
8.0 
38.5 
Range 
1.5 -13.5 
1.2 -18.8 
7.6 - 30.0 
3.0 - 48.9 
0.5 - 7.9 χ 103 
between IdUrd kinetics and the nonnumerical clinical and experimental data 
(growth pattern, spontaneous clonogenic growth capacity, sex, FAB type, and de 
novo vs. secondary AML). However, there was a trend (P = .10) to a lower median 
LI (6.3%) in secondary AML compared with de novo AML (7.9%) and a trend to a 
shorter median Tpotm patients with a normal karyotype (7.7 days) compared with 
those with an abnormal karyotype (10.6 days). 
Clonogenic growth. No correlation was found between the number of CFU-L and 
all of the numerical parameters (Table 2; r values < .50). There was neither any 
other relationship between data from the clonogenic assays (CFU-L, CFU-L growth 
pattern and spontaneous clonogenic growth capacity) and all of the clinical and 
experimental data. However, we observed a nearly significant trend to higher WBC 
counts in patients with spontaneous clonogenic growth capacity compared with 
those without (median values: 5.6 and 46.2 χ 109/1Ρ = .057). 
Relationship of Clinical and Experimental Parameters with 
Response to Induction Therapy 
Table 3 summarizes the numerical experimental data of patients categorized by 
outcome of induction therapy. A comparison was made between patients who 
obtained a CR after the first induction course (first responders) and those who did 
not (non-first responders). No association between the numerical proliferation 
parameters and induction response rate was noticed. Neither was there any rela­
tionship between induction response rate and clonogenic growth pattern and spon­
taneous clonogenic growth capacity. Analysis of the clinical characteristics showed 
that first responders were characterized by a higher frequency of normal karyotype 
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Table 3 
Relationship of Experimental and Clinical Parameters with Response to 
Induction Therapy 
Parameter 
S-phase cells (%) 
LI (%) 
T
s
(h) 
T p o t (days) 
CFU-L 
(per 105 cells) 
First 
responders 
7.2a 
7.4 
14.1 
7.7 
38.5 
Non-first 
responders 
5.9 
7.6 
14.4 
8.8 
180 
Statistics 
Ρ = 0.37 
Ρ = 0.62 
Ρ = 0.77 
Ρ = 0.34 
Ρ = 0.97 
" Median value 
and a lower pretreatment percentage CD34+ cells compared with non-first-re-
sponders: normal karyotype 12/18 and 4/13, respectively (P = .045) and median % 
CD34+ cells 6% and 43%, respectively (P = .004). No typical profile of IdUrd cell 
kinetics and clonogenic growth was observed in the small group of patients with 
resistant disease (data not shown). 
Relationship of Clinical and Experimental Parameters with 
Survival 
The cell kinetic data and clonogenic growth were not significantly discriminatory 
for predicting the EFS and overall survival. However, some trends were observed 
towards a longer overall survival for patients with a LI < 7.6% (Wilcoxon Ρ = .13), a 
longer EFS for patients with a T
s
 <14.3 h (Wilcoxon Ρ = .10) and a longer overall 
survival for patients without spontaneous clonogenic growth capacity (Wilcoxon 
Ρ = .15). Of the clinical characteristics, only the diagnosis of de novo AML ap­
peared to be a predictor of prolonged survival (EFS: Wilcoxon Ρ = .04; overall 
survival: Wilcoxon Ρ = .10). 
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Relationship of Clinical and Experimental Parameters with 
Survival in De Novo AML 
Because of the differences in survival rates between de novo AML and secondary 
AML, we performed a separate analysis of the first group. The group of secondary 
AML was too small for a survival analysis. Again, we found a trend to better 
survival for patients with below-median LI (<7.6%), more obvious for the EFS: 
Wilcoxon Ρ = .12 and Log-Rank Ρ = .08. The evidence for a longer EFS for patients 
with a below-median T
s
 value (< 14.3 h) reached now statistical significance: EFS 
stratified by T
s
, Wilcoxon Ρ = .02, Log-Rank Ρ = .06). The respective survival curves 
are shown in Fig. 2 and 3: The EFS at 18 months after the onset of the disease for 
patients with a LI < 7.6% was 70%, for patients with a LI > 7.6%, 25%; the EFS at 18 
months for patients with a T
s
 < 14.3 h was 64%, for patients with a T
s
 > 14.3, 27%. 
The EFS at 18 months after the onset of the disease were 53% and 33% for patients 
without and with spontaneous clonogenic growth capacity, respectively, but this 
did not reach statistical significance (Wilcoxon Ρ = .36). With respect to the clinical 
data, we observed a trend (.05 < Ρ < .10) to a prolonged EFS for patients with FAB 
subtypes M0, Ml, M2 compared with those with FAB subtypes M4, M5 and to a 
prolonged overall survival for patients with a below-median age. 
A : LI < 7.6 % 
В : LI > 7.6 % 
Wilcoxon : ρ = 0 . 1 2 
Log-Rank : ρ = 0.08 
Fig. 2. Relationship of labeling index (LI) and event-free survival in untreated de novo 
AML patients. 
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A : Ts S 14J h 
В : Ts > 14J h 
Wilcoion : ρ - 0.02 
Log-Rank : ρ =· 0.06 
Fig. 3. Relationship of DN A synthesis time (T
s
) and event-free survival in untreated de 
novo AML patients. 
Cell Cycle Kinetics In Untreated versus Relapsed AML 
Four patients were studied at primary diagnosis and after relapse. In all four 
patients we observed an increase in percentage S-phase cells (median values: S-
phase cells 5.6 and 9.6%, respectively), an increase in LI (median values: 5.7 and 
10.3%, respectively), and a shortening of the Tpot (median values: 13.2 and 9 days, 
respectively). We found no essential differences in T
s
 values (median values: T
s 
12.8 and 12.8) and CFU-L (median values: 94 and 108 per 2 χ 105 cells, respectively). 
Я Discussion 
Leukemic cell growth in AML is dependent on proliferation of committed leukemic 
progenitor cells and on the amplification and differentiation of these cells to end-
stage cells. Our study demonstrates that assays for cell proliferation of leukemic 
cells can easily be implemented in a clinical setting. A simultaneous application of 
different assays gives additional insight into the processes that result in the produc-
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bon of malignant cells in AML. Furthermore, these assays tend to have prognostic 
relevance in AML. 
We observed no correlation between clonogenic growth characteristics and the in 
vivo cell cycle kinetics. This is in contradiction with the observations of Marie et al. 
[38], who found a relationship between percentage S-phase cells and the CFU-L 
plating efficiency. The discrepancy with our findings may be due to the differences 
in cell kinetic and clonogenic techniques used. Our findings suggest that the clono­
genic growth potential of progenitor cells and cell cycle kinetics of more mature 
cells are two independent biologic characteristics of leukemic cell growth, e.g., a 
high proliferative activity does not necessarily seem to be associated with a high 
efflux of leukemic progenitor cells from the leukemic stem cell compartment. 
Intercurrent (apoptotic) cell loss, regulated by hematopoietic growth factors, may 
contribute to this disparity [39,40]. 
In normal bone marrow, the CD34 immunophenotype is associated with an imma­
ture differentiation level [41,42]. One may anticipate that leukemic bone marrow 
aspirates with a high percentage CD34+ cells will give rise to a high proportion of 
clonogenic cells in a CFU-L assay. However, our data do not support this assump­
tion. This may be explained by the growing evidence that leukemic bone marrow 
cells may show aberrant antigen expression compared with their normal counter­
part cells [43]. Another explanation is a suboptimal stimulation of CFU-L in vitro, 
which may be overcome in the future when new growth factors become available 
[9]. 
The clinical relevance of clonogenic properties is still questionable. This may be 
due to the differences in treatment protocols, in culture systems, in stimulating 
factors and media, and in categorizing growth patterns used in the various studies. 
Some investigators reported an increased response rate in patients with a growth 
pattern of small clusters, in this study defined as growth pattern В [3,44]. We and 
others failed to prove such a relationship [45] or even observed an unfavorable 
response rate [46]. The prognostic relevance of the number of CFU-L is also not 
defined. In accordance with the findings of Marie et al. [38], we found no relation­
ship with the outcome of induction therapy, while Beran et al. [3] reported a 
decreased response rate in patients with a high number of aggregates grown from 
the bone marrow or peripheral blood. Only the spontaneous growth property of 
CFU-L tended to have some clinical relevance in this study. Spontaneous clono­
genic growth capacity was associated, although not statistically significant, with an 
impaired survival rate. One may speculate on the biologic explanation of this 
finding. Spontaneous growth may result from autocrine production of growth 
factors from the progenitor cells and/or accessory cells, like monocytes [47]. But it 
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is undoubtedly a mechanism that makes the leukemic progenitor cells less depend­
ent upon the growth-control mechanisms that exists for normal hematopoiesis [9]. 
The introduction of in vivo cell kinetic methods using administration of halogen-
ated thymidine analogues has greatly facilitated cell kinetic studies. It enables the 
analysis of a detailed cell kinetic profile without substantial discomfort to the 
partent. Until now, only two research groups have applied these studies to AML 
patients. One group used FCM [2] and another used immunohistochemistry of 
double-labeled cells with BrdUrd in vivo and either tritiated thymidine in vitro [1,4] 
or IdUrd ш vivo [48]. 
We observed a wide variation of cell kinetic parameters in untreated AML patients, 
indicating that, from the cell kinetic point of view, we are dealing with a heteroge­
neous disease. Riccardi et al. found that responsive patients were characterized by a 
high proliferation activity (indicated by a high LI, a short T
s
, and a short Tpot) 
compared with nonresponsive patients [2]. Our study, like that of the group of 
Raza et al. [1,4], did not show an association between cell cycle kinetics and re­
sponse rate. It is noteworthy that the same controversy existed in earlier studies 
measuring the percentage S-phase cells or the in vitro thymidine LI. Some investi­
gators found that a high proliferation activity was predictive for achieving CR 
[12,16], while other groups failed to find such a relation [10,14,18]. 
For the survival studies we analyzed both the overall survival and the event-free 
survival (EFS). The EFS gives a useful impression of the course of the disease, as it 
is influenced by both treatment response and relapse or death after entering com­
plete remission. We observed a trend to longer survival rates in patients with 
below-median LI. The better survival for patients with a low LI corresponds with 
the results of earlier in vitro cell kinetic studies [15,16,18] and the recent findings of 
HI vivo labeling studies of Bokhari et al. [4]. In contrast, Riccardi found a signifi­
cantly higher median LI of patients with above-median CR duration or survival [2]. 
These discrepancies may, at least in part, be due to differences in treatment proto­
cols. 
We performed the cell kinetic measurements with bone marrow aspirates rather 
than with crista biopsies. Variable hemodilution does not affect the analysis of the 
T
s
 [49], but it may affect the analysis of the LI. Bokhari et al. [4] found a lower LI in 
bone marrow aspirates compared with biopsies from patients with AML, although 
the LI obtained by the two sampling techniques appeared correlated (P = .0001, 
and r = .48). In our study the aspirates were drawn from the sternum. This punc­
ture site usually gives less hemodilution compared with aspirates drawn from the 
iliac crest [50]. The peripheral admixture of nucleated blood cells was evaluated in 
all aspirates and appeared relatively low (median values: 19%). The blood admix-
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ture was even more reduced by collecting low-density BM cells using density 
gradient centrifugation. 
The IdUrd kinetic methods enabled, for the first time, an analysis of dynamic cell 
kinetic parameters, describing the duration of certain cell cycle phases, like the Ts. 
The Ts appeared to be an independent kinetic parameter, not correlated with the LI. 
Therefore, a high proliferative activity, deduced from a high LI, is not necessarily 
associated with a short Ts. We observed a positive correlation between the number 
of WBC and the Ts. The present study does not provide further insight into the 
underlying mechanism of this relationship. One could speculate about a negative 
feedback on the transition of the cells through the S-phase, in case of an accumula-
tion of WBC. Our data demonstrate a longer EFS in patients with a short duration 
of Ts. This fits with the results of Riccardi et al, who observed a trend to a shorter Ts 
in patients with a long duration of their CR [2]. The prognostic benefit of a short Ts 
could suggests an increased sensitivity of fast proliferating cells for cytotoxic treat-
ment regimens. 
The Tpot equals the Tc, assuming a growth fraction of unity in leukemic blasts, 
although this assumption is still controversial [51]. In our study the Tp0[ appeared 
not to be a prognostic indicator, as it was not associated with survival (overall 
survival or EFS). Riccardi et al. observed a significantly shorter Tpot in patients with 
a favorable course of the disease. This contrasts with the findings of the group of 
Raza et al. who reported a shorter remission duration in patients with a below-
median Tc value [1,4]. 
In conclusion, our knowledge regarding the complex processes of leukemic cell 
growth has been extended, thanks to new assays that are now available in a clinical 
setting. Despite the partly conflicting results and the limited number of patients 
studied by FCM techniques, there is a strong evidence that these assays will give 
important additional information that can be used to predict the clinical course in 
individual AML patients. The most challenging task for the future will be to 
improve and individualize treatment modalities based upon biologic features of 
the disease. This hope could become reality, as nowadays a new group of agents 
are available that have the potential to modulate cell growth and differentiation at 
different levels, like the hematopoietic growth factors [9]. For example, pilot stud-
ies already have been initiated that use GM-CSF treatment in AML to push leuke-
mic cells into proliferation in order to increase their sensitivity to cytotoxic agents 
[52-54]. We feel that cell cycle kinetic assays are essential to monitor the effects of 
these approaches and to find out which patient will benefit and which will not. 
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In Vivo Cell Cycle Kinetics in Malignant Lymphomas 
В Abstract 
Cell cycle kinetics of malignant lymphoma were investigated using in vivo labeling 
with iododeoxyuridine (IdUrd) and subsequent flow cytometry (FCM) of IdUrd/ 
DNA and Ki-67/DNA. This approach provides an extensive cell kinetic profile 
from only one single tumor biopsy, including data upon the percentage of S-phase 
cells, the IdUrd labeling index (LI), Кі-67-derived growth fraction, duration of the 
S-phase, duration of the Gi-phase, potential doubling time, cell production rate, 
and total cell cycle time. Tissue samples from 33 patients were studied: non-
Hodgkin's lymphoma (NHL; и = 22), Hodgkin's disease (HD; η = 7), and reactive 
hyperplasia (н = 4). In NHL, the percentage of S-phase cells, LI, growth fraction, 
potential doubling time, and cell production rate were significantly correlated with 
the histologic malignancy grade according to the Working Formulation (P < .02). 
Data found in HD were not essentially different from those in low-grade NHL and 
reactive hyperplasia. Remarkably, the duration of the S-phase, the Gi-phase, and 
the total cell cycle time appeared to be rather independent of histologic malignancy 
grade within the NHL category. A significant correlation was observed between 
the IdUrd LI and the percentage of S-phase cells, the growth fraction, the potential 
doubling time, and the cell production rate (P < .001) but not with the duration of 
the separate cell cycle phases (P > .05). 
Our data demonstrate (1) that it is feasible to obtain detailed information on the in 
vivo growth characteristics of malignant lymphoma; and (2) that the transition time 
through the different cell cycle phases widely varies, even within distinct histologic 
subgroups. 
Ш Introduction 
Malignant lymphomas constitute a heterogeneous group of lymphoproliferative 
disorders with respect to presentation, clinical course, response to treatment, and 
prognosis. Histopathologic classification and clinical staging are considered subop­
timal to predict the biological and clinical behavior of these tumors. Therefore, 
additional parameters are urgently needed. 
The role of proliferative activity has received special attention. Different techniques 
have been used to study cell kinetics in lymphomas: measurement of the percent­
age of S-phase cells by DNA flow cytometry (FCM) [1-10], assessment of the 
labeling index (LI) by in vitro incorporation of tritiated thymidine and autoradio­
graphy [11,12], and staining with the Ki-67 monoclonal antibody (MoAb), which 
reacts with a proliferation-associated nuclear antigen [13-17]. The clinical impact of 
cell kinetics with respect to classification and prognosis of lymphomas remains 
questionable [18]. This might be due to the limitations of the techniques available in 
a clinical setting. Measurement of the S-phase fraction is difficult to assess in 
aneuploid tumors [1]. Overesrimation of the proliferative activity may occur due to 
arrested S-phase cells [19]. Assessment of the thymidine LI requires ex vivo undis-
turbed growth of the tumor cells, and is time-consuming. However, the major 
limitation of these techniques is that they provide only a partial and static kinetic 
profile, since only the distribution of cells in certain cell cycle phases at one particu-
lar moment can be determined. 
Measurement of dynamic kinetic parameters, representing the duration of distinct 
cell cycle phases, has now become feasible by the introduction of in vivo administra-
tion of bromodeoxyuridine (BrdUrd) or iododeoxyuridine (IdUrd) and FCM [20]. 
BrdUrd or IdUrd are non-radioactive pyrimidine analogues that are incorporated 
into the DNA during the S-phase. Simultaneous flow cytometric detection of 
IdUrd/BrdUrd incorporation and DNA content is possible using specific MoAbs 
directed against these pyrimidine analogues [21,22] combined with appropriate 
cytochemical protocols [23,24]. Using in vivo IdUrd/BrdUrd administration, both 
static and dynamic growth characteristics, such as the LI, DNA synthesis time (Ts), 
potential doubling time (Tpot), and cell production rate (CPR), can be calculated 
with data obtained from a single tumor sample [20]. The dose of IdUrd adminis-
tered to adults for in vivo cell kinetic analysis in this study (200 mg) is far below the 
concentration that may induce cytotoxic effects [25]. IdUrd/BrdUrd kinetic studies 
have been performed in various malignancies [26-31]. Until now, none of these 
studies has been directed to lymphomas. 
We present the results of in vivo IdUrd kinetics in 29 patients with malignant 
lymphoma and four patients with reactive hyperplasia. We show the feasibility of 
the technique and relate the kinetic data (LI, Ts, Tpot, and CPR) to the histologic 
classification. In addition, we show how the kinetic information can be extended to 
data on cell cycle time (Tc) and duration of the Gi-phase (TG;) by determining the 
Ki-67 derived growth fraction [32]. 
/η Vivo Cell Cycle Kinetics In Malignant Lymphomas 
Ш Materials and Methods 
Patients 
Forty-three patients clinically suspected of primary or relapsed malignant 
lymphoma were eligible for this study and received IdUrd prior to diagnostic 
biopsy. None of the patients had received any cytostatic treatment or radiotherapy 
within 8 weeks before the cell kinetic analysis. Permission to administer IdUrd was 
obtained by the local ethical committees and from the National Cancer Institute 
(NCI; Bethesda, Maryland), with the NCI supplying the drug. Written informed 
consent was obtained from all patients. In six cases, no tissue or insufficient tissue 
was available to separate material for research purposes. In one case, the tumor was 
localized in the gastric mucosa, and it was not possible to prepare an adequate cell 
suspension of the tissue. Three tumor biopsies 'were diagnosed as carcinomas. 
These 10 cases were excluded from this study, leaving 33 cases for analysis. 
In Vivo IdUrd Labeling 
The NCI supplied us with vials of 200 mg freeze-dried IdUrd. The vials were stored 
at 5°C until use. Before the infusion, the IdUrd was dissolved in 30 ml isotonic 
saline. All patients received 200 mg IdUrd as a 15-min intravenous infusion. The 
end of the infusion was defined as time zero (To). 
\ Tissue Sampling and Tissue Preparation for Flow Cytometry 
Between 3.8 and 7.5 h (median, 5.5 h) after in vivo IdUrd labeling fresh tissue 
samples were obtained from surgically removed lymph nodes (и = 31) or spleen 
(H = 1). In one case, cells were aspirated from bone marrow (BM) completely 
infiltrated by lymphoma. The biopsies were immediately submerged in an ice-cold 
solution of glucose phosphate buffer to stop cell growth. The BM aspirate was 
collected in ice-cold buffered acid-citrate dextrose formula A (pH 7.0). One part of 
the biopsy material was processed for histopathology, another part was snap-
frozen in liquid nitrogen for immunohistology, and a third part was used for 
IdUrd/DNA FCM, Ki-67/DNA FCM and CD3/DNA FCM. The cells from the 
latter were suspended by mincing and washing in glucose phosphate buffer. Low-
density nucleated BM and spleen cells were collected by density centrifugation 
[33]. All cell suspensions were divided in two portions. The cells from one portion, 
to be used for IdUrd/DNA FCM, were fixed in cold 75% ethanol [24], stored at -
20°C, and protected from light before analysis. The cells from the other portion, to 
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be used for Ki-67/DNA and CD3/DNA staining, were cryopreserved using a 
temperature-controlled freezing program [34]. 
Histopathology and Immunohistology 
For routine histologic examination, the biopsy material was fixed in neutral buff­
ered formalin and embedded in paraplast. Sections of 4 urn were stained with 
hematoxylin and eosin (H&E), Giemsa, methylgreen pyronin, periodic acid Schiff, 
and Laguesse reticulin stain. The non-Hodgkin's lymphomas (NHL) were typed 
according to the Kiel Classification [35], with determination of the histologic grade 
of malignancy according to the criteria of the Working Formulation [36]. For Τ cell 
NHL, we used the updated Kiel Classification [37]. In all cases of NHL, the histo­
logic diagnoses and the origin of the tumor cells were established or confirmed by 
immunohistochemical staining of cryostat sections and paraffin sections with com­
mercially available MoAbs using standard techniques and criteria. Cases of 
Hodgkin's disease were typed according to the criteria of the Rye Classification 
[38]. Immunohistochemical staining with antibodies against CD15 and CD30 re­
sulted in a pattern consistent with HD in all cases. 
IdUrd/DNA, Ki-67/DNA, and CD3/DNA Staining 
Bivariate staining for IdUrd incorporation and DNA content was performed using 
the simultaneous proteolytic enzyme digestion and acid denaturation technique 
[24]. The anti-IdUrd HN-IU MoAb, developed at our department, and a fluorescein 
isothiocyanate (FTTC)-conjugated IgG goat antimouse second-step antibody 
(GAM-FTTC; American Qualex International, La Mirada, California) were used for 
detection of IdUrd. The HN-IU MoAb shows cross-reactivity with BrdUrd, but not 
with fluorodeoxyuridine. It allows for a good separation of labeled and nonlabeled 
cells. Propidium iodide was used for DNA staining. IdUrd/DNA staining of the 
lymphoma cell suspensions was always performed in duplicate and all incubation 
steps were executed in the dark. Non-IdUrd-labeled low-density blood cells served 
as negative controls. 
Cryopreserved cell suspension samples were thawed rapidly at 37°C. Aliquots of 1 
χ 106 cells were stained for DNA content and nuclear Ki-67 expression, according to 
the method of Palutke el al. [39], and with use of the Ki-67 MoAb purchased from 
Dako (Glostrup, Denmark) and the GAM-FTTC second-step antibody. Staining of 
the lymphoma cell suspensions was always performed in duplicate. A sample 
incubated with only the second step antibody served as the control sample for 
nonspecific Ki-67 staining. 
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Bivariate CD3/DNA staining was performed on aliquots of 1 χ IO6 thawed cells for 
the determination of the number of reactive T-cells in B-cell NHL and their percent­
age of S-phase cells. A previously described staining protocol was used, producing 
high-resolution DNA histograms while preserving cell-surface immunofluore­
scence [33]. Cells labeled with only GAM-FITC served as the negative control. 
Flow Cytometry 
The IdUrd/DNA stained samples of the first 20 patients were analyzed on an 
Ortho 50H Cytofluorograf (Ortho Instruments, Westwood, California), with filter 
settings as described previously [24]. Thereafter, a Coulter Epics Elite (Coulter, 
Hialeah, Florida) was used, equipped with a 40 mW Argon ion laser running at 15 
mW, on which the remaining IdUrd/DNA samples, as well as all the Ki-67/DNA-
and CD3/DNA-stained samples, were analyzed. Control measurements showed 
no differences in the results of the IdUrd analyses between the two flow cyto-
meters. A high-pass filter of 610 nm for red fluorescence (propidium iodide), a 
band-pass filter 525/30 for green fluorescence (FITC), and a dichroic mirror of 550 
nm were used. A minimum of 20,000 cells was analyzed in duplicate. In cases with 
a low LI, this was extended up to 200,000 cells. The fluorescence signals were 
recorded on a linear (DNA and IdUrd) or logarithmic (Ki-67 and CD3) scale in list 
mode. Cell debris and cell doublets were eliminated based upon their DNA content 
and the ratio area / peak of the red fluorescence signal [40]. 
Calculation of Kinetic Parameters 
The duration of the S-phase (T
s
) was determined from the bivariate IdUrd/DNA 
analysis according to the model of Begg et al. [20]. This model calculates the T
s
 from 
the increase in mean DNA content of the IdUrd labeled nondivided cells since the 
start of the labeling, assuming that the mean DNA of the labeled cells at time zero is 
3n DNA. 
The LI was defined as the percentage of IdUrd-labeled cells. A correction was made 
for the cells that had divided since the start of the IdUrd labeling (actually, the 
nonlabeled G2+M cells plus the IdUrd labeled cells that have divided and entered 
the Gj- and early S-phase). The fractions of these cells were halved in both the 
denominator and the numerator: 
L I , % ) = IdUrdNon-divided + (IdUrdpjyided * 0-5) χ ш 
100 - (IdUrdbivided x °·5) - (G2+M-phase χ 0.5) 
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The Tpot represents the tumor doubling time, assuming that no cell loss occurs. The 
Tpot and the CPR are both indirectly calculated from the T
s
 and LI: 
T
s
 100 
LI 24 Tpot (days) = - | x -
CPR (cells/100 cells/day) = ^ χ 24 
Ts 
The growth fraction (GF; measured as a percentage) was estimated from the frac­
tion of Ki-67 positive cells. The percentage of positively labeled cells in the control 
sample was subtracted to correct for nonspecific staining (usually < 2%). 
The T
c
 was calculated from the T
s
, the LI, and the Ki-67 GF: 
GF 
LI 
Tc(h) = ^ x T s 
Finally, the duration of the Grphase (TGJ) was calculated from the T
c
 and the Gi-
phase fraction of the cycling population (Ki-67 positive cells, F^Cycling): 
T G ! (h) = T
c
 χ FG-, Cycling 
In cases of DNA aneuploidy with an admixture of diploid cells, the cell kinetic 
analysis was performed of the aneuploid population by creating an appropriate 
window for selecting these cells. 
Analysis of percentage of S-phase Cells in the Overall Popu­
lation and in CD3+ Cells 
DNA histograms of the overall population were derived from the IdUrd/DNA 
analyses. Calculation of S-phase DNA in cases with unimodal DNA distributions 
was performed according to the method of Baisch et al, model 4 [41]. No appropri­
ate model is available for calculating percentage of S-phase cells in cases with 
bimodal distributions. However, an estimate of the percentage of S-phase cells in 
those cases was made by selecting the cells with hyperdiploid and tetraploid DNA 
content. In B-cell NHL, the percentage of S-phase cells of the reactive T-cells was 
calculated from the DNA histograms of the CD3+ cells, derived from the bivariate 
CD3/DNA analysis. 
Statistics 
Correlations between cell kinetic parameters were assessed with Spearman's rank 
correlation analysis. The Kruskal-Wallis Test, a nonparametric test for independent 
samples, was employed to test differences in the values of the kinetic parameters 
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between the three malignancy grades in NHL. Statistical analyses were performed 
using the software package of SAS Institute Incorporation (Сагу, NC). 
• Results 
Patient Characteristics and Histopathologic Diagnosis 
Table 1 shows some relevant clinical and histologic data. Five histologic categories 
were defined: reactive hyperplasia (и = 4), Hodgkin's disease (HD; π = 7), low-
grade NHL (LG-NHL; и = 7), intermediate-grade NHL (IG-NHL; η = 10), and high-
grade NHL (HG-NHL; η = 5). Only one NHL of T-cell origin was found; all other 
NHL were of the B-cell phenotype. 
Cell kinetic data 
The IdUrd U could be measured in 31 of the 33 patients, and the T
s
, Tpot, and CPR 
in 30 of the 33 cases. In one case, the DNA analysis was impeded, and in another 
case the kinetic analysis was hampered due to a large overlap in DNA content of 
proliferating aneuploid and diploid cells. In a patient with reactive hyperplasia, the 
very low LI (0.1%) prohibited the calculation of the T
s
, Tpot, and CPR, although 
200,000 cells could be analyzed. 
As an example, Figure 1 shows results of DNA/IdUrd analysis in three patients 
with an HG-NHL. Even in a linear presentation, the clear separation between 
labeled and unlabeled cells is evident in all the three samples. A high LI is seen in 
Figure 1A and В (24.4% and 34.4%, respectively). However, the transition time 
through the S-phase is completely different. The labeled cells in Figure 1A have 
moved relatively fast through the S-phase and after 6.00 h many have already 
undergone mitosis and entered the Gi-phase. In contrast, the majority of the la­
beled cells in Figure IB are still in the S-phase after 5.47 h. This results in a shorter 
T
s
 in patient A in comparison with patient В (14.6 and 31.5 h, respectively). Figure 
1С shows an example of an HG-NHL with a low LI (3.6%). 
The median values and range of the cell kinetic data of each subgroup and the 
results of the statistical analysis are summarized in Table 2. IdUrd/DNA analysis 
in NHL revealed a low median LI in the LG-NHL (1.0%), a higher median LI in the 
IG-NHL (9.1%), and the highest value in the HG-NHL (18.4%) (P < .01). However, 
there was considerable overlap in LI values between these three subgroups. Ex-
pectedly, the median percentage of S-phase cells displayed a similar pattern with 
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Diagnosis 
Reactive 
hyperplasia 
(n = 4) 
HD (η = 7) -
LG-NHL 
(я =7) 
IG-NHL 
(η = 10) 
HG-NHL 
(π = 5) 
Table 1 
Clinical and Histologic 
Median 
Age (yr) 
(range) 
55 
(45-73) 
36 
(19-58) 
32 
(28-58) 
62 
(42-76) 
47 
(19-69) 
Sex 
(M:F) 
1:3 
5 : 2 
2 : 5 
5 : 5 
4 : 1 
Characteristics 
Clinical 
Presentation 
(primary:relapse) 
NA 
5 : 2 
3 : 4 
4 : 6 
2 : 3 
Histologic 
Type 
RH 
NS (η = 4) 
MC (η = 2) 
LD (и = 1) 
CB-CC foil 
(η = 7) 
CB diff (л = 7) 
1С pm (и = 2) 
CC diff (η = 1) 
IB (и = 2) 
B T - L B ( H = 2 ) 
T-LB(rt = l) 
Abbreviations: NA, not applicable; RH, reactive hyperplasia; NS, nodular sclerosis; MC, 
mixed cellularity; ID, lymphocyte depletion; CB-CC fol, centroblastic-centrocy tic follicular; 
CB diff, centroblastic diffuse; 1С pm, immimoajtoma polymorphic; CC diff, centrocytic 
diffuse; IB, B-immunoblastic; BT-LB, Burkitt type lymphoblastic; T-LB, T-lymphoblastic. 
the lowest values in the LG-NHL and the highest in the HG-NHL (P < .01). In 
contrast, a significant relationship between malignancy grade and the duration of 
the S-phase (T
s
) could not be shown. There was a wide range in the T
s
 values in the 
NHL (8.4 to 50.2 h) and the overlap between the three histologically defined 
subgroups was considerable. A very long median Tpot was found in the LG-NHL 
(57.2 days) as compared with IG-NHL (6.3 days). The shortest value was seen in 
HG-NHL (4.6 days) (P = .02). The reciprocal value, CPR, showed an opposite 
relationship with a short median CPR in LG-NHL and a higher median CPR in IG-
NHL and HG-NHL (P = .02). 
The number of HD was too small to study the relationship between IdUrd kinetics 
and histologic subtyping within this group. The median values of the percentage of 
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Fig. 1. Bivariate linear analyses of DNA content versus IdUrd incorporation of three 
patients with malignant lymphoma. Cells were labeled in vivo with 200 mg IdUrd and 
after 5-6 h a biopsy was obtained. To visualize the nonfluorescent cells in the scatter 
plot, 400 fluorescent units wereadded to the level of green fluorescence (IdUrd) of each 
cell. The horizontal lines indicate the level used for discrimination between IdUrd-
labeled and non-IdUrd-labeled cells. The vertical lines are set to discriminate between 
IdUrd-labeled cells that had not yet divided since the start of the labeling and those that 
had already entered Gj- and early S-phase. (A) Malignant lymphoma with a high 
IdUrd LI and a rapid transition of the labeled cells through the S-phase. After 6.00 h, 
many cells have already undergone mitosis and reentered the G-¡- and early S-phase. 
(B) Malignant lymphoma with a high U and a slow transition through the S-phase. 
After 5.47 h, the majority of the cells are still in S-phase. (C) Malignant lymphoma 
with a relatively low U. 
S-phase cells and the LI were close to those observed in the LG-NHL. The Ts was 
relatively short in this group with a median value of 10.6 h. This explains the 
somewhat shorter median Tpot and higher CPR, as compared with the LG-NHL. 
The small number of patients with reactive hyperplasia prohibited a kinetic charac-
terization of this subgroup. Nevertheless, it can be concluded that this group 
appears to be rather heterogeneous with respect to percentage of S-phase cells, LI, 
Ts, Tpot, and CPR. 
I Ki-67 Derived Growth Fraction 
Ki-67 discriminates between cycling (Gi-, S-, and G2+M-phase cells) and resting 
cells (Go-phase cells). Figure 2 shows examples of bivariate measurements of Ki-
67/DNA. It demonstrates that the Ki-67 MoAb reacts with all S-phase cells and the 
majority of G2+M-phase cells, except for some residual cell clumps. In the Go/G]-
phase the Ki-67 staining discriminates between G] cells (positively labeled) and Go 
cells (negatively labeled). Figure 2A represents a lymphoma with a high GF (95%) 
and few GQ cells, Figure 2B an intermediate GF (19%), and Figure 2C a low GF (5%) 
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Fig. 2. Bivariate analyses of DNA content (linear scale) versus nuclear Ki-67 staining 
(logarithmic scale) of three patients with a malignant lymphoma. The horizontal lines 
indicate the levtl used for discrimination between cells positive and negative for Ki-67 
staining. The GF is derived from the percentage of cells expressing the Ki-67 antigen. 
All S-phase cells and the majority of G2+M-phase cells, except for some residual cell 
clumps, are positive for Ki-67 staining. In the Gg/G^phase, the Ki-67 staining dis­
criminates between Gj cells (positively labeled) and G0 cells (negatively labeled). (A) 
Malignant lymphoma with a high GF (95%) and few GQ cells. (B) Malignant lympho­
ma with an intermediate GF (29%). (C) Malignant lymphoma with a low GF (5%) and 
many GQ cells. 
with many Go cells. These lymphomas were classified as HG-NHL, IG-NHL and 
LG-NHL, respectively. The Ki-67 GF could be adequately measured in 30 of 33 
cases. The results are summarized in Table 2. In two cases, the same reasons that 
hampered the determination of the LI precluded the Ki-67/DNA analysis. In one 
patient, substantial non-specific Ki-67 staining was encountered. Within the NHL, 
a low median GF was found in the LG-NHL (6%), and a high median GF in the IG-
NHL (26%) and HG-NHL (34%) (P = .02). In HD, a relatively low median GF was 
observed (7%). Cases with reactive hyperplasia showed both low as well as inter­
mediate values. 
Calculation of Tc and TGT Derived from IdUrd/DNA and 
Ki-67/DNA Data 
Combining the data derived from the IdUrd/DNA and Ki-67/DNA analysis, two 
additional dynamic kinetic parameters could be calculated: the duration of the cell 
cycle (T
c
) and of the Gi-phase ( T^) (Table 2). Both IdUrd/DNA as well as Ki-67/ 
DNA kinetic data were available in 29/33 patients. There was a wide range in T
c 
and TGJ, but even within each histologic subgroup, the T
c
 and TGJ showed great 
variations. In NHL, the longest median duration of the T
c
 and TQJ were noted in 
LG-NHL (107 and 80 h, respectively), and the shortest in HG-NHL (57 and 36 h, 
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respectively) while the median values in IG-NHL were in between (69 and 47 h, 
respectively). However, these differences did not reach statistical significance. In 
HD the median T
c
 (62 h) and TQ^ (37 h) were close to the values observed in the IG-
NHL and HG-NHL. The T
c
 and TGJ in reactive hyperplasia was successfully 
assessed in only three of the four patients . 
Relationship Between distinct Kinetic Parameters 
Statistical analysis showed a significant correlation with a strong r coefficient value 
between the IdUrd LI and each of the two other static kinetic parameters: the 
percentage of S-phase cells (P < .001, r = .97) and the Ki-67 GF (P < .001, r = .91). 
However, the ratio of the median Ki-67 GF and the median IdUrd LI decreased 
with increasing malignancy grade (1:6 in LG-NHL, 1:3 in IG-NHL, and 1:2 in HG-
NHL). In addition, a strong correlation was observed between the IdUrd LI and the 
Tp0t (P < .001, r = -.96) and CPR (P < .001, r = .96). There was no significant correla­
tion between the LI and the dynamic kinetic parameters T
s
 (P = .10), T
c
 (P = .05), and 
TG] (P - 06), with poor г coefficient values (T
s
, r = .31; T 0 r - -37; and JQV 
r = - .35). 
Reactive T-cells and their S-phase DNA Content in B-cell NHL 
IdUrd FCM provides no information on the proliferative activity of distinct sub-
populations, e.g., nonmalignant reactive cells in B-cell NHL. Therefore, we as­
sessed to what extent the results might have been jeopardized due to cell heteroge­
neity. The percentage of reactive T-cells (CD3+) and their S-phase DNA content 
were determined retrospectively in 17 cryopreserved NHL. The median number of 
CD3+ cells was 14% (range: 1-70%). In only 4 of 17 NHL, the fraction CD3+ cells 
exceeded 30%. The proliferative activity (percentage of S-phase cells) of the CD3+ 
cells was low (median value: 3.2%; range: 0.1-20.7%) compared with the overall cell 
population (median value: 6.5%; range: 0.6-39.4%). This suggests that the low 
proliferating CD3+ cell population will barely affect the results of analysis of the 
dynamic parameters (T
s
, T
c
, and TQJ) in the cycling population. 
The representativity of the examined cell suspensions was studied by comparing 
the number of T-cells in frozen séchons with those found in cytospin preparations 
from the cryopreserved cell suspensions, using Pearson's correlation analysis. This 
was retrospectively performed in 6 NHL (1 LG-NHL; 3 IG-NHL; and 2 HG-NHL). 
The numbers of T-cells in the histologic sections and in the cytospin preparations 
were significantly correlated (P < .01, r = .92). Therefore, a selective loss of tumor 
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cells compared with reactive T-cells during the preparation of the cell suspensions 
is unlikely, as this would result in a relative increase of the reactive cell population. 
S Discussion 
The present study demonstrates the feasibility of obtaining a detailed profile of in 
vivo growth kinetics in patients with malignant lymphoma using in vivo IdUrd 
labeling and subsequent bivariate FCM. Data are obtainable from only one single 
tumor biopsy that has to be performed for diagnostic purposes. No side effects of 
the IdUrd administration were observed. In our series, we found a wide range in 
the values of static kinetic parameters, e.g., percentage of S-phase cells, IdUrd LI, 
and percentage of Ki-67 positive cells. In the 22 patients with NHL, there was a 
statistically significant increase in the median values of these parameters with 
increasing histologic malignancy grade of the tumor. Most strikingly, the dynamic 
kinetic parameters, e.g., duration of the different cell cycle phases (Tc, Ts, and TG^ 
did only weakly or not at all correlate with the static kinetic parameters and the 
histologic malignancy grade. This suggests that the dynamic parameters may repre-
sent a new class of independent variables. 
Our cell kinetic data confirm the heterogeneity of NHL. Although the classification 
in three histologic malignancy grades affords a clinically useful guidance with 
regard to selection of treatment and prognosis [42], the predictive power is far from 
perfect. Additional parameters are therefore urgently needed for the identification 
of distinct subgroups of NHL. Conflicting results have been reported in literature 
on the clinical relevance of measurement of the percentage of S-phase cells [18] or 
the percentage of Ki-67 positive cells [13-17]. This might not be too unexpected 
because our data show, in accordance with others [1,7,18], that these kinetic param-
eters and the histologic classification in three malignancy grades are strongly 
interrelated: a low percentage of proliferating cells in LG-NHL and significantly 
higher numbers in the IG-NHL and HG-NHL. Within distinct histologic subgroups 
the clinical relevance of these parameters is not clearly evident. In LG-NHL, the 
poor prognostic influence of a high proliferation activity is well documented, while 
in HG-NHL the relationship with survival, especially on long-term survival, re-
mains equivocal [18]. LG-NHL is characterized by a protracted and, apart from 
stage I disease, virtually incurable course of disease [43]. This may be related, at 
least in part, to the relatively low fraction of proliferating cells, making these 
tumors less susceptible to current treatment regimens. Indeed, we found a low 
median percentage of S-phase cells of 1.2, a low IdUrd LI of 1.0, and a small Ki-67 
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derived growth fraction of only 6% in the group of LG-NHL. These findings were 
reflected in a significantly longer median potential tumor doubling time of 57 days, 
as opposed to 6.3 and 4.6 days in the IG-NHL and HG-NHL, respectively. Unex-
pectedly, the low proliferative activity of low-grade NHL was not accompanied by 
a prolonged duration of the S- and the G]-phase. Neither did the HG-NHL show a 
short duration of the S- and the Gi-phase, despite their high proliferative activity. 
So far, we cannot draw definite conclusions from these data because of the rela-
tively low number of patients studied and the wide range in calculated values. 
However, the remarkable divergence in the duration of the transit times through 
the different cell cycle phases, which appeared to be independent of the histologic 
malignancy grade, may reflect distinct characteristics of the respective lymphomas. 
These results may prove to be useful in understanding biology and clinical beha-
vior. 
Several factors may limit the performance of adequate in vivo analysis of cell cycle 
kinetics in malignant lymphoma. First, IdUrd has to be administered several hours 
before the surgical procedure, necessitating close cooperation between the investi-
gator and the surgical team. Another prerequisite for this study is the feasibility of 
obtaining a full kinetic profile. In our study this was achieved in 29 out of 33 cases. 
Another problem might be intratumoral heterogeneity of cell populations, raising 
the question of representativity of the examined tumor specimen. Data reported by 
Cowan et al. [3] in lymphomas and of Begg et al. [44] in solid tumors indicate that 
the possible bias introduced by supposed intratumor heterogeneity is marginal. A 
drawback of studying percentage of S-phase cells with conventional methods is the 
number of arrested S-phase cells that, although measured as S-phase cells, do not 
actively contribute to proliferation [19]. Our data show considerable concordance 
in the percentage of S-phase cells and the in vivo IdUrd LI. Because arrested S-phase 
cells do not incorporate IdUrd, these results indicate that arrested S-phase cells 
occur only infrequently in these NHL. 
A major problem in the interpretation of our results might be that the in vivo 
dynamic data represent characteristics of the overall cell population rather than 
those of the tumor cells per se. Admixture of nonmalignant cells is well known in 
NHL and may account for up to 60% of the overall population [2]. This feature is 
largely restricted to the LG-NHL and IG-NHL and is less relevant in HG-NHL [5]. 
In accordance with other reports [2,45], the median proportion of "reactive" T-cells 
in our B-cell NHL was 16% and exceeded 30% in only 4 out of 22 cases. More 
importantly, the percentage of S-phase cells, analyzed separately in the "reactive" 
T-cell population, accounted for only a median value of less than 50% of the 
percentage of S-phase cells in the tumor cell population. Therefore, the results of 
the analysis of the dynamic parameters, e.g., the duration of the different cell cycle 
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phases in the overall cell population, will barely be affected because these param-
eters are calculated exclusively in the population of cycling cells. 
In HD, heterogeneity is more complex. In fact, the exact nature of the malignant cell 
population has not yet been unraveled. Apart from the neoplastic cells, infiltrating 
B- and T-cells may contribute considerably to tumor growth. Thus, the results of in 
vivo dynamic studies in HD may be expected to approximate those obtained in 
reactive lymph nodes. For comparison, we included data from four patients with a 
histologic pattern of reactive hyperplasia. Nevertheless, also in HD, proliferative 
characteristics of the overall cell population analyzed with DNA FCM have been 
reported to correlate with histologic subtyping [10] and survival [6]. In our small 
group of seven patients with HD, the percentage of proliferating cells was low, 
consistent with other reports [4,6,46]. The IdUrd LI of 1% was comparable with the 
results obtained in LG-NHL. As in the NHL, a wide range in dynamic cell kinetic 
parameters was observed in HD. The median duration of the G]-phase and the 
total cell cycle time approximated that observed in the IG-NHL and HG-NHL 
rather than that of the LG-NHL. This finding might fit in the clinical response to 
treatment when we assume that kinetic parameters indeed have a prognostic 
impact on the response to currently available treatment regimens. Obviously, 
further studies should be directed towards obtaining kinetic data on distinct, 
immunophenotypically defined, subpopulations of cells, especially in HD. 
The kinetic data derived from the IdUrd/DNA analysis were calculated using the 
single sample model of Begg et al. [20]. Information on the tumor growth fraction 
(GF) and the fraction of cells in Gi-phase is a prerequisite for the calculation of Tc 
and JQV The GF of the tumor is difficult to assess. Prolonged, continuous labeling 
with tritiated thymidine combined with multiple tissue sampling may be consid-
ered as the standard approach. However, with regard to in vivo measurements in 
humans, this method is not suitable [47]. An estimation of the GF can also be 
obtained by measurement of IdUrd or BrdUrd incorporation at a single time point 
after continuous in vivo labeling, especially after sequential administration of 
IdUrd/BrdUrd [48]. Although this method of analysis is more feasible than the 
tritiated thymidine approach, it is still unsuitable for routine use in vivo. Therefore, 
we have selected a more indirect but clearly more practical method, e.g., staining 
with the Ki-67 MoAb. Ki-67 reacts with a nuclear antigen expressed in the Gì-, S-, 
and G2+M-phases but not in the Go-phase [32]. Comparison with GF determination 
with in vivo continuous thymidine labeling in xenografts revealed that Ki-67 pro-
vides a reliable estimate of the tumor GF [49,50]. 
Apart from the alleged clinical significance of detailed in vivo cell kinetic profiles in 
malignant lymphoma, it is tempting to speculate that this method will give new 
insights in the mechanisms of tumor cell proliferation and progression. Since 
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proliferative activity is, at least in part, regulated by an orderly expression of genes, 
simultaneous analysis of dynamic cell kinetics in vivo and of altered (onco)-gene 
expression may show relevant new information [51]. Novel staining protocols for 
simultaneous measurement of IdUrd incorporation, DNA content, and oncogene 
expression in both the overall cell population as well as immunophenotypically 
defined subpopulations, are likely to increase the significance of the results and are 
presently under study. 
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Cell Cycle Kinetics in Refractory Anemia after Treatment with GM-CSF 
Ш Abstract 
GM-CSF administration to patients with refractory anemia (RA) induces an in­
crease in neutrophils and eosinophils. We studied cell kinetic mechanisms underly­
ing this observation using clonogenic assays and in vivo iododeoxyuridine labeling 
of bone marrow cells. Cell cycle kinetics were studied in three patients before and 
during GM-CSF administration (two daily subcutaneous injections of 54 or 108 μg). 
No consistent effect on the relative number of bone marrow CFU-GM was noticed. 
The DNA synthesis time and potential doubling time of low density bone marrow 
cells remained essentially the same. A slight decrease (1.5-3.7%) in labeling index 
was found originating from the myelo(-mono)cytic lineage. In all three patients the 
release time of labeled granulocytes from the bone marrow into the peripheral 
blood was shortened (before GM-CSF treatment 5-7 days and during GM-CSF 3-4 
days, respectively). Cell cycle kinetics of CD34+ cells were studied in order to 
obtain kinetic information on immature precursor and progenitor cells. The DNA 
synthesis time of the CD34+ cells was shortened during GM-CSF therapy resulting 
in a shorter potential doubling time. 
In conclusion, GM-CSF administration to patients with RA results in a rise in 
granulocytes that might be partly due to an accelerated release of granulocytes 
from the bone marrow compartment into the circulating blood and partly to an 
increased proliferative activity of the immature precursor and progenitor cells. 
Ш Introduction 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) belongs to a group 
of glycoproteins that plays an essential role in the regulation of hematopoiesis. It 
stimulates the proliferation, differentiation and functionality of myeloid hemato­
poietic cells but also the proliferation of erythroid burst-forming units (BFU-E) [1]. 
Recently phase I/II studies have been initiated to evaluate the therapeutic benefit 
of GM-CSF treatment in patients with impaired granulopoiesis, either induced by 
chemotherapy or due to primary bone marrow diseases like myelodysplastic syn­
dromes (MDS) [2]. MDS are a group of stem cell disorders characterized by a 
normocellular or hypercellular bone marrow with ineffective hematopoiesis and 
dysplasia of one or more hematopoietic cell lineages which manifests as cytopenia, 
and cellular dysfunction [3]. GM-CSF administration to patients with MDS leads to 
a stimulation of hematopoiesis with a rise in white blood cells (WBC), neutrophils, 
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monocytes and eosinophils. Only a few patients respond with a rise of platelets or 
reticulocytes [4-10]. 
Until now little is known about the effect of GM-CSF treatment on in vivo cell cycle 
kinetics of hematopoietic cells. Thus far only data of non-hematological patients 
[11-13] and five patients with acute myeloid leukemia have been published [14]. 
Insight in the kinetic effects of GM-CSF therapy in MDS may extend our knowl­
edge of its biological and clinical activities and it may be an important guideline for 
defining new rational treatment regimens. 
In this paper we describe the hematological and cell kinetic effects of recombinant 
human GM-CSF treatment in three patients with refractory anemia (RA) who were 
included in a multi-center randomized phase I/II study of the Leukemia Coopera­
tive Group of the European Organization for Treatment and Research in Cancer 
(EORTC) [10]. Cell cycle kinetics were studied before and 4 weeks after the start of 
continuous GM-CSF treatment at a daily dose of 108 or 216 μg subcutaneously. The 
kinetic parameters studied included measurements of: a) the number of colony-
forming units in colony-forming assays, b) the S-phase DNA content of distinct 
hematopoietic cell lineages, c) the labeling index (LI), DNA synthesis time (T
s
), and 
potential doubling time (Tpot) of low density bone marrow cells, d) the LI, TS/ and 
Tpoi of CD34+ cells, and e) the demargination kinetics of granulocytes from the 
bone marrow. 
Ш Materials and Methods 
Patients 
Three patients with primary RA were included in this study. Two patients were 
male (age 26 and 63 years) and one female (age 63 years). The patients were 
included in a multi-center randomized phase I/II study of recombinant human 
GM-CSF in MDS patients with a relatively low risk of developing acute leukemia 
[10]. The diagnosis RA was established according to the FAB-criteria for MDS [3]. 
All three patients were dependent on red cell transfusions, two had a thrombocyto­
penia of < 50 χ 109/1 and a neutropenia of < 2.5 χ 109/1 (patient A and C). Patient A 
had a history of recurrent infections. None of the patients had hemorrhagic compli­
cations. Cytogenetic analysis revealed in two cases a normal karyotype and in one 
case (patient B) a 5q- syndrome (Dr. D Smeets, Department of Human Genetics). 
The patients had not received any therapy other than transfusions and supportive 
care. All had Karnovsky performance scores of >50%. No patient had febrile 
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episodes within two weeks prior to the cell kinetic studies. Permission for GM-CSF 
therapy and for intravenous administration of IdUrd was obtained from the Ethical 
Committee of our Hospital and from the National Cancer Institute Bethesda, USA. 
(Protocol NCI T89-0075). All patients gave written informed consent. 
: Study design 
Patients received twice daily subcutaneous injections of GM-CSF (mammalian, 
glycosylated, Sandoz/Schering-Plough) at a daily dose of either 108 pg glycopro­
tein (Patient A ) or 216 μg glycoprotein (patient В and С ) for 8 weeks [10]. 
A bone marrow aspirate for morphological, cell cycle kinetic and in vitro culture 
studies was obtained after in vivo labeling with IdUrd before as well as during GM-
CSF therapy. At regular time intervals peripheral blood samples were drawn for 
blood counts and for monitoring the release time of granulocytes from the bone 
marrow compartment into the peripheral blood. The interval between the first 
(before GM-CSF) and second kinetic observation (during GM-CSF) ranged from to 
6 to 13 weeks. The kinetic observation during GM-CSF administration was started 
4-5 weeks after the onset of GM-CSF therapy. 
Hematologic Parameters 
From each bone marrow aspirate a differential analysis was made on May-
Griinwald stained slides. The differentiation ratio of myeloid series was defined as: 
myelocytes + metamyelocytes + bands + segmented neutrophils 
blasts + promyelocytes 
In addition, a complete blood cell count, including differential and reticulocyte 
counts was performed on the same day. 
In vivo IdUrd labeling and sampling 
Cell cycle kinetics were studied by in vivo labeling with IdUrd. The National Cancer 
Institute supplied vials of 200 mg sterile freeze dried IdUrd. Prior to the infusion 
IdUrd was dissolved in 30 ml NaCl 0.9%. All patients received twice (before and 
during GM-CSF treatment) 200 mg IdUrd as a 15 min intravenous infusion. Five 
hours after in vivo IdUrd labeling a bone marrow aspirate was obtained from the 
sternum. The bone marrow aspirate was collected in buffered acid-citrate dextrose 
formula A (pH 7.0) on ice. 
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Cell separation 
The peripheral admixture of nucleated blood cells was determined in each bone 
marrow aspirate [15]. The median value was 10% (range 1-32%). Low density 
(immature) nucleated bone marrow cells were collected by density centrifugation 
on Ficoll (density 1.077 g/ml), eliminating the mature bone marrow and peripheral 
blood cells. Cell suspensions were divided into four portions for: 1) IdUrd/DNA 
FCM of low density bone marrow cells 2) IdUrd/DNA FCM of CD34+ cells (enrich­
ment of CD34+ cells will be described later) 3) measurement of S-phase DNA in 
distinct bone marrow subpopulations, and 4) clonogenic assays. 
The cells used for IdUrd/DNA FCM were fixed in cold 75% ethanol [16] and stored 
at -20 °C in the dark until analysis. The other assays were performed on unfixed cell 
suspensions and were initiated within 2 hours after sampling. 
High density (mature) nucleated peripheral blood cells (> 1.077 g/ml) were col­
lected for monitoring the release of granulocytes from the bone marrow compart­
ment. This was done by collecting the cell pellet obtained after density centrifuga­
tion of peripheral blood (1.077 g/ml) and subsequent lysis of the red blood cells 
with cold ammonium chloride ([17]). Differential counting revealed that the ob­
tained peripheral blood cell suspensions consisted for more than 90% of granulo­
cytes (neutrophils and eosinophils). 
Measurement of in vivo cell cycle kinetics 
Measurement of cell kinetic parameters after in vivo labeling with IdUrd was 
performed as described previously [16,18]. Briefly: ethanol fixed bone marrow cells 
were stained for IdUrd incorporation and DNA content using the anti-IdUrd HN-
IU MoAb, developed at our department, and a FITC-conjugated IgG goat anti-
mouse second step antibody (GAM-FTTC; American Qualex International, La 
Mirada, CA). Propidium iodide was used for DNA staining. IdUrd/DNA staining 
of the low density bone marrow suspensions was always performed in duplicate, 
the low number of CD34+ cells allowed only one single measurement. All incuba­
tion steps were executed in the dark. An amount of 20,000 cells was analyzed for 
IdUrd incorporation (green fluorescence) and DNA content (red fluorescence) on a 
Coulter Epics Elite flow cytometer (Coulter Corporation, Hialeah, FL). 
The T
s
 was determined from the bivariate IdUrd/DNA analysis according to the 
model of Begg et al. [19]. The LI was defined as the percentage IdUrd-labeled cells. 
A correction was made for the cells that had divided since the IdUrd labeling [20]. 
From the T
s
 and the LI, the potential doubling time (Tpot) is calculated [19]. 
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S-phase DNA content of distinct hematopoietic cell line­
ages 
In one patient information upon the proliferation activity of distinct hematopoietic 
subpopulations was obtained by simultaneous FCM of cell-surface immunofluore­
scence and DNA content [21]. Briefly: Low density bone marrow cells were stained 
for indirect immunofluorescence using a panel of monoclonal antibodies (MoAb's) 
discriminating the main hematopoietic cell lineages: T-lymphoid (CD2, OKT11); B-
lymphoid (CD19, B4); lymphoid (CD2+CD19); erythroid (anti-Glycophorin A, 
MCA 233); monocytic (CD14, My4); myelomonocytic (CD13, My7), (CD33, My9) 
and (CD13+CD33 (My7+My9); myelocytic CD15, Myl), progenitor cells (CD34, 
MylO). 
OKT11 was purchased from Ortho Diagnostic Systems (Raritan, NJ), MCA 233 
from Instruchemie (Hilversum, The Netherlands) and all other MoAb's from Coul­
ter Corporation. GAM-FITC was used as second step antibody. The cells were 
subsequently stained for DNA with propidium iodide and an amount of 20,000 
cells was analyzed. S-phase DNA measurement was only applied to subpopula­
tions > 4% of the overall population, to avoid inclusion of small subpopulations 
with a relatively large admixture of non-specific fluorescent cells. 
Enrichment of CD34+ cells 
M450 Dynabeads (magnetic beads conjugated with the CD34 MoAb; Dynal, Oslo, 
Norway) were used for positive selection of CD34 cells, and were detached using 
Detach-a-Bead (Dynal). Dynabeads were washed once using a magnet tube holder 
(Dynal). The cell-to-bead ratio was chosen 2:1. The cell-bead mixture was incubated 
for 45 min at 4°C under continuous rotation. The cell-bead complexes were re­
moved using a magnetic tube holder in 8 washing steps using glucose phosphate 
buffer with 1% bovine serum albumin (GPB). Finally the cell-bead complexes were 
resuspended in 100 μΐ GPB, mixed with Detach-a-bead, 10 μ1/106 cell, at a mini­
mum of 100 μΐ and incubated under continuous rotation for 60 min, 20°C The 
mixture was diluted to 3 ml with GPB and the beads were removed using the 
magnetic tube holder. This procedure was repeated 3 times. Finally the pooled 
supernatants were washed in 50 ml GPB by centrifugation (10 min, 450 g) and 
resuspended in GPB. The purity of the cells was flow cytometrically checked by 
staining with the anti-CD34 monoclonal antibody 8-G12-FITC (Becton & Dickin­
son, San Jose, CA) and appeared >85%). 
141 
Chapter в 
Monitoring the release of myeloid end cells from the bone 
marrow compartment 
The granulocyte release time (T
re
i
ease
) represents the interval between the last cell 
cycle of the granulocyte precursor cells in the bone marrow compartment (marked 
by IdUrcl labeling) and the release of IdUrd labeled mature granulocytes into the 
peripheral blood. The release was monitored by collecting high density peripheral 
blood cells at regular time intervals (trice weekly) after IdUrd labeling. IdUrd 
incorporation was measured as described in the previous section. The Τ
Γ6ιεί5ε was 
defined as the time at which the percentage of IdUrd-labeled peripheral granulo­
cytes exceeded the 10% level. The range of the T
re
i
case
 estimation corresponds with 
the day at which the 10% level was reached and the preceding day(s) at which no 
peripheral blood sample was drawn. 
l
* In vitro bone marrow culturing 
The CFU-GM assay was performed as described previously [22,23] and duplicate 
cultures were scored after 14 days. Aggregates of more than 3 cells were counted as 
CFU-GM. 
S Results 
Hematologic parameters 
The hematologic parameters are summarized in the first rows of Table 1. All 
patients showed an increase in neutrophil, eosinophil, and consequently also in 
WBC counts during GM-CSF therapy. No consistent effect was observed on plate­
let, monocyte or lymphocyte counts. Reticulocyte count and transfusion require­
ment were essentially unaltered (not shown). All patients had stable disease with­
out significant changes in percentage of blasts or maturation indices of the bone 
marrow. 
Cell cycle kinetics 
IdUrd kinetics of low density bone marrow cells 
Cell cycle kinetics in each patient was studied before and during GM-CSF treat­
ment using in vivo IdUrd labeling and flow cytometry. Therefore each patient 
served as its own control. Interference of the first IdUrd labeling (before GM-CSF) 
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Table 1 
Hematologic, Cell Cycle kinetic and Clonogenic Assay Parameters 
Before and During GM-CSF Therapy 
Blood counts (xl0 9/l) 
WBC 
Platelets 
Neutrophils 
Eosinophils 
Monocytes 
Lymphocytes 
Bone Marrow 
Blasts (%) 
Maturation Index 
Cell Cycle Kinetics1 
LI (%) 
T
s
(h) 
Tpot (days) 
Trelease (days) 
range Trelease (days) 
Clonogenic assay 
CFU-GM (per 2x10s 
plated cells) 
Patient A 
before 
2.8 
32 
2.30 
-
0.11 
0.39 
1 
44 
24.4 
11.1 
1.9 
7 
(5-7) 
74 
during 
7.0 
57 
4.20 
1.82 
0.21 
0.56 
1 
12 
20.7 
10.8 
2.2 
4 
(3-4) 
107 
Patient В 
before 
5.8 
650 
3.48 
0.12 
0.12 
2.03 
5 
10 
13.7 
12.8 
3.9 
7 
(5-7) 
320 
during 
9.0 
446 
5.22 
2.61 
0.09 
0.99 
2 
21 
12.2 
11.1 
3.8 
4 
(3-4) 
261 
Patient С 
before 
1.7 
42 
1.04 
0.15 
0.12 
0.29 
2 
13 
23.5 
14.8 
2.6 
5 
(4-5) 
669 
during 
4.8 
24 
2.69 
1.49 
0.19 
0.43 
2 
12 
21.2 
15.0 
3.0 
3 
(1-3) 
135 
Analyzed from low density bone marrow cells. The cell cycle kinetic data ofCD34+ cells of 
patient A are demonstrated in Figure 3. 
with the second IdUrd labeling (during GM-CSF) was excluded: before the start of 
the second labeling the number of labeled bone marrow or peripheral blood cells 
was < 0.5%. Figure 1 shows the results of DNA/IdUrd analysis of low density bone 
marrow cells in patient A before (Fig. 1A) and during (Fig. IB) GM-CSF treatment. 
The scatter plots appear to be similar. The transition rate of the cells after pulse 
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Fig. 1. Bwariate analysis of DNA content (linear scale) versus IdUrd incorporation 
(logarithmic scale) before (A) and during (B) GM-CSF administration of low density 
bone marrow cells. The horizontal lines indicate the level used for discrimination 
between IdUrd+ and IdUrd' cells. The vertical lines are set to discriminate between 
IdUrd+ cells that had not yet divided since the start of the labeling and those that had 
already entered С
г
- and early S-phase. The two scatter plots and the calculated kinetic 
parameters are almost identical. 
labeling from the S-phase to the G2+M-phase and Gi-phase (reflecting T
s
) is almost 
identical. In all patients we observed a slight decrease (1.5-3.7%) in LI. The T
s
 and 
Tpot values remained essentially the same (Table 1). 
S-phase DNA content of bone marrow subpopulations 
The bone marrow in RA is morphologically heterogeneous. Of patient A bone 
marrow cells were available for additional kinetic analyses. The percentage S-phase 
cells of distinct subpopulations were determined using bivariate staining of DNA 
and cell-surface immunofluorescence. During GM-CSF therapy the expression of 
the CD15 marker (mature myelocytic cells) increased from 28% to 41%. The expres­
sion of all other markers remained unaltered (data not shown). The number of 
CD34+ cells (progenitor cells) and CD19+ cells (B-lymphoid cells) were too small (< 
4%) for analysis of their S-phase DNA content. The S-phase DNA content of the 
overall population, and distinct subpopulations both before and during GM-CSF 
treatment are represented in Figure 2. GM-CSF treatment induced a slight relative 
decrease (1-3%) in percentage S-phase cells of the myelomonocytic (CD13+, CD33+, 
CD13+CD33+, CD15+) cells and a more pronounced decrease (5%) of the monocytic 
cells (CD14+). 
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Fig. 2. S-phase DNA content of immunophenotypically defined subpopulations before 
and during GM-CSF treatment. 
IdUrd kinetics of CD34+ bone marrow cells 
Figure 3 shows the result of DNA/IdUrd analysis of isolated CD34+ cells in patient 
A before (Fig. ЗА) and during GM-CSF (Fig. 3B) treatment. The number of CD34+ 
cells that incorporated IdUrd did not increase during GM-CSF treatment and 
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Fig. 3. Bivariate analysis of DNA content (linear scale) versus IdUrd incorporation 
(logarithmic scale) before (A) and during (B) GM-CSF administration of isolated 
CD34+ bone marrow cells. The setting of the horizontal and vertical lines is explained 
in the legend of Figure 1. GM-CSF treatment induced a shortening of the T
s
 and Τ
 (. 
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consequently the LI remained stable. However, the T
s
 and the Tpot were shortened 
during GM-CSF therapy (T
s
, 13.6 h and 9.7 h; Tpot, 3.1 days and 2.1 days, before and 
during GM-CSF therapy, respectively). 
Granulocyte release time 
Figure 4 shows the fraction of labeled granulocytes in the peripheral blood of 
patient A, at different time intervals after labeling with IdUrd. The release rate of 
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Fig. 4. The fraction of labeled granulocytes in the peripheral blood at different time 
intervals after labeling with IdUrd, assessed before and during GM-CSF treatment. 
During GM-CSF treatment the curve is shifted to the left, indicating a shortening of 
the granulocyte release time from the bone marrow compartment into the peripheral 
blood. 
the labeled cohort into the peripheral blood is clearly shortened during GM-CSF 
treatment. The calculated T
re
iense w a s nearly halved in all three patients (Table 1). 
Clonogenic assay 
No consistent effect on the number of CFU-GM was noticed during GM-CSF 
treatment (Table 1). In all cases a growth pattern with many single cells was 
observed without significant alteration of the growth pattern due to GM-CSF 
therapy (data not shown). 
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Discussion 
Three patients with RA were treated as part of a phase I/II multi-center study with 
GM-CSF. They showed a rise in neutrophils, eosinophils, and consequently also in 
WBC. These hematological effects fit with the result of the respective phase I/II 
trial [10] and other studies in patients with MDS [4-7,9,24]. The rise in granulocytes 
might be induced by different cell kinetic mechanisms, some of them were studied 
in the present analysis. 
The number of bone marrow progenitor cells (CFU-GM) was unaltered during 
GM-CSF treatment. This is in agreement with other reports concerning patients 
with MDS [7,9,25,26], but not with the results of Visani et al. who observed an 
increase of CFU-GM [27]. However, a rise in the absolute number of progenitor 
cells might have been covered up by an associated increase of recognizable granu­
locyte precursor and mature granulocyte daughter cells. Some investigators re­
ported an increase of S-phase CFU-GM after GM-CSF treatment in MDS [26], acute 
myeloid leukemia [28] or non-hematological patients [13,29], but Rosenfeld at al. 
found no correlation in 20 patients with MDS [9]. Assessment of S-phase CFU-GM 
requires in vitro exposure to thymidine and subsequent in vitro culturing of pro­
genitor cells with stimulating factors. This may not necessarily reflect the in vivo 
kinetics of progenitor cells. 
Thus far, no data on in vivo cell cycle kinetics in patients with RA treated with GM-
CSF have been reported. Riccardi et al. who studied non-hematological patients, 
reported an increased LI of granulocyte precursor cells (myeloblasts, promyelo­
cytes and myelocytes), and a shortening of their T
s
 and Tp0t [Π]. In five patients 
with acute myeloid leukemia the effects of GM-CSF on cell cycle kinetics were less 
consistent and were even contradictory among patients [14]. In vivo cell cycle 
kinetics in mice revealed a slight decrease in the labeling of granulocyte precursors 
with no effects on T
s
 [30]. We found also a slight decrease in LI and an unaltered T
s 
and Tpot- An explanation for the decline in LI is not available. It could be due to an 
inhibition of apoptosis of myeloid cells. Such an effect of GM-CSF has been de­
scribed [31], but the present study was not focused on this subject. The slight 
decline in LI could even be flattered due to an early release of (non-proliferating) 
granulocyte end cells into the peripheral blood, leading to an increase in LI. How­
ever, the IdUrd assay is performed on low-density bone marrow cells, a cell 
fraction in which the mature granulocytes are removed by density gradient cen-
trifugation. 
The bone marrow compartment in patients with RA is heterogeneous and IdUrd 
FCM of unseparated low density bone marrow cells provides no information on 
distinct subpopulations. Therefore we used bivariate staining of DNA content and 
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cell-surface immunofluorescence as well as IdUrd kinetics of CD34+ cells. Bivariate 
staining of DNA versus cell-surface immunofluorescence showed that the slight 
decrease in overall proliferation activity during GM-CSF treatment mainly origi-
nates from altered kinetics of the myelo(-mono)cytic lineage. 
Until now no techniques were available that provide information on the in vivo cell 
cycle kinetics of pure human progenitor cells. However, morphologic immature 
cells, highly enriched for progenitor cells, can be selected using the CD34 mono-
clonal antibody [32,33]. The cell cycle kinetics of this fraction was measured using a 
two step method: selection with magnetic beads and subsequent IdUrd/DNA flow 
cytometry. This two step procedure was necessary since the IdUrd/DNA cyto-
chemical protocol completely strips off the CD34 cell-surface marker. As a conse-
quence of the disappearance of the cell-surface markers, the IdUrd/DNA analysis 
was not jeopardized by the previous CD34 labeling (unpublished observation). 
Although the data are restricted to one patient only, they showed an increase in 
proliferative activity of CD34+ cells indicated by a relative shortening of the Tpot by 
32%. This was due to a shortening of the Ts, despite an unchanged LI. The increased 
proliferative activity of the CD34+ cells may result in an associated increase in 
granulocyte production, amplified by the subsequent cell divisions of the CD34+ 
daughter cells. 
This is the first application of the IdUrd technique used to monitor directly the 
demarginarion kinetics of granulocytes from the bone marrow into the peripheral 
blood. Until now such studies required the in vivo administration of radioactive 
DNA precursors [12], or indirect calculation from other kinetic parameters [11]. In 
all three patients the release of labeled granulocytes from the bone marrow into the 
peripheral blood was accelerated, in accordance with the observations of Riccardi 
et al. in non-hematologic patients [11]. As such an effect would only be transient, 
this phenomenon does not explain the sustained increase in granulocyte counts. 
Lord et ai who studied four non-hematologic patients found an unaltered granulo-
cyte release time. Unfortunately the release of granulocytes was monitored partly 
after GM-CSF therapy was stopped, and the results were compared with historical 
controls [12]. Our demarginarion kinetics provides no data on peripheral half life 
times of hematopoietic cells. It would require prolonged and more frequent moni-
toring of peripheral blood granulocytes which was not feasible in an outpatient's 
department. In non-hematological patients both prolonged [12] and unaltered [34] 
half-life times of peripheral blood granulocytes have been described. 
In conclusion, GM-CSF administration to patients with RA results in a rise in 
granulocytes that might be partly due to a shortened release of granulocytes from 
the bone marrow compartment into the circulating blood and partly to an increased 
proliferative activity of the immature precursor and progenitor cells. 
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Ш Materials and Methods 
Patients 
BM aspirates were obtained from twelve healthy volunteers and eighteen patients 
with AML at first presentation. None of the patients had received chemotherapy or 
immunosuppressive treatment prior to diagnosis. The diagnoses and morphologic 
subclassification were made according to the FAB classification [21] and confirmed 
by the Netherlands Bone Marrow Committee, Rotterdam. FAB subtypes were: Ml 
(и = 2); M2 (и = 4); M3 (и = 1); M4 (и = 5); М5 (и = 3) and Мб (и = 3). Median age 
of the leukemic patients was 50 years (range 23-81 years) and of the normal 
volunteers 58 years (range 39-71 years). The median percentage of leukemic blasts 
in the BM smears of the patients was 50% (range 12-91%). The admixture of 
peripheral nucleated blood cells in the BM aspirates was determined according to 
the method from Holdrinet et al. [22]. The median values were 13% (range 3-33%) 
and 15% (range 1-40%) for normal and AML BM, respectively. 
Monoclonal Antibodies 
The following MoAbs were used: OKT11 (Ortho Diagnostic Systems, Raritan, New 
Jersey); MCA 233 (Instruchemie, Hilversum, The Netherlands); My7, My4, B4, and 
My9 (Coulter Corporation, Hialeah, Florida). The antibodies with their cluster 
designation [19], their specificity and references [23-31] are listed in Table 1. 
Staining of DNA Content and Cell-Surface Immunofluore­
scence 
Simultaneous staining of DNA and s-IF was performed as described previously 
[20]. Briefly: From the BM aspirates the low-density cells (< 1.077 g/ml) were 
collected by density centrifugation and stained for indirect immunofluorescence 
using the MoAbs listed in Table 1. A FITC-conjugated goat anti-mouse IgG F(ab')2 
fragment (GAM-FITC; American Qualex International, La Mirada, California) was 
used as second step fluorescent antibody. Cells incubated with GAM-FITC only, 
served as control to detect non-specific immunoglobulin binding. Cell suspensions 
were divided over two tubes. The cells of one tube were used for measurement of s-
IF before DNA staining and analyzed within 3 h after the last incubation step. The 
cells of the other tube were stained for DNA, using an overnight incubation on ice 
with a hypotonic propidium iodide solution, and analyzed for combined measure­
ment of DNA content and s-IF. 
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Cluster 
designation 
CD2 
CD19 
CD2/CD19 
• CD14 
CD13 
CD33 
CD13/CD33 
— 
Table 1 
(Cocktails of) Monoclonal Antibodies Used 
MoAb 
ΟΚΤΠ 
B4 
OKT11 + B4 
My4 
My7 
My9 
My7 + My9 
MCA 233 
glycophorin-A 
Specificity 
Pan-T cell (rosette receptor) 
Pan-B cell 
Pan-T + pan-B cell 
Pan-monocyte 
Monocytes; myelomonocytic 
progenitors; immature (+ 
mature) myeloid cells 
monocytes; myelomonocytic 
progenitors; immature + 
mature myeloid cells 
Monocytes; myelomonocytic 
progenitors; immature + 
mature myeloid cells 
Erythroid precursors; 
erythroid cells 
Reference 
[23] 
[24,25] 
[26,27] 
[27-29] 
[28] 
[30,31] 
Flow Cytometry 
Cells were analyzed on a flow cytometer (50H Cytofluorograf, Ortho Diagnostic 
Systems, Westwood, California) equipped with a 5 W Argon ion laser for simulta­
neous excitation of green fluorescence representing s-IF, and red fluorescence 
representing DNA content. A HeNe laser of 0.8 mW was used for detection of the 
forward scatter signal measuring cell size. After DNA staining the residual red 
blood cells were gated out based upon their lack of DNA content. Before DNA 
staining this was done by gating on the light scatter signal. Filter settings, data 
storage of the linear signals and correction for fluorescence crossover have been 
described previously [20]. A minimum of 20,000 cells were analyzed for s-IF and 
DNA content. For the DNA analyses cell doublets were excluded based upon the 
ratio area / peak of the DNA signal [32]. 
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Estimation of S-IF 
The percentages of positive immunofluorescent cells before DNA-staining were 
determined from a 256-channel histogram of the green fluorescence and after DNA 
staining from a two-dimensional presentation of the list data of the red fluores­
cence vs green fluorescence. In most cases the clear discrimination between the 
positively and negatively labeled cells allowed a manual discrimination between 
these two populations. Only for the dimly stained samples (usually CD13+ and 
incidentally CD19+ and CD33+) the discrimination was set according to the level 
obtained from the control sample. 
Measurement of S-Phase DNA Content in BM Subpopula­
tions 
Only subpopulations which amounted at least 4% of the overall population were 
included for detection of the S-phase fraction. This arbitrary level was chosen to 
avoid inclusion of small subpopulations with a relatively large admixture of non­
specific fluorescent cells. Calculation of S-phase DNA was performed according to 
the method of Baisch et al., model 1 [33]. 
Measurement of the DNA Index 
Measurement of the DNA index was performed using non-malignant autologous 
T-lymphocytes (CD2+) or Τ + B-lymphocytes (CD2/CD19+) as an intrinsic diploid 
reference. The DNA index was calculated as [Go-Gi peak channel of the negative 
fraction / Go-Gi peak channel of the positive lymphoid reference fraction]. In one 
patient with a M4 AML no labeling with lymphocytic markers was done and in this 
patient the glycophorin-A+ cells were used as reference. For comparison of this 
new approach of DNA indices determination with a more conventional method, 
the DNA index was also calculated using chicken red blood cells as a standard in 
7/12 normal BM samples. 
Cytogenetics 
Chromosome studies on non-stimulated BM samples of all the patients with acute 
myeloid leukemia were performed at the Department of Human Genetics of our 
institute by Dr D. Smeets. Preparations were G-banded. In all but one cases at least 
15 metaphases were analyzed. In the latter case only three metaphases could be 
analyzed which showed a normal karyotype. 
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Statistics 
The Mann-Whitney U test, a non-parametric test for two independent samples, was 
employed to test differences in percentages of S-phase cells of the distinct subpopu­
lations between normal and M1-M5 leukemic bone marrow. The number of pa­
tients with M6 AML was to small for statistic analysis. 
S Results 
Cell-Surface Immunofluorescence 
s-IF after DNA staining of low-density human BM cells labeled with different 
Mo Abs is shown in Figure 1. In each column the data of one MoAb are shown. 
Within each column the circles indicate the results in normal BM cells, the triangles 
BM cells from AML M1-M5 and the rectangles BM cells from AML Мб. The median 
values, the range and the number of observations are listed in columns 2-4 of Table 
2. No essential difference was observed between the percentages immunofluore-
scent cells before and after DNA staining [20]. 
Obviously the immunophenotypic composition of normal low-density BM is rather 
heterogeneous with a wide range in percentage positive cells for the MoAbs used. 
The CD33+ and CD13/CD33+ cells represent the major subpopulations. Neverthe­
less, in all cases the other subpopulations (CD2+, CD19+, CD2/CD19+, glycopho-
rin-A+, CD14+ and CD13+) were at least 4%. 
As expected, the BM from patients with M1-M5 AML showed higher median 
percentages of the myelomonocytic (CD13+; CD33+ and CD13/CD33"1") and mono­
cytic markers (CD14+) in comparison with normal BM. However in many patients 
other subpopulations were 4% or higher: CD2 8/13; CD2/CD19 8/8 and glycopho-
rin-A 8/15. In one patient there was evidence for a biphenotypic leukemia as the 
BM consisted of 50% cells expressing the CD19 antigen and 80% expressing the 
CD33 antigen. The CD19+ subpopulation of this patient was excluded for measure­
ment of S-phase DNA content, labeling with a cocktail of CD2 and CD19 was not 
performed. 
This study includes three cases of M6 AML. The first one was examined with a 
panel of only four MoAbs: CD2; CD19, glycophorin-A and CD33. In concordance 
with the morphological classification all cases demonstrated a high percentage of 
cells positive for the erythroid marker glycophorin-A. But still minor subpopula­
tions positive for the T-lymphoid and (myelo)-monocytic markers were present. 
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Chapter six describes in a prospective study of 33 newly diagnosed patients with 
AML the relationship of proliferation parameters with clinical parameters (age, 
sex, % blasts, white blood cell count, FAB subtype, cytogenetics, and % CD34+ 
cells), response to induction therapy, and survival. It included experimental data 
on clonogenic growth (number of colony-forming units, growth pattern, spontane­
ous clonogenic growth capacity) and cell cycle kinetics (percentage of S-phase cells, 
labeling index, T
s
 and T ^ ) . No or only weak relationships were observed between 
the experimental and clinical parameters. Also no association between the prolif­
eration parameters and induction response rate was noticed. Trends to longer 
overall survival and event-free survival were observed in patients with a below-
median labeling index (<7.6%), below-median T
s
 value (<14.3h) and without 
spontaneous clonogenic growth capacity. Some of these trends were more pro­
nounced in the group of de novo AML (и = 23), where the prolonged event-free 
survival in patients with below-median T
s
 reached statistical significance (P = .02). 
This study shows that proliferation parameters in leukemic cells provide additional 
information on the cell biologic characteristics of AML, and may have prognostic 
value for response and duration of survival in AML 
Chapter seven describes the in vivo cell cycle kinetics of lymphoma, including 22 
patients with non-Hodgkin's lymphoma, seven patients with Hodgkin's disease, 
and four patients with reactive hyperplasia. The cell kinetic information derived 
from the IdUrd/DNA analysis was extended by additional Ki-67/DNA flow cyto­
metry. The Ki-67 monoclonal antibody discriminates between cycling and non-
cycling (Gg-phase) cells. The combined analysis provided data upon the percentage 
of S-phase cells, labeling index, Кі-67-derived growth fraction, T
s
, Τ
 t, cell produc­
tion rate, duration of the Gj-phase and total cell cycle time. In non-Hodgkin's 
lymphoma, the percentage of S-phase cells, labeling index, growth fraction, Τ
 o t, 
and cell production rate were significantly correlated with the histologic malig­
nancy grade according to the Working Formulation (P < .02). Data found in Hodg­
kin's disease were not essentially different from those in low-grade non-Hodgkin's 
lymphoma and reactive hyperplasia. Remarkably, the T
s
, the duration of the Gj-
phase, and the total cell cycle time appeared to be rather independent of histologic 
malignancy grade within the non-Hodgkin's lymphoma category. No significant 
correlation was observed between the IdUrd labeling index and the growth frac­
tion with the duration of the separate cell cycle phases (P > .05). We conclude that 
the transition time through the different cell cycle phases in non-Hodgkin's lym­
phoma varies widely, even within distinct histologic subgroups. 
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In chapter eight we report on a cell kinetic study in patients with refractory anemia 
(л = 3) treated with granulocyte-macrophage colony-stimulating factor (GM-CSF) 
for eight weeks. GM-CSF induces an increase in neutrophils and eosinophils. Cell 
cycle kinetics were studied before and during GM-CSF administration. Two exten­
sions of the IdUrd in vivo labeling technique were applied: 1) the measurement of 
the release (T
re
j
ease
) of granulocytes from the bone marrow into the peripheral 
blood, and 2) in vivo cell cycle kinetics of isolated CD34+ cells, a subpopulation 
highly enriched for granulocyte-macrophage precursor cells (CFU-GM). No con­
sistent effect of GM-CSF treatment on the relative number of CFU-GM aggregates 
was noticed. ThevT
s
 and Τ
 t of low density bone marrow cells remained essentially 
the same. A slight decrease (1.5-3.7%) in labeling index was found originating from 
the myelo(-mono)cytic lineage. In all three patients the T
r e l e a s e was shortened. Cell 
cycle kinetics of CD34+ cells were studied in order to obtain kinetic information on 
immature precursor and progenitor cells. The DNA synthesis time of the CD34+ 
cells was shortened during GM-CSF therapy resulting in a shorter potential dou­
bling time. In conclusion, GM-CSF administration to patients with refractory ane­
mia results in a rise in granulocytes that might be partly due to an accelerated 
release of granulocytes from the bone marrow compartment into the circulating 
blood and partly to an increased proliferative activity of the immature precursor 
and progenitor cells. 
Samenvatting 
Ш Samenvatting 
De celkinetiek houdt zich bezig met het bestuderen van gegevens over de celgroei 
(proliferatie) van een tumor. De celgroei van hematopoïetische weefsels, zoals 
beenmerg en lymfeklieren, wordt onder normale omstandigheden nauwkeurig 
gereguleerd door een ingewikkeld netwerk van groeifactoren en cytokines, die de 
aanmaak van nieuwe stamcellen en proliferatie, differentiatie en celdood van he-
matopoïetische cellen controleren. Deze nauwkeurige regulatie is bij hematologi-
sche maligniteiten verstoord. Het doel van dit proefschrift was om de proliferatie 
van hematologische maligniteiten in kaart te brengen door gebruik te maken van 
nieuwe flowcytometrische technieken. Een voorwaarde was dat deze methoden 
ook gemakkelijk toepasbaar zouden zijn in een klinische setting. 
Hoofdstuk één geeft een korte introductie over celkinetiek. Het geeft een overzicht 
van de beschikbare methodieken voor het bestuderen van de celkinetiek van hema-
tologische maligniteiten. 
Hoofdstuk twee heeft betrekking op het bestuderen van proliferatie-activiteit in 
heterogene hematopoïetische weefsels, zoals b.v. beenmerg. Tot voor kort beston-
den er geen technieken om m.b.v. flowcytometrie het percentage S-fase cellen (als 
maat voor proliferatie-activiteit) in afzonderlijke subpopulaties van beenmerg-
cellen te meten. In dit hoofdstuk wordt een relatief simpele flowcytometrische 
methode beschreven die dit mogelijk maakt. Met behulp van monoklonale antili-
chamen tegen cellulaire oppervlakte-antigenen kunnen de belangrijkste hemato-
poïetische cellijnen herkend worden. De cellen worden daarbij aangekleurd via een 
indirecte immunofluorescentie techniek waarbij als tweede stap een antilichaam 
gekoppeld aan een fluorochroom (FITC) gebruikt wordt. Het DNA wordt vervol-
gens gekleurd door de cellen ongefixeerd te incuberen met een hypotone oplossing 
van propidium iodide. Voor het meten van DNA en immunofluorescentie kan 
volstaan worden met een flowcytometer die uitgerust is met één laser. De kleuring 
met hypotone propidium iodide heeft geen nadelige invloed op de intensiteit van 
het immunofluorescentiesignaal en de gevoeligheid van de DNA meting is van 
hoge kwaliteit. Met behulp van deze techniek werd de proliferatie-activiteit van 
een aantal hematopoïetische subpopulaties in normaal beenmerg (н = 10) gemeten. 
Het onderzoek toonde aan dat er grote verschillen zijn in percentage S-fase cellen 
tussen de diverse subpopulaties (P<.0001): Erythroïde voorlopercellen (26.4% 
±4.7), myelomonocytaire cellen (8.5% ±1.4), monocytaire cellen (6.1% ±0.9) en 
lymfoïde cellen (2.5% ± 0.8). Het percentage S-fase cellen van de T-lymfoïde cellen 
(2.0% ±0.7) was significant lager dan dat van de B-lymfoïde cellen (5.1% ±1.5; 
P<.0001). 
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In hoofdstuk drie wordt de boven beschreven methode gebruikt om de celkinetiek 
van leukemisch beenmerg te bestuderen. In beenmerg van patiënten met een acute 
myeloïde leukemie (AML) werd een sterke toename van de aantallen myelomono-
cytaire en monocytaire cellen (M1-M5 AML) of erythroïde voorlopercellen (M6 
AML) gevonden. Meestal waren er ook resterende normale hematopoïetische cel-
lijnen aanwezig (lymfoïde cellen; T-lymfoïde cellen; myelomonocytaire en mo-
nocytaire cellen in M6 AML; en erythroïde voorlopercellen in M1-M5 AML), vaak 
van voldoende omvang om hiervan het percentage S-fase cellen te kunnen bereke-
nen. Van diverse subpopulaties vergeleken wij het percentage S-fase cellen in 
leukemisch beenmerg (n = 18) met dat van normaal beenmerg (и = 12). De medi­
ane waarden waren niet wezenlijk verschillend van elkaar maar de spreiding was 
veel groter in leukemisch beenmerg. Deze bevinding suggereert dat leukemisch 
beenmerg niet gekenmerkt wordt door een verlaagde dan wel verhoogde prolifera-
tie-activiteit, maar door een proliferatie-activiteit die in vergelijking met normaal 
beenmerg aan grotere variaties onderhevig is. Flowcytometrische analyse van 
DNA/immunofluorescentie blijkt ook uitermate geschikt te zijn om kleine afwij­
kingen (>2%) in het DNA gehalte aan te tonen doordat de niet-maligne cellen (b.v. 
CD2+ of CD2/CD19+) als interne controle fungeren. Dit betekent dat maligne 
populaties met monosomie of trisomie van slechts één chromosoom op grond van 
hun afwijkend DNA gehalte opgespoord kunnen worden. In 4/6 patiënten met 
dergelijke cytogenetisch afwijkingen kon inderdaad een DNA aneuploïdy worden 
vastgesteld. 
Hoofdstuk vier beschrijft een flowcytometrisch protocol voor het simultaan meten 
van bromodeoxyuridine (BrdUrd) of iododeoxyuridine (IdUrd) en DNA in hu-
mane cellen. BrdUrd en IdUrd zijn niet-radioactieve thymidine-analoga die tijdens 
de S-fase in het DNA worden ingebouwd. IdUrd en BrdUrd kunnen derhalve 
worden gebruikt als functionele markers voor het meten van proliferatie-activiteit. 
Voor de voorgenomen celkinetische studies gebaseerd op IdUrd labeling was het 
een vereiste om een geschikte flowcytometrische methode te ontwikkelen om 
simultaan IdUrd incorporatie en DNA te kunnen meten. Het DNA moet namelijk 
gedeeltelijk gedenatureerd worden om het ingebouwde IdUrd of BrdUrd toegan-
kelijk te maken voor een monoklonaal antilichaam. Vooral bij hematopoïetische 
cellen kan dit leiden tot een onacceptabel hoog celverlies. Een goed resultaat werd 
bereikt met behulp van zure denaturane in 2N HCl gedurende 30 min. bij kamer-
temperatuur en gelijktijdige proteolytische enzymdigestie met pepsine (0.2 mg/ 
ml). Deze bepalingsmethode is relatief eenvoudig, snel en gevoelig. De procedure 
is zeer geschikt voor hematopoïetische cellen en geeft daarbij weinig celverlies en 
fraaie DNA histogrammen. 
160 
Hoofdstuk vijf is in dit proefschrift opgenomen omdat het de principes en moge­
lijkheden laat zien van celkinetisch onderzoek met behulp van IdUrd labeling in 
vitro. In tegenstelling tot in vivo onderzoek, kan bij in vitro onderzoek op meerdere 
tijdstippen een monster genomen worden voor analyse. Van twee leukemische 
cellijnen (Molt-4 en K562) werd de celkinetiek vervolgd na blootstelling aan doxo-
rubicine (0-1.0 μg/ml gedurende 2 uur). De cellen werden gedurende korte tijd 
gelabeld met IdUrd, waarna vervolgens op regelmatige tijdstippen een monster 
genomen werd voor flowcytometrische analyse van IdUrd opname en DNA. Op 
deze wijze is het mogelijk om nauwkeurig de passage van de gelabelde cellen door 
de celcyclus te vervolgen. Blootstelling aan doxorubicine leidde tot een vertraging 
van de celcyclus te zien die dosis-afhankelijk en gedeeltelijk reversibel bleek te zijn. 
De drie volgende hoofdstukken zijn gewijd aan celkinetische studies in hematolo-
gische maligni tei ten met behulp van in vivo labeling met IdUrd. In vivo IdUrd 
labeling en IdUrd/DNA flowcytometrie maakt het mogelijk om uit slechts één 
tumormonster een aantal celkinetische gegevens te verkrijgen, zoals: de labeling 
index, de duur van de S-fase (Ts), de potentiële verdubbelingstijd van een tumor 
(T
 t) en de celproduktie snelheid. 
Hoofdstuk zes beschrijft de resultaten van een prospectieve studie bij 33 patiënten 
met AML tijdens eerste presentatie. De studie laat de relatie zien tussen parameters 
van celproliferatie enerzijds en klinische parameters (leeftijd, geslacht, % blasten, 
aantal leukocyten, FAB typering, cytogenetica en % CD34 cellen), resultaten van 
inductiechemotherapie en overleving, anderzijds. De parameters van celprolifera-
tie betreffen: klonogene groei (aantal kolonievormende cellen, klonogene groeipa-
tronen en het vermogen om spontaan kolonies te vormen), en celkinetiek (percen-
tage S-fase cellen, labeling index, Ts en Tpot). De parameters van celproliferatie 
bleken niet of nauwelijks gerelateerd te zijn aan de bestudeerde klinische parame-
ters. Evenmin was er een relatie tussen deze parameters en de resultaten van 
inductiechemotherapie. Er waren trends wijzend op een langere "overall" en 
"event-free" overleving bij patiënten met een lage labeling index (< 7.6%), korte Ts 
(<14.3 h) en het ontbreken van het vermogen om spontaan kolonies te vormen. 
Sommige van deze trends waren meer uitgesproken bij patiënten met de novo 
AML (и = 23), waarbij de langere overleving van patiënten met een korte Ts (< 
14.3 h) significant was (P = .02). Dit onderzoek laat zien dat celkinetiek aanvullende 
informatie geeft over de celbiologische eigenschappen van leukemisch beenmerg, 
en dat deze informatie prognostische waarde kan hebben voor patiënten met AML. 
Hoofdstuk zeven beschrijft de resultaten van een studie betreffende de in vivo 
celkinetiek bij lymfomen, waaronder 22 patiënten met een non-Hodgkin lymfoom, 
zeven patiënten met morbus Hodgkin en vier patiënten met een reactieve lymfe-
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klierhyperplasic. Van elk monster werd naast de IdUrd/DNA meting tevens een 
Ki-67/DNA meting verricht. Hierdoor kon een aantal aanvullende celkinetische 
gegevens bepaald worden, zoals de tumor groeifractie, de duur van de Gj-fase en 
de celcydustijd. Het percentage S-fase cellen, de labeling index, de tumor groei­
fractie, Τ
 t en de celproduktie snelheid toonden een sterke relatie met de histologi­
sche maligniteitsgraad van de non-Hodgkin lymfomen, ingedeeld volgens de 
Working Formulation (Ρ < .02). De celkinetiek bij morbus Hodgkin toonde veel 
overeenkomst met die van non-Hodgkin lymfomen van lage maligniteitsgraad en 
reactieve lymfeklierhyperplasie. Opvallend was dat bij de non-Hodgkin lymfomen 
de T
s
, de duur van de Gj-fase en de celcydustijd nagenoeg onafhankelijk waren 
van de histologische maligniteitsgraad. Evenmin werd er een relatie gevonden 
tussen de IdUrd labeling index en groeifractie, enerzijds, en de duur van de ver­
schillende celcyclusfasen anderzijds (P > .05). Deze studie laat zien dat er bij non-
Hodgkin lymfomen een grote spreiding bestaat in de duur van de verschillende 
celcyclusfasen, zelfs binnen histologische subgroepen. 
Hoofdstuk acht beschrijft een celkinetische studie bij patiënten met een refractaire 
anemie (и = 3) die gedurende 8 weken behandeld werden met granulocyten-ma-
crofaag kolonie-stimulerende factor (GM-CSF). GM-CSF veroorzaakt een stijging 
van het aantal neutrofiele granulocyten en eosinofiele granulocyten in het bloed. 
Zowel voor als tijdens behandeling met GM-CSF werd de celkinetiek van been­
mergcellen vastgelegd. In deze studie werden tevens twee nieuwe toepassingen 
van de in vivo IdUrd labelingstechniek gebruikt: 1) de meting van de "release"-tijd 
(T
r e l e a s e) van granulocyten vanuit het beenmerg naar het perifere bloed, en 2) de in 
vivo celkinetiek van CD34+ cellen, een subpopulatie die sterk verrijkt is voor granu-
locyten-macrofaag voorlopercellen (CFU-GM). Behandeling met GM-CSF bleek 
geen effect te hebben op het relatieve aantal CFU-GM aggregaten, een maat voor 
het aantal klonogene voorlopercellen. Ook de T
s
 en Τ
 t van de beenmergcellen 
veranderden niet wezenlijk. Wel werd er tijdens GM-CSF therapie een lichte daling 
van de labeling index gevonden welke voor rekening van de myelo(-mono)cytaire 
cellen kwam. Opmerkelijk was dat er bij alle patiënten een verkorting van de 
Trelease op^d- Om een indruk van de celkinetiek van jonge voorlopercellen te 
krijgen, werd de celkinetiek van geïsoleerde CD34 cellen gemeten. Tijdens GM-CSF 
therapie bleek de Ts van deze subpopulatie verkort te zijn, met als gevolg een 
kortere Τ
 t. Wij concluderen uit deze studie dat langdurige therapie met GM-CSF 
bij patiënten met een refractaire anemie leidt tot een stijging van het aantal granulo-
cyten welke voor een deel veroorzaakt lijkt te worden door een versnelde release 
van granulocyten en voor een deel door een verhoogde proliferatie-activiteit van 
jonge voorlopercellen. 
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